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ABSTRACT 
 
Children with Down syndrome (DS; trisomy 21) have markedly increased susceptibility to 
acute megakaryoblastic leukaemia (AMKL) and acute lymphoblastic leukaemia (ALL) which, 
at least for AMKL, have their origin in fetal life. My project aims to identify and characterise 
abnormalities in haematopoiesis in human fetal DS in order to understand how T21 leads to 
the increase in leukaemia susceptibility in DS.  
 
Since both AMKL and ALL are increased in DS, I first investigated the hypothesis that T21 
perturbs the earliest multipotent progenitor (MPP) and/or haematopoietic stem cell (HSC) 
compartment and found that the HSC compartment is always expanded in DS FL compared to 
normal FL and that this had markedly increased CD7 expression.  The DS FL HSC/ MPP 
compartment was also functionally abnormal with increased clonogenicity and  
megakaryocyte-erythroid potential and a distinct gene expression signature. Since no 
mutations in GATA1 or JAK2 were detected, my data support a direct role for T21 in the 
abnormalities of HSC number and function. To investigate whether differences in the FL 
microenvironment contribute to the abnormal HSC/myeloid progenitor compartment in DS 
FL, I analysed HSC/progenitors in fetal BM in DS by flow cytometry and in vitro assays. 
Although both MEP and myeloid progenitor/HSC clonogenicity and self-renewal were 
increased, this was less marked than in DS FL, indicating the effects of T21 are not limited to 
FL haematopoiesis but also supporting a role for the HSC/progenitor microenvironment. 
 
To investigate the role of T21 in initiation of ALL, I tested the hypothesis that T21 perturbs 
lymphopoiesis by characterising the lymphoid progenitor population in FL and fetal BM. I 
found a marked reduction in B progenitors, particularly at the committed B progenitor (CBP) 
level in DS FL and fetal BM which was confirmed by in vitro lymphoid cultures and gene 
expression patterns.  
 
These studies have characterised normal human fetal haematopoiesis for the first time and 
show that HSC, MPP and LMPP populations with full lymphoid differentiation are present in 
FL indicating that FL, and not just BM, is an active site of lymphopoiesis during fetal life 
which has implications for the origin of infant ALL.  I have also demonstrated that T21 
perturbs haematopoiesis at the HSC level, leading both to myeloid progenitor expansion and a 
 4
block to B-cell differentiation. These findings increase our understanding of the role of T21 in 
initiating and maintaining leukaemia-initiating cells and suggest a tractable model for 
investigating the effects of aneuploidy on cell growth and differentiation. 
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CHAPTER 1 
INTRODUCTION 
INTRODUCTION 
 
1.1 Down syndrome 
 
Children with Down syndrome (DS) have a markedly increased risk of developing acute 
leukaemia compared to individuals without DS even though their risk of developing solid 
tumours is much lower than the general population (Adams and Scadden, 2006; Hasle et al., 
2000; Patja et al., 2006). There has therefore been considerable interest in understanding the 
reasons for this unique predisposition and the role of the pathognomonic cytogenetic 
abnormality in DS, an extra copy of all or part of chromosome 21 (trisomy 21; T21), in the 
pathogenesis of leukaemia in individuals with DS.  Clinical and biological studies have 
clearly shown that, at least for DS-associated acute myeloid leukaemia (AML), leukaemic 
transformation occurs during fetal life. The work in this thesis aims to identify and 
characterise abnormalities in haematopoiesis in human fetal DS in order to provide insight 
into how T21 leads to the increase in leukaemia susceptibility in DS.  
 
 
1.1.1 Incidence and prevalence of DS  
 
DS (MIM190685), which is the commonest chromosomal abnormality in humans, was first 
described by Down in 1866 (Down, 1866).  However, it was only recognised in 1959 that the 
manifestations of DS all result from the presence of three copies of all (or part) of 
chromosome 21, usually in all cells (Lejeune et al., 1959). The most recent data for DS in the 
UK comes from the National Down Syndrome Cytogenetic Register, which reported a total of 
1877 diagnoses of DS in the UK in 2006.  
(NDSCR, http://www.wolfson.qmul.ac.uk/ndscr/reports/NDCSRreport0708.pdf). In 1132 
cases (60%) the diagnosis was made antenatally; >90% of these resulted in terminations; and 
there was a total of 767 live births with DS, giving a prevalence of 1.2 children with DS per 
1000 live births. Trisomy for some other autosomes occurs more frequently than T21 but 
nearly always results in fetal loss; the relatively high frequency of survival in DS is believed 
to be mainly due to the small number of genes on chromosome 21 (Hsa21), which is the 
smallest and least dense of the autosomes (Hassold and Hunt, 2001). 
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1.1.2 Clinical features and genetics of DS 
 
Although the clinical features of DS are very variable between patients, several of the 
characteristics are commonly shared by most patients (reviewed in (Hoyme, 2004a; Roizen and 
Patterson, 2003). These include a typical facial appearance, hypotonia, a small and hypocellular 
brain with cognitive impairment, developmental delay and early onset dementia (Hoyme, 
2004b). In addition, congenital cardiac anomalies occur in almost 50% of patients and gut 
anomalies, such as tracheo-oesophageal fistula, duodenal atresia and Hirschsprung disease, 
are also fairly common (Ferencz et al., 1989; Roizen and Patterson, 2003).  A variety of 
haematological abnormalities, including the increased susceptibility to acute leukaemia 
discussed in more detail below, are recognized (Webb et al., 2007), but poorly documented, 
and it is only with very recent detailed prospective studies that their frequency is now being 
accurately documented for the first time (Norton, 2010).   
 
Around 95% of all individuals with DS have classical T21 i.e. three independent copies of 
chromosome 21 (Antonarakis et al., 2004)). A large majority of these cases are caused by 
non-disjunction in meiosis and are almost always of maternal origin (Antonarakis, 1991). The 
remaining 5% of cases is made up of T21 mosaics and unbalanced translocations (Antoniarkis 
et al, 2004). 
 
The exact relationship between T21 and the DS phenotype(s) is not completely clear though 
there is a long-standing belief that it is likely to involve over expression of genes on 
chromosome 21 (Roper and Reeves, 2006). There is also some evidence that loss of 
heterozygosity and disomic homozygosity may play some part (Shen et al., 1995). Direct 
evidence of the over expression of chromosome 21 genes in DS is sparse though one study 
looked at gene expression assays of 78 triplicated genes in the Ts65Dn partial trisomy mouse 
model (Kirsammer et al., 2008). Gene expression was around 150% normal in 37% of the 
genes studied, in 45% it was between 100 and 150% normal, in 9% it was not increased  and 
in 18% significantly greater than 150% (Lyle et al., 2004; Roper and Reeves, 2006).  
However, human studies of gene expression in T21 increasing show a complex picture, with 
considerable variation in T21-related gene expression between different tissues (Liu et al., 
2008; Prandini et al., 2007; Sommer and Henrique-Silva, 2008).  Furthermore several studies 
have now found evidence of changes in microRNA expression in patients with DS (Kuhn et 
al., 2008).  
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1.1.3 Genes on chromosome 21 and Down Syndrome Critical Region (DSCR) 
 
There are approximately 324 recognised genes on Hsa21 (Antonarkis et al, 2004). 
Although the majority of patients with DS have a complete additional chromosome 21, 
a proportion of patients have partial T21. The phenotypic expression of DS in these 
patients has been pivotal in identifying limited subsets of genes on a region of Hsa21, 
known as the DS critical region- DSCR (Figure 1.1), which appear to be responsible for 
all or most of the characteristic features of DS (McCormick et al., 1989).  Various 
different critical regions have since been reported, of varying sizes down to 4.3 MB 
(Ronan et al., 2007), and associated with different phenotypic features of DS.  
 
It is not yet clear if there is a DSCR associated with leukaemia susceptibility, although 
one recent paper localises the critical chromosomal region of Hsa21 involved in AML 
and DS-associated transient myeloproliferative disorder (TMD) to an 8.3Mb segment 
which, as discussed below, contains a number of genes of interest  (Korbel et al., 2009). 
Nevertheless, an important limitation of this paper was the small number of patients 
studied- indeed, there was only 3 patients with AML (Korbel et al., 2009).  Thus, 
although this approach may well be useful in narrowing down the genes likely to be 
important in AML pathogenesis, much larger studies with a very much larger number of 
patients with AML would be required to draw secure conclusions.  
 
An alternative approach is to investigate the expression and effects of all of the 
candidate genes in the DSCR likely to be relevant to haematopoiesis. This strategy has 
mainly been applied to studies in murine primary haematopoietic cells although very 
recently, IPS (induced pluripotent stem cells) derived from fibroblasts of patients with 
DS have also begun to be investigated (Park et al., 2008). Candidate genes on 
chromosome 21 of most potential relevance include some of the interferon receptor 
genes (IFNγ1 and 2 and IFNα2), ERG, RUNX1, SON, BACH1 and ETS2, are shown in 
Figure 1.1).   
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Figure 1.1 The Down Syndrome Critical Region (DSCR) on human chromosome 
21 
 
Modified from Gurbuxani et al, 2004 
 
Using this approach, ERG in particular has been implicated since over expression, with or 
without GATA1 mutation, causes leukaemic transformation of murine fetal HSC; 
(Stankiewicz and Crispino, 2009)) and is crucial for normal development of murine 
megakaryocytes (Rainis et al., 2005); (Loughran et al., 2008). However, there is no evidence 
of increased ERG expression in DS-AML or TMD (Bourquin et al., 2006); (McElwaine et al., 
2004). Similarly, RUNX1 is well recognised as oncogenic in haematopoietic cells and is also 
important for megakaryocyte differentiation (Song et al., 1999); (Ichikawa et al., 2004); 
(Growney et al., 2005). In addition, .there is some evidence that it interacts physically with 
the N-terminal region of the GATA1 gene where the AML-associated mutations cluster 
BACH1  
SOD1 
FNGR2 
IFNAR1 
IFNGR2 
SON 
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RUNX1 
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DYRK1A 
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ETS 2 
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(Elagib et al., 2003) although more recent work implicates the C-terminal, rather than the N-
terminal part of GATA1 as more important for RUNX interaction (Xu et al., 2006). In 
addition, RUNX1 is important for megakaryocyte differentiation (Growney et al., 2005; 
Ichikawa et al., 2004; Song et al., 1999). However, surprisingly, levels of expression of 
RUNX1 are actually reduced, rather than increased, in DS AML (Bourquin et al, 2006) and 
two of the DS mouse models (discussed below) have also ruled out increased expression of 
RUNX1 in the pathogenesis of abnormal megakaryopoiesis observed in these models 
(Kirsammer et al., 2008). By contrast, levels of SON, a gene with homology to c-MYC and of 
BACH1, which represses megakaryocyte differentiation, (Toki et al., 2005) have been shown 
to be increased in DS AML (Bourquin et al., 2006) although neither of these genes have yet 
been directly implicated in the pathogenesis of AML.  Finally, over expression of ETS2 has 
been shown to increase megakaryocytes derived from in vitro culture of murine fetal liver 
progenitors (Stanciewicz and Crispino, 2009); suggesting that it too may play a role in the 
MEP expansion seen in human fetal liver progenitors in DS (Chou et al., 2008; Tunstall-
Pedoe et al., 2008). 
 
 
1.1.4 Mouse models of trisomy 21 
 
Several mouse models have also been used to investigate which gene(s) on chromosome 21 
are crucial for, or contribute to, the pathogenesis of DS leukaemias (Table 1.1). The two most 
studied are the Ts65Dn and the Tc1Cje mice which are partially trisomic for regions of mouse 
chromosome 16 synteneic with human chromosome 21 and contain 143 and 94 of the genes 
in the DSCR respectively (Carmichael et al., 2009; Davisson et al., 1990; Huang et al., 2000; 
Kirsammer et al., 2008; Ng et al., 2010). A theoretically more attractive mouse model is the 
Tc1 mouse model of DS which carries an almost completely segregating copy of Hsa21 and 
is trisomic for 269 of the 324 genes on Hsa21 (Alford et al., 2010; O'Doherty et al., 2005).  
All of these mice have haematological abnormalities (summarised in Table 1.1).  However, 
only one of these models (Ts65Dn) develops a myeloproliferative disorder (and this is only in 
older mice) and none develop leukaemia (Alford et al., 2010; Carmichael et al., 2009; 
Kirsammer et al., 2008). Crucially, none of the mice have consistent abnormalities of fetal 
haematopoiesis (although TC1Cje mice fetal HSC have been reported to have reduced 
reconstitution ability) suggesting that mouse models alone will be insufficient to fully 
understand DS leukaemias. 
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  Ts65Dn 
Davisson et al, 1990  
Kirshammer et al, 2008
Tc1Cje 
Huang et al,1997 
Carmichael et al, 2009 
Tc1 
O'Doherty et al, 2005;  
Alford et al, 2010 
Number of trisomic 
gene orthologues 
143 94 269/324 on Hsa21 
Mouse  
chromosome 
Mmu 16 Mmu 16 N/A 
Myeloproliferative  
disorder / leukaemia 
MPD- age 15 months 
No leukaemia 
None at 24 months None at 24 months 
Haematological 
abnormalities 
Macrocytic anaemia 
Thrombocytosis 
Immature erythroblasts
 increased 
Macrocytic anaemia 
Megakaryocytes, 
erythroblasts and GM 
increased in spleen 
Macrocytic anaemia 
Probable thrombocytosis 
Megas, erythroblasts and 
GM increased in spleen 
Fetal liver 
haematopoiesis 
Not studied Reduced reconstitution 
ability of HSC 
Normal 
 
 
Table 1.1  Haematological abnormalities in mouse models of Down syndrome 
 
 
These mouse DS models are nevertheless likely to be useful in identifying genes which affect 
the behaviour of haematopoietic stem cells (HSC) and their progenitors in DS and may 
therefore contribute to leukaemic transformation.  Indeed, comparison of the different 
haematological phenotypes between the models is interesting. All, for example, have 
macrocytic anaemia (macrocytosis is also common in DS; (Henry et al., 2007; Norton, 2010), 
suggesting that increased expression of one or more genes trisomic in all 3 models (Alford et 
al., 2010; Carmichael et al., 2009; Kirsammer et al., 2008). By contrast, comparison between 
Ts65Dn mice, which develop a myeloproliferative disorder, and Tc1Cje, which do not, 
identifies 23 genes present in Ts65Dn but lacking in TC1Cje, which may underlie the 
myeloproliferation. In addition, recent work has provided further evidence for a pathogenic 
role for ERG in the megakaryocytic hyperplasia and myeloproliferative disorder seen in 
Ts65Dn mice (Ng et al., 2010).  
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1.2 Haematological abnormalities in Down syndrome  
Haematological abnormalities in individuals with DS are widely reported, although their 
exact prevalence is unknown. The spectrum of haematological abnormalities includes a 
variety of benign and malignant abnormalities of the blood count and blood film (David et al., 
1996; de Hingh et al., 2005; Henry et al., 2007; Kivivuori et al., 1996; Starc, 1992; Watts et 
al., 1999; Webb et al., 2007) which are summarised in Table 1.2.  In addition, population-
based (Hasle et al., 2000) and cancer-based registries (Hasle et al., 2000; Zipursky, 2000; 
Zipursky et al., 1992) and clinical trials (reviewed in (Lange, 2000) indicate that there is a 10-
27-fold increased risk of acute lymphoblastic leukaemia (ALL) in patients with DS and a 46-
83 fold increased risk of AML with a particular susceptibility to acute megakaryoblastic 
leukaemia (DS-AMKL).  
 
The overall incidence of leukaemia in DS is estimated to be in the order of a 10-36 fold 
excess risk. There is also a virtually unique predisposition to TMD, a clonal, transient 
myeloproliferative disorder characterised by circulating peripheral blast cells and dysplastic 
features, most marked in the red cell and megakaryocyte lineages.  Acute leukaemia and 
TMD are discussed in detail in section 1.3. The remaining haematological abnormalities are 
discussed below. 
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Age Haematological abnormalities References 
 
Neonates 
 
 
• Transient myeloproliferative disorder 
(TMD); also known as Transient 
Abnormal Myelopoiesis  
 
• Non-specific changes: neutrophilia, 
thrombocytopenia, macrocytosis  
      and polycythaemia 
 
• Abnormal myeloid cell granulation,  
      giant platelets 
 
Zipursky, 2003 
Massey et al, 2006 
Klusmann et al, 2008
 
Starc, 1992 
Kivivuori, et al 1996
Henry et al, 2007 
 
Norton et al, 2010 
 
Infants and children
 
 
• Acute myeloid (megakaryoblastic) 
leukaemia (AMKL) 
 
• Myelodysplasia 
 
• Acute lymphoblastic leukaemia 
 
• Macrocytosis 
 
• Immune deficiency 
 
 
 
Zipursky et al, 1992
Hasle et al, 2008 
 
Lange et al, 1998 
 
Whitlock et al, 2005
Hasle et al, 2008 
David et al, 1996 
 
Loh et al 1990 
de Hingh et al, 2005
Douglas, 2005 
 
Adults 
 
• ALL 
• Macrocytosis 
• Myelodysplasia 
 
 Hasle, 2008 
 David et al, 1996 
 McLean et al, 2009
 
Table 1.2 Haematological abnormalities in Down syndrome 
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1.2.1 Haematological abnormalities in the DS fetus 
 
It has been well recognised for some time that there is an increased frequency of 
thrombocytopenia in fetuses with T21, as well as those with trisomy 13 and trisomy 18 
(Hohlfeld et al., 1994; Watts et al., 1999).  In some cases this is associated with TMD 
presenting either with in utero death or preterm delivery with marked hepatosplenomegaly 
and progressive hepatic fibrosis with blast cell infiltration (Heald et al., 2007; Robertson et 
al., 2003; Smrcek et al., 2001).  In others no evidence of TMD is apparent and the mechanism 
of the thrombocytopenia was unclear until recently.  
 
Holmes et al suggested that the haematological abnormalities in DS fetuses, including 
thrombocytopenia, might be due to reduced numbers of HSC secondary to accelerated 
telomere shortening (Holmes et al., 2006). However, since this work was carried out on fetal 
blood samples, rather than liver or bone marrow (BM), and the results were compared with a 
group of fetuses with Rhesus haemolytic anaemia rather than with normal disomic controls, 
the data are difficult to interpret (Holmes et al., 2006). Subsequently, studies in our lab 
(Tunstall-Pedoe et al., 2008), confirmed by others (Chou et al., 2008), 2008), instead found 
that the main haematological abnormality in fetal life in DS was a marked expansion of fetal 
liver (FL) megakaryocyte-erythroid progenitor cells (MEP). The increased frequency of fetal 
thrombocytopenia was also confirmed and megakaryocyte production in vitro was impaired 
despite the increased MEP (Tunstall-Pedoe et al., 2008).  Furthermore, self-renewal of 
common myeloid progenitors (CMP) which are the less differentiated progenitors which are 
believed to give rise to MEP was increased (Tunstall-Pedoe et al., 2008).  
 
 
1.2.2 Haematological abnormalities in DS neonates 
 
Previous studies of haematological indices in neonates with DS suggest that haematological 
abnormalities are seen more frequently in these children compared to neonates without DS 
(Henry et al., 2007; Kivivuori et al., 1996; Starc, 1992).  However, all of these studies have 
been retrospective and even the largest study, which reported the results on 158 of the 226 
babies diagnosed in their centre with DS during the study, evaluated a very limited set of 
haematological data (Henry et al., 2007). A recent study from our lab, reviewing the first 100 
babies in a prospective study of blood counts and blood films in neonates with DS, reported 
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11 babies with TMD and a very high frequency of haematological abnormalities (including a 
high Hb, increased nucleated red cells, thrombocytopenia and increased numbers of abnormal 
monocytes, basophils and blast cells) even in the DS babies without TMD (Norton, 2010).  
These data suggest that the perturbed fetal haematopoiesis found in second trimester fetuses 
with DS persists at least until birth and further supports a direct role for T21 in mediating 
these changes. 
 
 
1.2.3 Haematological abnormalities in DS children and adults 
 
There are few reports of the haematology of older children and adults with DS. Although it is 
clear that DS-associated AMKL is limited to children under the age of 5 years, DS associated 
ALL is seen throughout childhood, apart from the first year of life, and is also reported in 
adulthood (Hasle, 2001; Hasle et al., 2000).  In addition, children with DS are known to be 
lymphopenic, with a progressive decline in B and T cell lymphocyte numbers during 
childhood (de Hingh et al., 2005; Douglas, 2005). DS children also have increased 
susceptibility to infections and autoimmune disorders (Garrison et al., 2005; Gillespie et al., 
2006; Karlsson et al., 1998).  B lymphocyte function may also be abnormal since preliminary 
studies have reported evidence of abnormal thymic maturation, impaired lymphocyte 
activation and variable degrees of immunoglobulin deficiency (Lin et al., 2001; Loh et al., 
1990; Murphy and Epstein, 1990). 
 
Similarly to neonates, children with DS have been reported to have macrocytosis (David et 
al., 1996; Roizen and Amarose, 1993) and  higher Hb compared to controls (David et al., 
1996). More recently, an interesting cohort of nine adults with DS and haematological 
abnormalities was reported including two with myelodysplasia, one of who developed 
progressive bone marrow failure (McLean et al., 2009). In addition, macrocytosis was also 
very common in this cohort suggesting ongoing dyserythropoiesis in DS throughout life. 
Indeed, taken together with the data in neonates, children and mouse models of DS, there is 
very strong evidence for a role of abnormal expression of one or more genes on Hsa21 in the 
pathogenesis of the macrocytosis. 
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1.3 Down syndrome and acute myeloid leukaemia (AML) 
 
As mentioned above, children with DS have a markedly increased susceptibility to acute 
leukaemia (Table 1.3) despite not being caner prone in general (Hasle et al., 2000; Patja et al., 
2006).  It is particularly interesting that there is an increase in both ALL and AML. This not 
only directly implicates T21 in the pathogenesis of the leukaemias, but also raises the 
possibility that T21 may affect HSC as well as the myeloid progenitor population since both 
myeloid and lymphoid lineage leukaemias are found.  
 
  
Type of leukaemia Frequency 
observed 
in population 
Frequency 
observed 
in DS 
Excess risk in DS 
Acute leukaemia 
 
1 in 2800 1 in 100-200 10-20 x 
ALL  
 
1 in 3500 1 in 300 12 x 
AML  
 
1 in 14 000 1 in 300 46 x 
AMKL total 
 
1 in 233 000 1 in 500 466 x 
 
Table 1.3  Frequency of acute leukaemia in children with DS 
Collated from data in Hasle et al, 2000. 
 
  
1.3.1 Acute megakaryoblastic leukaemia (AMKL) in DS 
 
One of the most characteristic features of DS-associated AML is that the vast majority of 
cases are megakaryoblastic (Vyas and Crispino, 2007). AMKL in DS has a number of distinct 
features and it is now considered a specific sub-type of AML in DS in the World Health 
Organization (WHO) classification (Hasle et al., 2003). Virtually all cases of DS-AMKL 
occur within the first 5 years of life (Hasle et al., 2008) and have a distinct molecular 
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signature (discussed below) (Bourquin et al., 2006) which together identify this as an acute 
leukaemia originating in fetal life. By contrast, AML in older DS patients is rarely 
megakaryoblastic and is much less common (Hasle et al., 2008).   
 
Overt leukaemia in DS children is preceded in ~70% of cases by an indolent pre-phase 
characterised by thrombocytopenia and dysplastic changes in the BM, often with 
accompanying marrow fibrosis (Klusmann et al., 2008; Massey et al., 2006).  Other 
distinctive characteristics of DS-AMKL are a low presenting white blood cell (WBC) count 
and lack of meningeal involvement; the blood typically shows dysplastic changes in all 
myeloid lineages and circulating blasts; the BM shows dysplasia, increased blasts, abnormal 
megakaryocytes and variable myelofibrosis (Creutzig et al., 1996; Gamis et al., 2003; Lange 
et al., 1998; Rao et al., 2006; Ross et al., 2005; Webb et al., 2007; Zeller et al., 2005).  Blast 
cells typically co-express erythroid and megakaryocytic markers and a high proportion is 
CD7+ (Creutzig et al., 1996; Lange et al., 1998; Langebrake et al., 2005; Massey et al., 2006) 
 
Although the morphological, immunophenotypic and cytochemical profile of the blasts is 
similar to that of blasts seen in TMD (Creutzig et al., 1996; Lange et al., 1998; Langebrake et 
al., 2005; Massey et al., 2006), the cytogenetic profile in DS-AMKL is distinct from TMD in 
which cytogenetic abnormalities, apart from T21, are uncommon (Forestier et al., 2008).  
Neither the non-random favourable cytogenetic changes that characterise sporadic AML, such 
as t(8;21), t(15;17), t(9;11) and inv(16), nor the AMKL-associated translocations, t(1;22) and 
t(1;3), occur in DS-AMKL (reviewed in (Lange, 2000; Lange et al., 1998; Malinge et al., 
2009) like sporadic AML, the cytogenetic abnormalities which are described do not provide 
clear insight into the molecular pathogenesis of DS-AMKL. The most frequently occurring 
cytogenetic abnormalities are additional copies of chromosome 8 and/or 21 (in addition to 
+21c) which occur in ~10-15% of cases (Creutzig et al., 1996; Forestier et al., 2008; Lange et 
al., 1998); monosomy 7 and –5/5q-occur in ~10-20% of cases) (Gamis, 2005; Gamis et al., 
2003; Rao et al., 2006).  
 
Children with DS-AMKL have a superior outcome when compared with children with 
sporadic AML with long-term survival of 74-91% (Creutzig et al., 2005; Frost et al., 2000; 
Gamis et al., 2003; Rao et al., 2006; Ravindranath, 2003; Taub et al., 1997; Yamada et al., 
2001; Zeller et al., 2005; Zwaan et al., 2002).  The relatively good outcome of treatment in 
DS-AMKL has been attributed, at least in part, to hypersensitivity of DS-AMKL blasts to 
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chemotherapy compared to AML/AMKL blasts from children without DS (Frost et al., 2000; 
Ravindranath, 2003; Taub et al., 1997; Yamada et al., 2001; Zwaan et al., 2002).  The 
increased sensitivity of DS-AMKL blasts to cytarabine has been linked to increased 
expression of cystathionine-beta-synthase on Hsa21 (Taub and Ge, 2005; Taub et al., 2000; 
Taub et al., 1999; Taub et al., 1996).  Interestingly, DS ALL blasts have not been reported to 
be more sensitive to chemotherapy (Frost et al., 2000; Zwaan et al., 2002). 
 
 
1.3.2 TMD in DS 
 
TMD presents during fetal life (usually with hydrops fetalis) (Heald et al., 2007; Robertson et 
al., 2003; Smrcek et al., 2001), at birth or within the first 2 months of life (Klusmann et al., 
2008; Massey et al., 2006). Indeed, data from three recent prospective studies involving more 
than 200 neonates found a median age at diagnosis of 3-7 days (Klusmann et al., 2008; 
Massey et al., 2006; Muramatsu et al., 2008). The frequency is estimated to be ~10% although 
the true incidence is unknown since blood counts/films are not routinely performed on all DS 
neonates (Massey, 2005; Zipursky, 2003).  TMD is unique to DS although it may occur in 
neonates with mosaicism who only have T21 in their haematopoietic cells making diagnosis 
difficult as they have none of the other clinical features of DS (Carpenter et al., 2005). 
 
TMD has a variable clinical presentation from asymptomatic neonates with increased blast 
cells (~25%) to fulminant hepatic failure due to liver fibrosis and blast cell infiltration with a 
mortality of ~20%. (Klusmann et al., 2008; Massey et al., 2006; Muramatsu et al., 2008; 
Zipursky, 2003) (Table 1.4). Other clinical signs include hepatosplenomegaly and serous 
effusions. Leucocytosis and thrombocytopenia are common and thrombocytosis and/or 
anaemia are sometimes a feature, although usually only in very severe cases; about a quarter 
of patients have abnormal liver function tests and/or coagulation parameters (Klusmann et al., 
2008; Massey et al., 2006; Muramatsu et al., 2008). 
 
Blast cells in TMD are typical 'blebby' megakaryoblasts and typically express CD38, CD117, 
CD34, CD7, CD56, CD36, CD71, CD42b, C-MPL (thrombopoietin receptor), EPOR 
(erythropoietin receptor) and CD123 (interleukin 3α receptor) (Girodon et al., 2000; 
Karandikar et al., 2001; Langebrake et al., 2005; Yumura-Yagi et al., 1992). Virtually all 
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neonates with TMD have N-terminal truncating mutations in the key megakaryocyte 
transcription factor gene, GATA1 (Ahmed et al., 2004; Groet et al., 2003; Hitzler et al., 2003; 
Malinge et al., 2009; Mundschau et al., 2003; Rainis et al., 2003; Xu et al., 2003). 
 
Clinical 
 
• Pericardial effusion, ascites and pulmonary oedema 
• Hepatosplenomegaly, hepatic fibrosis 
• Obstructive jaundice and liver failure 
• Skin rash 
 
Haematological 
 
• Leucocytosis; peripheral blood blast cells 
• Abnormal platelet count: reduced or raised (may be normal) 
• Haemoglobin: may be reduced, raised or normal 
 
 
Table 1.4  Summary of the clinical and haematological features of TMD 
 
Most neonates with TMD do not need chemotherapy as the clinical and laboratory 
abnormalities spontaneously resolve within 3-6 months after birth; however, ~20-30% 
subsequently go on to develop full-blown AMKL in the first 5 years of life (Klusmann et al., 
2008; Massey et al., 2006; Muramatsu et al., 2008; Zipursky, 2003).  Symptomatic babies 
with TMD may benefit from low-dose cytarabine as TMD blasts, like DS-AMKL blasts, are 
highly sensitive to cytarabine (Klusmann et al., 2008). 
 
 
1.3.3 TMD and AMKL as a model of myeloid leukaemogenesis 
 
A number of lines of evidence point to TMD and DS-AMKL being linked clonal conditions 
with a distinct pathogenetic basis.  
 
First, at least 30% of cases of DS-AMKL are preceded by a documented history of TMD and, 
similarly, at least 30% of patients with TMD subsequently develop AMKL. The frequencies 
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are a minimal estimate as DS neonates have not been systematically screened for TMD and 
many cases are known to be clinically silent.   
 
Second, haematopoietic cells in both conditions are uniquely marked by the presence of 
acquired, N-terminal truncating mutations in GATA1 while  GATA1 mutations are almost 
never found in other DS and non-DS leukaemias (Ahmed et al., 2004; Groet et al., 2003; 
Hitzler et al., 2003; Rainis et al., 2003; Wechsler et al., 2002; Xu et al., 2003) and GATA1 
mutations are not detectable in remission after treatment of DS-AMKL establishing their 
pathogenic role (reviewed in (Vyas and Crispino, 2007).   
 
Further, in cases of TMD progressing to AMKL, the same GATA1 mutations have been found 
in both TMD and AMKL cells, confirming the clonal relationship between the two disorders 
(Ahmed et al., 2004).  Finally, TMD and AMKL blasts both have an identical, or very similar, 
and distinct immunophenotype, characterised by co-expression of megakaryocytic and 
erythroid markers as well as the T cell marker, CD7 (Langebrake et al., 2005). 
 
Thus, there are three known distinct sets of genetic events in the pathogenesis of DS 
TMD/AMKL (Figure 1.2). First, a fetal haematopoietic cell needs to be trisomic for 
chromosome 21 (see 1.3.1).  Second, acquired fetal GATA1 mutations are required (given the 
high frequency of GATA1 mutations in T21 neonatal blood cells and that children with DS are 
not cancer prone in general, this suggests that the T21/GATA1 interaction imparts a selective 
advantage rather than the T21 being a mutator phenotype). Finally, as not all TMD cases 
progress to AMKL, additional, as yet unidentified, genetic or epigenetic events are required 
for progression to AMKL.  
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Figure 1.2    DS-AMKL and TMD- a multistep model of leukaemogenesis 
Three sets of genetic events are known in the pathogenesis of DS TMD/AMKL. First, a fetal 
haematopoietic cell needs to be trisomic for chromosome 21 (T21).  Second, acquired fetal N-
terminal truncating GATA1 mutations, which give rise to a truncated protein (GATA1s), are 
required. Third, as 70-80% of cases of TMD spontaneously resolve and only 20-30% of TMD 
cases progresses to AMKL, additional, as yet unidentified, genetic or epigenetic events are 
required for progression to AMKL.  
 
 
1.3.3.1. The role of trisomy 21 in initiation of DS-AMKL and TMD 
T21 is essential for TMD and DS-AMKL since, apart from those with DS; the only children 
developing TMD or DS-AMKL in association with GATA1 mutations have acquired T21 in 
their haematopoietic cells (Carpenter et al., 2005; Cushing et al., 2006; Rainis et al., 2003). 
GATA1 mutations occur at high frequency in T21 patients (~5% of all DS neonates from a 
recent study of 526 neonatal blood spots; (Pine et al., 2007) and 25% of patients with DS-
AMKL have multiple, independent GATA1 mutations (Ahmed et al., 2004). Furthermore, 
truncating GATA1 mutations in the absence of T21 are not leukaemogenic (Hollanda et al., 
2006) These data suggest GATA1 mutations impart a growth advantage to haematopoietic 
cells only in the context of T21 and that T21 predisposes to the development of GATA1 
mutant clones by expanding the leukaemia-initiating cell population and/or by altering the 
proliferation and differentiation of HSC/progenitor cells such that subsequent acquisition of 
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GATA1 mutation(s) confers a leukaemic phenotype.  Candidate genes on Hsa21 which may be 
involved are discussed in section 1.1.1.4. 
  
1.3.3.2  Abnormalities of myelopoiesis in FL in DS 
Several lines of evidence indicate the leukaemia-initiating population in DS-AMKL is in FL. 
First, the natural history of TMD provides strong indirect evidence of involvement of FL 
HSC/progenitor cells: the disease develops in utero and spontaneously resolves within months 
of birth as haematopoiesis in FL ceases and fully switches to BM (Klusmann et al., 2008; 
Massey et al., 2006; Muramatsu et al., 2008; Zipursky, 2003).  Second, severe TMD cases 
have progressive blast cell liver infiltration with relative sparing of BM (Zipursky, 2003). 
Third, data from transgenic mice expressing N-terminal truncated GATA1 show an altered 
megakaryocyte lineage proliferation/differentiation phenotype only in FL progenitors and not 
post-natal cells (Li et al., 2005).  Finally, as discussed in section 1.2.1, our laboratory recently 
found that perturbation of FL haematopoiesis in human DS precedes acquisition of GATA1 
mutations with an expansion of MEP and increased clonogenicity strongly suggesting the 
presence of a myeloid leukaemia-initiating population within FL in all fetuses with DS 
(Tunstall-Pedoe et al., 2008).  This was confirmed by another group who also showed that 
mice transplanted with T21 FL CD34+ cells had enhanced erythroid and megakaryocytic 
engraftment (Chou et al., 2008).  
 
 
1.4. Down syndrome and acute lymphoblastic leukaemia (DS-ALL) 
 
DS-ALL also has unique clinical and biological features contrasting with non-DS ALL. Most 
children present at >1 year of age and have a lower incidence of 'favourable' cytogenetic 
abnormalities (e.g. ETV6-RUNX1) (Whitlock et al., 2005). In addition, cytogenetic 
abnormalities associated with a poor prognosis, such as MLL translocations and Ph' positive 
disease, are rare (Forestier et al., 2008).  Interestingly, virtually all cases of ALL in DS are of 
B lineage and most series have been unable to identify any cases of T-ALL (Whitlock et al., 
2005),  Together these data  argue the case for intrinsic differences in the leukaemic cells and 
leukaemogenesis in DS-ALL compared to non-DS ALL and in DS-AMKL compared to DS-
ALL. Indeed GATA1 mutations are not found in DS-ALL (Hellebostad et al., 2005).  
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1.4.1 Clinical and haematological features of DS-ALL 
 
Data from national studies of childhood ALL indicate that many of the clinical features are 
similar in children with or without DS (Arico et al., 2008; Bassal et al., 2005; Chessells et al., 
2001; Dordelmann et al., 1998; Whitlock et al., 2005).  The peak age at presentation is around 
5 years although very few cases present under the age of 12 months, some studies reporting 
no DS patients at all in this age group (Whitlock et al., 2005). In the US Children's Cancer 
Group review of the outcome of children enrolled in 12 consecutive CCG protocols between 
1983 and 1995, there were no significant differences between DS and non-DS patients in 
initial WBC count, racial or ethnic distribution, the presence of central nervous system disease 
at diagnosis, hepatomegaly, and assignment to risk groups.  Interestingly, they found that 
children with DS-ALL were more likely to have a low platelet count (P <0.001) and less 
likely to have a low haemoglobin level (P <0.006) at diagnosis. Most ALL-DS patients (90%) 
have a precursor B-cell immunophenotype (CD79a+, CD10+, CD19+), and T cell disease is 
uncommon. 
 
The prognosis of children with Down syndrome and ALL has improved since clinicians 
became convinced of the appropriateness of optimal treatment. However, although most 
children with DS-ALL are cured (60–70%) they have a poorer outcome than non-DS children 
with the difference in survival being mainly due to increased treatment-related toxicity 
(Whitlock et al., 2005; Zeller et al., 2005). Most deaths have occurred in anthracycline-
containing phases of treatment (induction and delayed intensifications) and there is a greater 
risk of induction failure and of relapse (Whitlock et al., 2005).  
 
 
1.4.2 Cytogenetic and molecular characteristics of DS-ALL 
 
The most characteristic cytogenetic abnormality in DS-ALL is an additional X chromosome 
which occurs in up to 50% of patients (Forestier et al., 2008; Pui et al., 1993).  There is also 
an increased frequency of t(8;14) and del (9p) (Forestier et al., 2008; Lo et al., 2008). As 
mentioned above, DS patients with ALL typically do not have any translocations associated 
with adverse outcome (t(9;22), t(4;11) (Forestier et al., 2008; Whitlock et al., 2005).   
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1.4.2.1 JAK2 mutations in DS-ALL 
Until recently, there were no clues to the molecular pathogenesis of ALL in DS. However, in 
the last 2 years several groups have identified mutations in JAK2 in ~20% of children with 
DS-ALL (Bercovich et al., 2008; Kearney et al., 2009), following an earlier case report of a 
single case of a small activating deletion in JAK2 in a DS child with ALL (Malinge et al., 
2007).  All the JAK2 mutations affect Arg683 and surrounding residues in the JH2 
pseudokinase domain and are distinct from the JAK2 mutations found in myeloproliferative 
disorders (V617F). In the larger study, Bercovich found that DS-ALL patients with JAK2 
mutations presented at a younger age (4.5 years) than those without JAK2 mutations (8.6 
years) perhaps implicating a fetal origin for the leukaemia, although no studies have 
demonstrated JAK2 mutations at birth. 
 
1.4.2.2 Abnormalities in CRLF2 expression in DS-ALL 
Another very important clue to the pathogenesis of DS-ALL was provided by a series of 
papers published in the last year (Hertzberg et al., 2010; Russell et al., 2009).  Russell and 
colleagues were the first to report the presence of two novel, cryptic chromosomal 
abnormalities in 5% of cases of non-DS childhood ALL and 52% of DS-ALL which caused 
deregulated expression (i.e. increased expression) of CRLF2, also known as the thymic 
stromal-derived lymphopoietin receptor (TSLPR). They also noted that increased CRLF2 
caused activation of the JAK-STAT pathway.  
 
Hertzberg et al subsequently reported aberrantly high expression of CRLF2 in an extremely 
high frequency of DS-ALL patients (62%).As in the cohort described by Lisa Russell, this 
was mostly due to IgH@ translocations or interstitial deletions but 3 novel activating 
mutations were also described (Hertzberg et al., 2010). Of note, like Russell and colleagues, 
they also found that all of the DS-ALL patients with Arg 683 JAK2 mutations had increased 
CRLF2 expression and showed in vitro cooperation between the Arg 683 JAK2 mutation and 
aberrant CRLF2 expression which conferred both a growth and survival advantage to BaF3 
cells (Hertzberg et al., 2010). Since increased CRLF2 expression blocks B cell differentiation 
(Russell et al., 2009), these recent exciting studies suggest a model for ALL pathogenesis in 
DS where T21 predisposes, for unknown reasons, to increased CRLF2 expression and that 
additional genetic changes, such as the Arg683 JAK2 mutation, may then be sufficient to 
cause ALL (Figure 1.3).  
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1.4.3 Initiation of DS-ALL in fetal life: a model for leukaemogenesis 
 
There is now a wealth of evidence to support Greaves' original hypothesis that many cases of 
childhood ALL arise as a result of mutations in fetal life although this has not yet been 
investigated in DS-ALL (Greaves, 2005). By studying a monochorionic twin pair, one 
preleukaemic and one with frank leukaemia, Hong et al recently documented the linear 
relationship between the leukaemic and preleukaemic stem cell in which the TEL-AML1 
fusion arose and suggested that TEL-AML1 functions as a first-hit mutation by endowing this 
preleukaemic cell with altered self-renewal and survival properties (Hong et al., 2008). 
Together with these data and the evidence discussed above of alterations in CRLF2 
expression in DS-ALL, there is a strong argument for investigating the fetal lymphoid 
progenitor compartment in DS for evidence of a preleukaemic lymphoid progenitor 
population.  
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Figure 1.3    DS-ALL and AMKL - multistep models of leukaemogenesis 
Three sets of genetic events are known in the pathogenesis of DS-ALL. Firstly, fetal or infant 
haematopoietic cells are trisomic for chromosome 21 (T21).  Second, acquired translocations 
or interstitial deletions lead to deregulation of CRLF2 expression (this is known to occur in 
50-60% of DS-ALL cases and it is possible that a similar functional defect, e.g. involving a 
different cytokine receptor, may be present in the remaining 40% of cases). Third, additional 
genetic or epigenetic events are likely to be required for development of ALL, such as 
Arg683JAK2 mutations. In contrast to the DS-AMKL/TMD model shown in Figure 1.2, no 
clearly preleukaemic phase has yet been identified.  
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1.5 Human fetal haematopoiesis  
 
1.5.1. Overview of fetal haematopoiesis  
In mammals, haematopoiesis begins in the yolk sac where a transient wave of primitive 
haematopoiesis occurs, predominantly devoted to erythropoiesis (Huyhn et al., 1995; Tavian 
et al., 2001). In humans this occurs at a gestational age (GA) of ~3 weeks (Godin and 
Cumano, 2005; Oberlin et al., 2002). This is followed by the onset of definitive 
haematopoiesis in the aorta-gonad mesonephros (AGM) (de Bruijn et al., 2000; Godin and 
Cumano, 2005; Medvinsky and Dzierzak, 1996) where HSC/progenitor cells have been 
isolated from 5 weeks of gestation in human embryos (Marshall et al., 1999; Tavian et al., 
1999a) (Figure 1.4). Subsequently fetal haematopoiesis is established in FL at a GA of 5-8 
weeks (Tavian et al., 1999b) and at 8-12 weeks in BM although this is not the major site of 
haematopoiesis until after birth when FL haematopoiesis ceases (Charbord et al., 1996).  
 
 
Adapted from Tavian M et al:.Int J Dev Biol. 2005;49(2-3):243-50 
Figure 1.4  Chronology of appearance of HSC in the human embryo and fetus 
 
 
1.5.2 Definition and properties of fetal HSC 
 
Fetal HSC, like adult HSC, are defined on the basis of three key properties: (1) multipotency, 
(2) long-term self-renewal; and (3) long-term haematopoietic reconstitution in vivo of 
myeloablated recipients. In vitro haematopoietic progenitor assays, immunophenotyping and 
transplantation of haematopoietic sub-populations have given rise to a generally accepted 
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model of human haematopoiesis (Kondo et al., 2003) in which HSC differentiate into 
multipotent progenitors committed either to the lymphoid lineage, Common Lymphoid 
Progenitor (CLP) or to the myeloid lineage, Common Myeloid Progenitors (CMP) (Figure 
1.5).  
 
CLP have the potential, depending on the environment, to become B lymphocytes, T 
lymphocytes or NK cells but not granulocytes, monocytes, erythrocytes or megakaryocytes 
both in humans (Galy et al., 1995; Hao et al., 2001) and in mice (Kondo et al., 1997). CMP 
may differentiate into Granulocyte-Macrophage Progenitors (GMP) which can give rise to 
neutrophils, eosinophils, basophils, mast cells or monocytes/macrophages but not 
lymphocytes, erythrocytes or megakaryocytes (Akashi et al., 2000; Manz et al., 2002). 
Alternatively, CMP may give rise to MEP which are committed solely to the megakaryocyte 
and erythroid lineages (Figure 1.5). 
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Figure 1.5   Human haematopoietic differentiation Schematic representation of the 
accepted model of adult human haematopoiesis 
 
 
 
 
Key:  
HSC, haematopoietic stem cell; MPP, multipotent progenitor; CMP, common myeloid progenitor 
MEP, megakaryocyte erythroid progenitor; GMP, granulocyte macrophage progenitor; CLP, 
common lymphoid progenitor 
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1.5.3 Fetal myeloid and lymphoid primed multipotent progenitor cells 
 
Recent evidence suggests that the “classical” hierarchy diagram shown in Figure 1.5 may be 
overly simplified. Several investigators have found evidence in murine BM of an early 
multipotent progenitor (MPP) downstream of HSC, which sits at the lineage branching step 
between myeloid and lymphoid commitment but which, unlike HSC, does not have long-term 
self-renewal capacity (Christensen and Weissman, 2001; Guenechea et al., 2001; Mazurier et 
al., 2004; McKenzie et al., 2006). MPP have also been described in the CD34+CD38-/lo 
compartment of human BM where they are distinguishable from HSC immunophenotypically 
on the basis of their CD90 expression (Majeti et al., 2007).  
 
Other investigators have recently suggested that MPP are the antecedents of CMP and CLP 
and that in some circumstances MPP may give rise to a lymphoid-primed MPP (LMPP) 
which rather than having solely lymphoid-generating capacity, has combined 
granulocyte/macrophage and B/T lymphoid potentials, with little or no megakaryocyte/ 
erythroid potential (Figure 1.6a) (Adolfsson et al., 2005; Lai and Kondo, 2006; Mansson et 
al., 2007; Yoshida et al., 2006). LMPP have been identified in murine adult BM and very 
recent data suggest that LMPP are also present in human adult BM (Goardon, 2010).   
 
A slightly different differentiation hierarchy has been proposed for fetal cells based on data 
from murine FL which suggest the existence of progenitors with combined 
granulocyte/macrophage and B cell (MB) and those with combined granulocyte/ macrophage 
and T cell potential (MT) (Figure 1.6b) (Buza-Vidas et al., 2007; Katsura, 2002; Kawamoto et 
al., 2000; Kawamoto et al., 1998; Lu et al., 2002; Luc et al., 2007); however, there are 
currently no data indicating whether MPP, LMPP, MB or MT progenitors exist in human fetal 
life. 
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Figure 1.6   Alternative pathways of haematopoietic differentiation in the mouse 
 
 
 
 
 
 
 
  (Adapted from Buza-Vidas et al 2007; Curr Opin Hematol 14:315–321) 
 
Schematic representation of proposed alternative models of adult bone marrow and fetal liver 
haematopoiesis in the mouse 
 
Key: HSC, haematopoietic stem cell; LT, long term; ST, short term; MPP’ multipotent progenitor; 
LMPP, lymphoid-primed mutipotent progenitor; CMLP, common myelo-lymphoid progenitor; CMP, 
common myeloid progenitor; CLP, common lymphoid progenitor; MEP, megakaryocyte/erythroid 
progenitor; GMP, granulocyte/macrophage progenitor; MT, myeloid and T cells; MB, myeloid and B 
cells; p-B, B progenitor; p-T, T progenitor 
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1.5.4  Fetal lymphopoiesis 
 
1.5.4.1 Overview of fetal lymphopoiesis 
The main site of fetal lymphopoiesis in mice and humans is the BM, although AGM-derived 
cells are able to give rise to B and T lymphocytes and NK cells (mouse) and B and NK cells 
(human) at least in vitro (Oberlin et al., 2002; Tavian et al., 2001). In the mouse, the main site 
of B lymphopoiesis is the BM whereas T lymphopoiesis occurs in the thymus.  Understanding 
normal fetal lymphopoiesis has been made more difficult by the use of different purification 
and immunophenotyping strategies by different groups as well as the controversy surrounding 
the alternative routes of lymphoid progenitor differentiation (Bunting, 2009). In the traditional 
model (Figure 1.5) CLP are viewed as the only progenitors able to give rise to T and B 
progenitors (Kondo et al., 1997), whereas in the alternative model T and B progenitors may 
also arise from MPP and LMPP (Figure 1.6) (Bell and Bhandoola, 2008; Benz et al., 2008; 
Bhandoola et al., 2007; Boehm and Bleul, 2006; Pelayo et al., 2005; Wada et al., 2008).  
Since the distinction may be important for interpreting differences in fetal lymphopoiesis 
relevant to the pathogenesis of DS-ALL, the different definitions of lymphoid progenitor 
identification are considered below. 
 
1.5.4.2  Common/early lymphoid progenitors  
CLP were originally defined as a CD34+/CD38-/lo/Lin-/IL7R+/CD90-/Sca1lo/c-kitlo 
population; this population was found in mouse BM and was shown to give rise to T 
progenitors, B progenitors and NK cells (Kondo et al., 1997). Very recently, Weissman's 
group used rigorous cell sorting and in vitro assays and transplantation to confirm that CLP 
are the major source of T cell progenitors in mouse BM, rather than MPP/LMPP (Serwold et 
al., 2009). In this study Flk2 positivity was added to more reliably distinguish CLP 
(IL7R+/Flk2+/Sca1lo/c-kitlo) from MPP (IL7R-/Flk2-/Sca1hi/c-kithi).  
 
Cells with the same differentiation ability have also been described in human adult BM, fetal 
BM and cord blood although the immunophenotypic profiles used by different investigators to 
define CLP were different: Galy et al defined CLP in human adult and fetal BM as CD34+lin-
CD38+CD10+ (Galy et al., 1995) while Hao and Hoebeke used the definition CD34+CD38-
CD7+ for CLP in human cord blood (Hao et al., 2001; Hoebeke et al., 2007).  
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There is no definitive evidence of a true CLP with pure lymphoid potential in either mouse or 
human FL. Progenitors with various potentials, including M/E/T/B, M/E, M/T/B, M/T, and 
M/B, (M: myeloid; E: erythroid; T: T cell; B: B cell) as well as monopotent progenitors have 
been described in mouse FL (Katsura, 2002; Kawamoto et al., 2000; Kawamoto et al., 1998; 
Lu et al., 2002). However, CLP with purely T/B/ NK cell differentiation capacity were never 
found, even when the immunophenotypic fraction corresponding to mouse BM CLP was 
examined.(Mebius et al., 2001) 
 
1.5.4.3  B lymphopoiesis 
B lymphopoiesis in human fetuses is poorly understood with many gaps in knowledge 
compared to fetal and adult mice and adult human BM.  A summary of current understanding 
of normal human B cell differentiation in adult BM (based on detailed immunophenotyping, 
gene expression and xenograft models) is shown in Figure 1.7. 
 
 
 
Figure 1.7 Normal human B lymphoid differentiation in adult bone marrow (BM) 
 
 
 
 
 
 
 
 
 
(Modified from Davi et al; Blood: 90: 4014-2, 1997 and Ryan et al: Blood: 89: 929-40), 1997 
  
Key: CLP, common lymphoid progenitor; ELP, early lymphoid progenitor; EBP, early B progenitor 
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B lymphopoiesis in human fetal BM 
Several of the same B cell progenitors have also been reported in human fetal BM.  Early B 
progenitors (EBP), defined as CD34+CD127+CD10-CD19-, and more committed B 
progenitors (CBP), defined as CD34+CD10+CD19+/- have been reported in human fetal BM 
from the second trimester (Reynaud et al., 2003; Ryan et al., 1997; Uckun, 1990; Uckun and 
Ledbetter, 1988). There are very few data however and the time course of the establishment of 
B lymphopoiesis in fetal BM is unclear (Bofill et al., 1985; Dorshkind and Montecino-
Rodriguez, 2007; Hofman et al., 1984).  
 
B lymphopoiesis in human fetal liver 
There is even less information about B lymphopoiesis in human FL. Cytoplasmic IgM+ pre-B 
cells have been detected at ~8 weeks of gestation and sIgM+ B cells at 10-12 weeks gestation 
but it is not clear whether these cells are actually generated within the FL or may travel there 
via the circulation from other sites such as the AGM. CD10+ B lymphocyte progenitors, most 
of which were CD19- and therefore probably corresponding to CBP have also been reported 
in one study in human FL (Uckun, 1990). 
 
 
1.5.4.4  T lymphopoiesis 
 
During human fetal development, thymic T-cell differentiation is initiated at 7 - 9 weeks 
gestation, when the first waves of T-cell progenitors start to populate the thymus.  The earliest 
T cell progenitor committed to the T lineage is the ETP (early T progenitor) which recent 
murine data suggest arises directly from CLP (Serwold et al., 2009). These data also suggest 
that the CLP which seed the thymus derive from MPP which reside in other sites of 
haematopoiesis, presumably fetal BM or FL.  In humans there is very little haematopoiesis 
apparent in fetal BM at 7-9 weeks gestation when thymic T cell development begins, strongly 
suggesting that the MPP and CLP from which first trimester thymic progenitors derive 
originate in the FL.  
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1.6 Hypotheses and aims 
 
 
1.6.1 To investigate the hypothesis that abnormalities in the myeloid progenitor 
populations in DS fetal liver originate from perturbation of the MPP and/or HSC 
compartment by: 
  
i. characterising the HSC/MPP compartment in normal second trimester FL and determining 
whether LMPP were also present; and 
ii. determining whether there were any changes in the HSC/MPP compartment in DS FL 
compared to normal FL. 
 
 
1.6.2 To investigate the hypothesis that T21 causes abnormal lymphoid progenitor 
commitment and/or development in second trimester fetal liver and fetal BM by: 
 
i. characterising lymphoid progenitors, particularly B progenitors, in normal second trimester 
FL and determining whether CLP were also present;  
ii. determining whether there were any changes in the B progenitor compartment in DS FL 
compared to normal FL; and  
iii. determining whether there were any changes in the B progenitor compartment in fetal BM 
in DS. 
 
 
1.6.3 To further investigate the hypothesis that T21 perturbs the myeloid progenitor 
compartment in second trimester fetal liver and bone marrow and in cord blood by 
 
i. characterising the myeloid progenitor compartment in normal and DS second trimester FL 
and fetal BM; and  
ii. secondly, by carrying out a preliminary characterisation of DS cord blood myeloid 
progenitors and HSC/MPP.  
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2.1 Sample collection and processing 
 
2.1.1 Samples, ethics and consent 
 
Three main sources of samples have been used. 
(i) Fetal T21 samples were collected from elective second trimester (12-22 weeks gestational 
age) surgical terminations after identification of a T21 pregnancy by antenatal ultrasound and 
serum screening followed by cytogenetic analysis. Karyotyping performed on samples 
obtained by chorionic villus sampling or amniocentesis was carried out in all cases to confirm 
the presence of trisomy 21. Gestational age of the fetus was determined by crown rump length 
by ultrasound. (n = 9, median gestational age: 16 weeks; range 14- 19 weeks)  
 
(ii) Normal fetal tissue was collected from fetuses without T21 undergoing surgical 
termination usually for social reasons. All pregnant women undergoing termination had had at 
least one routine antenatal ultrasound scan and no structural anomalies were detected in the 
fetuses. FISH was used to confirm the lack of T21 in all samples at the Imperial College NHS 
Trust diagnostic cytogenetic laboratory. (n = 20; median gestational age: 17 weeks, range 15- 
22 weeks). 
 
(iii) Cord blood was aspirated from the umbilical vein as soon as possible after the umbilical 
cord was cut, usually after elective caesarean section, using 21G needles and immediately 
transferred to a 50ml Falcon (Becton-Dickinson, UK) containing preservative-free heparin 
(PFH) at a concentration of 10-50 IU/ml (CP Pharmaceuticals, UK). 
 
Prior to commencement of the project, all sampling, consent and experimental procedures 
were approved by the Hammersmith, Queen Charlotte’s & Chelsea and Acton Hospitals 
Ethics Committee, reference 04/Q0406/145. All pregnant women gave specific written 
informed consent for the collection and use of the fetal tissue. All samples were anonymised 
on receipt and assigned a study number. 
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2.1.2 Sample processing 
Fetal tissues were transported to the laboratory at 4°C. To obtain fetal BM, long bones were 
repeatedly cannulised with a 23G needle and flushed with Dulbecco's modification of 
Essential Medium (DMEM; Invitrogen, Paisley, UK). FL was identified macroscopically and 
rinsed twice with phosphate buffered saline (PBS) (Invitrogen, Paisley, UK). A small section 
of the liver tissue, (approximately 0.5cm2) was obtained by section with a scalpel and 
cryopreserved for future histopathology at -80°C. The rest of the liver tissue was passed 
through a 40μm cell filter (Becton-Dickinson, Oxford, UK) using the blunt end of a plastic 
syringe plunger as a pestle into a 50 ml Falcon to get a single-cell suspension.  The 
dissociation of the liver was continued until the majority of the red pulp had been recovered 
leaving behind a white-coloured tissue (biliary tree, ligament, etc). The single cell suspension 
was washed with PBS and centrifuged at 1600rpm for 10 minutes. The supernatant was 
discarded and the pellet re-suspended in PBS containing 2% Fetal Bovine Serum (FBS; 
Invitrogen, Paisley, UK) and 1mM EDTA (Sigma, Poole, UK).  
 
Cord blood and fetal samples were red cell and granulocyte depleted by density gradient 
separation. Samples were diluted 1:2 with PBS (Invitrogen, Paisley, UK) containing 2% FBS 
(Invitrogen Paisley, UK) and 1mM EDTA (Sigma, Poole, UK). The sample was then layered 
onto 1/3 volume 1.077 Lymphoprep (Axis Shields Diagnostics, Cambridgeshire, UK) and 
centrifuged at 1800rpm for 30 minutes. The interface layer of mononuclear cells (MNC) was 
collected and washed twice before further processing. 
 
 
2.2 Selection of CD34+ cells 
 
CD34 positive selection was carried out using magnetic columns as per the manufacturer's 
instructions.  Briefly, samples were suspended in Robosep buffer (Stem Cell Technologies, 
Vancouver, Canada) at 2 x108 MNC/ml and incubated with the StemSep CD34 positive 
selection antibody cocktail (Stem Cell Technologies, Vancouver, Canada) for 10 minutes at 
4°C. Magnetic colloid (Stem Cell Technologies, Vancouver, Canada) was then added and the 
sample was incubated for a further 10 minutes at 4°C before washing and sequentially passing 
through 2 MS positive selection columns (Miltenyi Biotec, Surrey, UK). The typical yield 
was >95% CD34+ cells (Figure 2.1) 
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              A) Pre enrichment                   B) Post enrichment 
            
 
Figure 2.1 CD34 enrichment by positive selection  
Representative FACS plots of cord blood MNC before (A) and after (B) enrichment for CD34 
cells by positive selection with MACS columns. In this example, CD34 cells comprised 2.9% 
of CB MNC (A) which increased to >99% post enrichment (B) 
 
2.3 Flow cytometric analysis and sorting 
2.3.1 Staining: Cells were stained using PBS/FBS 2% as a staining and washing buffer. 
After washing, cells were incubated with the fluorophore-conjugated monoclonal antibody 
(mAb) for 20-30 minutes at 4°C. They were then washed and re-suspended in 200-500μl 
buffer for analysis or cell sorting. The antibodies used for my studies are shown in Appendix 
1. 
 
2.3.2 Flow cytometric analysis: Samples were analysed using a dual-laser FACSCalibur 
(Beckton-Dickinson, Oxford, UK) or a FACSAria (Beckton Dickinson, Oxford, UK). For 
each sample stained with antigen-specific mAb, an isotypic control conjugated with the 
appropriate fluorophore was used. Compensation settings for 4-8 colour analysis were set 
using single or double-stained samples.  
 
2.3.3 Flow cytometric sorting 
Samples were sorted on FACSDiva or FACSAria (Beckton Dickinson, Oxford, UK) 
machines. As above, appropriate isotype controls and single-stained samples were used to set 
amplification and compensation.   
 
2.3.4 Analysis of flow cytometry data 
Data were analysed on FloJo software (Tree Star, Oregon, USA). Gating strategies are as 
described in the results. In all cases this involved an initial gate on viable cells. 
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2.4 Clonogenic assays 
 
2.4.1 Methocult medium and cytokines 
Methylcellulose haematopoietic progenitor assays were performed using Methocult H4230 
(Stem Cell Technologies, Vancouver, Canada) with a customised cytokine cocktail. 
Methocult H4230 consists of:  
• 40ml 2.6% Methylcellulose in Iscove’s Modification of Dulbecco’s Medium (IMDM)  
• 30ml FBS  
• 10ml 10% Bovine Serum Albumin (BSA)  
• 0.1ml 0.1M β-Mercaptoethanol  
• 1ml 200mM L-glutamine  
 
The cytokine cocktail used was a poly-potent cocktail taken from Manz et al's paper on CMP 
and MEP isolation (Manz et al., 2002). The cytokines and concentrations are given below. All 
cytokines were from Peprotech (Peprotech Inc, Rocky Hill, NJ, USA) except erythropoietin 
(EPO) which was from R&D (R&D Systems Europe, Abingdon, UK). 
 
Cytokine cocktail (from Manz et al 2002) 
    Conc ng/ml 
• IL-3     20 
• IL-6     10 
• IL-11    10 
• SCF     10 
• Flt3 Ligand    10 
• GMCSF    50 
• TPO     50 
• EPO     4 U/ml 
 
Cytokines, penicillin/ streptomycin and IMDM (Stem Cell Technologies, Vancouver, Canada) 
were added to 8ml Methocult H4230 to make up to a final volume of 10ml. 1.3ml aliquots of 
this 1% methylcellulose mix were then transferred to 1.5ml Eppendorf tubes via a blunt end 
needle and syringe. Cells were suspended at 11x final concentration (usually 2200 cells/ml). 
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130μl of the cell suspension was then added to Eppendorf tubes containing the Methocult 
media, vortexed and allowed to settle for at least 5 minutes. 
 
 
2.4.2 Plating, counting and colony identification 
1ml of the above cell suspension in Methocult was syringed into a 35mm petri plate (Stem 
Cell Technologies, Vancouver, Canada) and placed into a 100mm petri dish with 2 other 
35mm plates containing sterile PBS. They were then placed in an incubator at 37°C, 100% 
humidity and 5% CO2. Samples were plated in duplicate when cell numbers permitted. 
Smaller samples, especially sorted progenitor populations, were suspended in Methocult as 
above or sorted directly into Eppendorfs containing 500μl of Methocult medium and 
aliquoted into a flat bottomed 24-well plate (Beckton Dickinson, Oxford, UK) in 500μl 
aliquots/ well. Unused wells were filled with PBS. Colonies were identified on the basis of 
cell numbers, cell size, haemoglobinisation and morphology of the colony and individual 
cells. Colonies were counted at 7, 10 and 14 days depending on the maturity of the colonies. I 
checked technique and results by using Stem Cell Technology’s Progenitor Assay Proficiency 
Testing Scheme –results were consistent with those described. 
 
 
2.4.3 Colony assay of specific progenitors 
To establish clonogenicity and test sorting efficiency, I plated sorted myeloid progenitors 
(CMP, MEP and GMP) from normal second trimester FL in methylcellulose culture medium.  
Myeloid progenitors were defined as: CMP: CD34+CD38+CD19-CD2-CD45RA-CD123lo; 
MEP: CD34+CD38+CD19-CD2-CD45RA-CD123-; GMP: CD34+CD38+CD19-CD2-
CD45RA+CD123+. Other sorted progenitor populations plated included HSC: CD34+CD38-
CD90+CD45RA-; MPP: CD34+CD38-CD90-CD45RA-; LMPP: CD34+CD38-CD45RA+ 
 
 
2.5 Liquid culture lymphoid progenitor assays 
 
2.5.1 OP9 stromal co-culture system 
In order to establish whether T and B cells could be generated from FL CD34+ sub-
populations, I set up stromal cell-dependant lymphoid culture systems using OP9 stromal cells 
with and without Delta ligand (DL). OP9 cells are a murine stromal cell line. Since M-CSF is 
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thought to be responsible for the preferential differentiation of stem cells into the monocyte-
macrophage lineage, this cell line was established from calvaria of newborn (C57BL/6XC3H) 
F2-op/op mice which lack functional M-CSF because of a mutation in the M-CSF gene. 
(Nakano et al., 1994). OP9-DL stromal cells were used for T lymphoid differentiation  and 
OP9 control cells that do not express DL (OP9-GFP) were used for B lymphoid differentiation 
(Awong et al., 2008; La Motte-Mohs et al., 2005). OP9-DL cells are stromal cells that have 
been modified to ectopically express high levels of the notch receptor ligand Delta like 1 
(DL1) by retroviral-mediated gene transfer with a Delta-like-1-expression construct (Dll-
1:T7-IRES-GFP). These cells were found to successfully support T cell differentiation up to at 
least the double positive (DP) stage. (Schmitt and Zuniga-Pflucker, 2002). OP9-GFP and 
OP9-DL cells were a kind gift from Prof Adrian Thrasher (Institute of Child Health, 
University College, London). The ability of HSC, MPP, LMPP and more mature progenitor 
populations to mature into T and B lymphocytes was studied and is described in more detail in 
chapter 3 and 4.  
 
Maintenance of OP9 cells 
Preparation of OP9 medium: OP9 medium was prepared by supplementing alphaMEM 
medium (Invitrogen, Paisely, UK) with co culture-characterised FBS (20%) (Lonza, UK), L/ 
glutamine (Invitrogen, Paisely, UK), HEPES (1%), sodium pyruvate (1%) (Stem Cell 
Technologies, Vancouver, Canada), 2 mercaptoethanol (50 micromolar), penicillin (50U/mL) 
and streptomycin (50g/mL). (Invitrogen, Paisely, UK)  
 
Maintenance of OP9 cells: OP9 cells were thawed at 37°C and then transferred to a tube 
containing 5ml of OP9 media. The cells were spun down at 1000 rpm for 5 minutes and the 
pellet resuspended in 3ml of OP9 media and transferred to a 25cm2 flask containing 5ml of 
OP9 medium. Once a confluent plate was achieved, usually after 2-3 days of growth, the OP9 
cells were typically passaged every 2 days at 1:3 ratio, depending on growth rate and cell 
density at the time of passage. Therefore the cells had to be carefully observed under an 
inverted microscope before they were passaged.  
To passage OP9 cells at 80% confluency from a 25cm2 plate, the medium was removed and 
then 10 mL PBS added to wash off any remaining medium. After removing the PBS, the cells 
were incubated with 0.5 mL of 0.5% trypsin/EDTA (Invitrogen, Paisely, UK) for 5 min at 
37°C. Following trypsinisation, the flask was tapped to dislodge the cells, medium added and 
the cells vigorously pipetted to remove them from the surface of the flask. The cells were then 
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washed and resuspended in OP9 medium. The cells were then divided among 25cm2 flasks 
(one third of total cells) and/or 24-well plates (Beckton Dickinson, Oxford, UK ) (20,000 
cells/ well). The flask/ plate were gently rocked back and forth for even distribution.  
 
Initiation and maintenance of co-cultures:  
Stromal layers were prepared in 24 well plates (as above), 24-48 hours before sorted cells 
were plated. Before sort/plating, the wells were inspected under an inverted microscope and 
the confluency recorded.  
100-500 cells from the sorted CD34+ populations were seeded onto an 80% confluent well in 
OP9 medium supplemented with 5 ng/mL human IL-7 and 5 ng/mL human Flt3L. (Peprotech, 
Rocky Hill, NJ). Recombinant Flt-3L and IL-7 were added at initiation of co-culture and 
every 4-5 days during replating. Co-cultures were disaggregated by vigorous pipetting and 
passaged through a 70-µm filter to reduce stromal cell line aggregates and eliminate 
contaminating OP9 before re-plating on fresh OP9 stromal cells every 4-5 days. FACS 
analysis was done to check for lymphoid differentiation from day 6 onwards. Cultures were 
terminated on Day 21 for OP9-GFP and Day 35 for OP9-DL.  
 
 
   Add sorted HSC/ progenitors 
 
    Day -2  Day 0      Day 4 onwards   Day 21 
        (serial replating)   (readout) 
 
Figure 2.2 Schematic representation of OP9 co culture system 
 
The OP9-GFP system proved suboptimal in assessing B lymphoid differentiation and 
therefore I set up an alternative stromal cell dependant culture system using MS5 stromal cells 
(Doulatov et al., 2010; Kouro et al., 2005).  
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2.5.2 MS5 stromal co-culture system 
MS5 cells are a cloned murine bone marrow stromal cell line established after irradiation of 
the adherent cells in long-term BMC (bone marrow culture) (Itoh et al., 1989). MS5 stromal 
cells were a kind gift from Dr Paresh Vyas, University of Oxford, Oxford. The ability of HSC, 
MPP, LMPP and more mature progenitor populations to mature into B lymphocytes was 
studied and is described in more detail in chapters 3 and 4.  
 
Maintenance of MS5 cells 
Preparation of MS5 medium: MS5 medium was prepared by supplementing alphaMEM 
medium with co culture-characterised FBS (10%), L/ glutamine, HEPES (1%), sodium 
pyruvate (1%), 2 mercaptoethanol (50 micromolar), penicillin (50U/mL) and streptomycin 
(50g/mL). 
 
Maintenance of MS5 cells: MS5 cells were thawed at 37°C and then transferred to a tube 
containing 5ml of MS5 medium. The cells were spun down at 1000 rpm for 5 minutes and the 
pellet resuspended in 3ml of MS5 medium (as above) and transferred to a 25cm2 flask 
containing 5ml of MS5 medium. Once a confluent plate was achieved, usually 2-3 days of 
growth, the MS5 cells were typically passaged every 3 days at 1:3 ratio depending on growth 
rate and cell density at the time of passage. Therefore the cells were carefully observed under 
an inverted microscope before they were passaged.  
 
To passage MS5 cells at 80% confluency from a 25cm2 plate, the medium was removed and 
then 10 mL PBS added to wash off any remaining medium. After removing the PBS, the cells 
were incubated with 0.5 mL of 0.5% trypsin/EDTA (Invitrogen, Paisely, UK) for 5 min at 
37°C. Following trypsinisation, the flask was tapped to dislodge the cells, medium added and 
the cells vigorously pipetted to remove them from the surface of the flask. The cells were then 
washed and resuspended in MS5 medium. The cells were then divided among 25cm2 flasks 
(one third of total cells) and/or 96 well plates (3000 cells/well) or 24-well plates (20,000 cells/ 
well). (Beckton Dickinson, Oxford, UK ). The flask/ plates were gently rocked back and forth 
for even distribution.  
 
Initiation and maintenance of co-cultures:  
Stromal layers were prepared in 96 or 24 well plates (as above), 24-48 hours before sorted 
cells were plated. Before sort/plating, the wells were inspected under an inverted microscope 
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and the confluency recorded. 100-500 cells from the sorted CD34+ populations were seeded 
onto an 80% confluent well in MS5 medium supplemented with recombinant human Flt-3L 
(10ng/mL), SCF (20ng/ml), interleukin-2 (IL2) (10ng/ml), interleukin-7 (IL-7) (5ng/mL), 
GM-CSF (20ng/ml) and G-CSF (10ng/ml) (Peprotech, Rocky Hill, NJ). The cytokines were 
added at initiation of co-culture and every 4-5 days during replating. Each well was examined 
under an inverted microscope regularly to detect the proliferation of the plated human 
haematopoietic cells (Figure 2.3). Co-cultures were disaggregated by vigorous pipetting and 
passaged through a 70-µm filter to reduce stromal cell line aggregates and eliminate 
contaminating MS5 before re-plating on fresh MS5 stromal cells every 4-5 days for the wells 
containing mature progenitors. FACS analysis was done to check for lymphoid and myeloid 
differentiation from day 6 onwards. Wells containing HSC, MPP and LMPP were subjected to 
half medium change twice a week, but were not disaggregated or replated. They were 
harvested on Day14/ Day21 for FACS analysis. All MS5 co cultures were terminated by Day 
21. 
  x 4       x 10 
   
 
Figure 2.3 Proliferating human haematopoietic cells in MS5 stromal co culture system 
Appearance of proliferating human haematopoietic cells after 10 days of co-culture of FL 
HSC on MS5 stromal cells in alphaMEM supplemented with Flt-3L, SCF, IL-2, IL-7, GM-
CSF and G-CSF in a 96 well plate. 
 
Measuring absolute cell numbers in the lymphoid co culture systems 
In order to compare the efficiency of  production of differentiated B/ T/ NK and myeloid cells 
from different progenitors populations, I determined the absolute numbers of these cell types 
produced at the time points when cells were harvested from the MS5 and OP9-DL1 co 
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cultures for FACS analysis. This was done by using CountBright™ Absolute Counting Beads 
(Invitrogen, Paisley, UK) as per the manufacturer’s instructions.  
 
 
2.6 Cytospins 
 
Cytospins on cultured fetal cells were carried out using a Shandon Cytospin 2 (Fisher 
Scientific, Loughborough, UK). 104 cells were suspended in 100μl Robosep buffer (Stem Cell 
Technologies, Vancouver, Canada) and spun for 5 minutes at 300rpm. Cytospins and blood 
films were stained using a May-Grunwald Giemsa Stain (MGG) as follows. A working 
solution of May-Grunwald stain was made by diluting May-Grunwald Eosin Stain (Sigma) 
1:1 with pH 6.8 buffered distilled water. A working solution of Giemsa was prepared by 
diluting Giemsa Stain (Sigma) 1:10 with pH 6.8 buffered distilled water. Slides were fixed by 
incubating in methanol (Sigma) for 5 minutes. They were then stained in May-Grunwald for 
2.5 minutes, Giemsa for 2.5 minutes, Giemsa again for 2.5 minutes, then placed in pH 6.8 
buffered water for 2.5 minutes before being washed under the cold water tap for 30 seconds 
and left to dry. 
 
2.7 Gene expression assays 
 
2.7.1 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)  
2.7.1.1 RNA Extraction: Primary cells were initially suspended in RLT plus lysis buffer 
(Qiagen, Crawley, UK) or Trizol to preserve RNA prior to extraction and stored at -80°C. 
Sorted CD34 subpopulations were directly sorted into RLT plus lysis buffer, spun down and 
stored as above. When ready for RNA extraction, the RNA extraction was carried out with 
Qiagen RNeasy kits (Qiagen RNeasy micro plus kit was used for small number of cells), 
following the manufacturer’s protocol. For larger samples, spectroscopic photometry was 
carried out to estimate RNA concentrations. Smaller samples went straight to cDNA 
synthesis. All RNA was stored at -80°C. 
 
 
2.7.1.2 First strand cDNA synthesis: Directly after RNA extraction a 40μl reverse 
transcriptase reaction was performed using OligoDT (Invitrogen, Paisely, UK) and 
SuperScript III reverse transcriptase (Superscript III First Strand Synthesis System for RT-
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PCR, Invitrogen, Paisely, UK) following the manufacturer’s protocol. All cDNA samples 
were subjected to PCR to detect a 353 base pair (bp) fragment of human -actin as a positive 
control for cDNA integrity using the primers: sense 5’-GCTCG TCGTC GACAA CGGCT C-
3’ and antisense 5’-CAAAC ATGAT CTGGG TCATC TTCTC-3’ under the following 
conditions: 94°C for 15 seconds, 55°C for 30 sec, 68-72°C for 1 minute for 40 cycles.  
 
2.7.1.3 RT-PCR for gene expression: cDNA synthesis samples were stored at -20°C for 
active use or -80°C for longer-term storage. When needed cDNA samples were used with 
cDNA specific primers to amplify genes of interest.  
A basic PCR recipe was used in all cases; amounts given are in μl unless stated otherwise and 
are for a 40μl reaction. Smaller reactions were scaled down proportionately: 
 
10x PCR Buffer (Invitrogen)       4 
Forward Primer (10μM)      2 
Reverse Primer (10μM)      2 
dNTPs (dATP, dCTP, dGTP, dTTP) (10μM) (Invitrogen)  1.2 
MgCl2 (Invitrogen)       1.6 
cDNA         2 
Taq (Invitrogen)       0.2 
dH2O        to 40 μl 
The first round of amplification was for 35 cycles. A second round of amplification (20 
cycles) was performed using 1 μl of the PCR product from the first round and nested primers. 
cDNA specific primer sequences, including nested primers, are provided in Appendix 2. All 
primers used are from Sigma-Aldrich (Haverhill, England) unless stated otherwise and were 
designed using the online primer design site (Integrated DNA technologies). 
 
RT-PCR product was visualised on 2% agarose (Sigma-Aldrich, Haverhill, England) gel 
using SYBR Safe DNA gel stain (Invitrogen, Paisely, UK). A 100bp ladder (Invitrogen) was 
used to assess amplicon size. Gels were run at 75-100V for 30-90 minutes. 
 
 
2.7.2 Fluidigm real time PCR 
In order to quantify gene expression of selected genes in very small cell numbers (10- 50 
cells), especially transcription factors, in specific CD34 subpopulations, I used the BioMark 
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Real time PCR (qPCR) system (Fluidigm Corporation, California, USA). This work was done 
in collaboration with Dr Adam Mead, Weatherall Institute of Molecular Medicine, University 
of Oxford, Oxford. 
The BioMark™ Dynamic Arrays maximises efficiency for gene-expression analysis using 
real-time qPCR. The 48x48 Dynamic Array enables one to test 48 samples against 48 genes. 
The advantage of this system is that it saves on reagents, and time, as it uses very small 
amounts of fluids for the reaction. Each 48.48 Dynamic Array is capable of producing 2304 
real-time qPCR data points in the same amount of time as a single 384-well plate, while using 
just 1/200th the amount of reagents. It is especially useful for performing multiplex qPCR on 
very small numbers of cells.  
 
Preparing the Taqman assay mix: The 0.2 x Taqman assay mix was prepared by pooling up 
to 70 Taqman Gene Expression Assays (Applied Biosystems, Warrington, UK) and then 
diluting with TE buffer (Ambion, Huntingdon, UK) so that each assay was at a final 
concentration of 0.2x as shown below. This is the 0.2x Assay Mix  
Volume     µL 
Assay 1 (x20)     1 
Assay 2 (x20)     1 
     
 
Assay 100 (x20)    1 
TE (Ambion, ABI, UK) 0-99 
Total     100 
 
Preparing the RT-Specific Target Amplification (STA) mix: The RT-STA mix was 
prepared by combining the following reagents to make up a final volume of 10µL 
 
Volume           µL 
CellsDirect 2x Reaction Mix (CellsDirect™ One-Step qRT-PCR kit, Invitrogen)  5 
SUPERase12-In (Ambion, ABI, UK)        0.1 
TE Buffer (Ambion, ABI, UK)        1.2 
0.2x Assay mix (see above)         2.5 
RT/Taq Mix (CellsDirect™ One-Step qRT-PCR kit, Invitrogen)    1.2 
Total            10 
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Cell sorting and pre amplification of cDNA: Fifty cells from each FL CD34 subpopulation 
of interest were sorted directly into a 200 µL PCR tube containing 10 µL of RT-STA mix. 
Each population was done in triplicate. 
Immediately after sorting the samples were vortexed, spun down and transferred to a thermal 
cycler (Thermo-Hybaid PX2, Fisher Scientific) for one step RNA and cDNA synthesis and 
amplification using the following thermal conditions: 
 
Reverse transcription      500C for 15 minutes 
Inactivation of RTase/activation of Taq enzyme  950C for 2 minutes 
Specific target amplification     950C for 15 seconds    x 22 cycles 
        600C for 4 minutes       
 
The amplified reaction mix product was diluted with 40 µL of TE buffer and the pre amplified 
gene specific cDNA was stored at -800C for future use. 
 
48x48 dynamic array: The 48 samples, premixed with master mix, were pipetted into 
separate sample inlets and primer-probe sets into separate primer-probe inlets on the frame of 
the chip (Figure 2.4a). The chip was then placed on the integrated fluidic circuit controller to 
pressure load 48 samples and 48 primer-probe sets into dynamic array reaction chambers 
(Figure 2.4b) as per the manufacturer’s instructions. Subsequently, the dynamic array was 
placed on the BioMark qPCR system for thermal cycling and real time fluorescence detection 
(Figure 2.4c). The generated data (for 2304 PCR reactions) were analysed by BioMark Real-
time PCR Analysis software. (Figure 2.5) 
 
a)           b)                  c) 
   
Figure 2.4 BioMark 48x48 dynamic array and qPCR system  
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Figure 2.5  BioMark Real-time PCR analysis software: Heat map generated for ct values 
for individual PCR reactions: representative figure from one of 3 normal FL fluidigm 
experiments described in chapters 3, 4 and 5 . 
 
 
 
2.8 PCR 
 
2.8.1 DNA extraction 
DNA extraction was performed using QiAmp DNA Mini Kit (Qiagen, Crawley, UK) as per 
the manufacturer’s instructions. In brief, the cells were lysed; then the sample was transferred 
to a spin column where the DNA was adsorbed onto a silica membrane. This was followed by 
serial washings to remove impurities before elution and quantification. Up to 5 x 106 cells 
were used. 
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2.8.2.  Polymerase Chain Reaction (PCR)  
PCR was used for the amplification of target genomic DNA. Great care was taken to strictly 
segregate all PCR products from DNA, cDNA, RNA samples etc as well as all reagents. This 
was done by complete physical separation of pre-and post-PCR areas as well as using 
different sets of pipettes and other equipment. 
 
A basic PCR recipe was used in all cases; amounts given are in μl unless stated otherwise and 
are for a 40μl reaction. Smaller reactions were scaled down proportionately: 
 
10x PCR Buffer (Invitrogen)       4 
Forward Primer (10μM)      2 
Reverse Primer (10μM)      2 
dNTPs (dATP, dCTP, dGTP, dTTP) (10μM) (Invitrogen)  1.2 
MgCl2 (Invitrogen)       1.6 
cDNA         2 
Taq (Invitrogen)       0.2 
dH2O         to 40 μl 
 
PCR tubes were placed immediately in the PCR machine (Thermo-Hybaid PX2, Fisher 
Scientific) and set to cycle between denaturation, annealing and extension temperatures up to 
35 times.  
 
Target DNA specific primer sequences, are provided in Appendix 2. All primers used were 
from Sigma-Aldrich (Haverhill, England) unless stated otherwise and were designed using the 
online primer design site (Integrated DNA technologies). 
 
PCR products were run on a 2% agarose gel containing SYBR Safe Gel Stain (Invitrogen). A 
100bp ladder (Invitrogen) was used to assess amplicon size. Gels were run at 75-100V for 30-
90 minutes. 
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2.8.3 Sequencing  
To aid the accuracy and efficiency of sequencing, PCR products were cleaned up to remove 
DNA fragments less than 100bp using YM100 micro filter columns (Millipore Ltd, Watford, 
UK). The product was transferred to the column and spun at 2500rpm for 12 minutes. DNA 
was then eluted from the column by adding 25-50μl water and shaking. Sequencing was 
carried out by the on-site MRC genetics facility using BigDye technology (Applied 
Biosystems, Warrington, UK). PCR products were mixed with single primers for both 
forward and reverse reactions and transferred to the facility where the fluorescence-based 
cycle sequencing reactions were carried out. This involved adding Terminator Ready Reaction 
Mix (Applied Biosystems) and deionised water to a final volume of 20ul and run on ABI 
Prism DNA Sequencer as per the manufacturer’s instructions. Raw sequence traces were 
received back from the sequencing facility and analysed using a combination of Clustal 
(European Bioinformatics Institute) and Chromas (Technelysium Pty Ltd, Australia) software. 
Wild-type sequences were taken from ensembl.org. (http://www.ensembl.org/index.html) 
 
2.8.4 GATA1 mutation analysis 
Genomic DNA was extracted from FL MNC or CD34 cells and exon 2 and the first part of 
exon 3 of GATA1 were amplified using the following cycling conditions:  
95 0C for 10 mins; followed by 35 cycles of: 95 0C  for 1 min, 62  0C  for 1 min, 72 0C  for 1 
min;  then 72 0C for 3 minutes. PCR products were visualised on agarose gel and then directly 
sequenced  
 
2.8.5 JAK2 mutation analysis 
Genomic DNA was extracted from FL or FBM CD34 cells and exon 16 of JAK2 was 
amplified using the following cycling conditions:  
95 0C for 10 mins; followed by 35 cycles of: 95 0C  for 1 min, 62  0C  for 1 min, 72 0C  for 1 
min;  then 72 0C for 3 minutes. PCR products were visualised on agarose gel and then directly 
sequenced  
 
 
2.9 Statistics 
The difference in medians for two sample groups was tested for significance using the 
Wilcoxon 2 sample test. Data are expressed as the mean ± SEM (standard error of the mean) 
unless otherwise indicated.   
CHAPTER 3  
 
CHARACTERISATION OF THE HSC AND MPP 
COMPARTMENT IN DS FETAL LIVER 
3.1 Background 
 
3.1.1 Abnormal fetal haematopoiesis in DS 
Previous data from our lab had identified marked perturbation of the myeloid progenitor 
compartment in second trimester FL in DS in the absence of GATA1 mutations strongly 
suggesting that T21 itself was responsible for the abnormalities (Tunstall-Pedoe et al., 2008).  
In this work flow cytometric analysis of DS FL mononuclear cells had shown not only an 
increase in MEP, but also a reduction in CMP and GMP. Despite this, clonogenic assays of 
DS FL CD34+ cells had shown increased numbers of clonogenic granulocyte-monocyte 
progenitors and multilineage progenitors (CFU-GEMM). Furthermore, in contrast to normal 
FL CFU-GEMM, CFU-GEMM cultured from DS FL had markedly increased self-renewal 
ability and formed colonies in vitro even after 3 serial re-platings whereas DS FL MEP had no 
secondary or tertiary replating ability (Tunstall-Pedoe et al., 2008). These apparently 
contradictory findings suggested that the clonogenic myeloid cells in DS FL might be derived 
from the more immature HSC/MPP compartment rather than from the CMP/GMP 
compartment and that T21 might also perturb early HSC commitment and proliferation.   
 
 
3.1.2 The HSC/ MPP compartment in normal haematopoiesis 
 
Adult HSC, are defined on the basis of three key properties: (1) multipotency, (2) long-term 
self-renewal; and (3) long-term haematopoietic reconstitution in vivo of myeloablated 
recipients. In vitro haematopoietic progenitor assays, immunophenotyping and transplantation 
of haematopoietic sub-populations have given rise to a generally accepted model of human 
haematopoiesis (Kondo et al., 2003) in which HSC differentiate into multipotent progenitors 
that give rise to common lymphoid progenitors (CLP) or common myeloid progenitors (CMP) 
(Figure 1.5).  
 
Recent evidence suggests that the “classical” hierarchy model may be overly simplified. 
Several investigators have found evidence in murine BM of an early multipotent progenitor 
(MPP) downstream of HSC, which sits at the lineage branching step between myeloid and 
lymphoid commitment but which, unlike HSC, does not have long-term self-renewal capacity 
(Christensen and Weissman, 2001; Guenechea et al., 2001; Mazurier et al., 2004; McKenzie 
et al., 2006). HSC and MPP have also been described in the CD34+CD38-/lo compartment of 
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human BM and cord blood where they are distinguishable on the basis of their CD90 
expression (Majeti et al., 2007).  
 
Consistent with this model, other investigators studying adult murine BM have recently 
suggested that MPP are the antecedents of CMP and CLP and that in some circumstances 
MPP may give rise to lymphoid-primed MPP (LMPP) which, rather than having solely 
lymphoid-generating capacity, have combined granulocyte/macrophage and B/T lymphoid 
potentials, with little or no megakaryocyte/ erythroid potential (Adolfsson et al., 2005; Lai and 
Kondo, 2006; Mansson et al., 2007; Yoshida et al., 2006).  The identification of LMPP in 
human adult BM has also very recently been described (Goardon, 2010).   
 
A slightly different differentiation hierarchy has been proposed for fetal cells based on data 
from murine FL which suggest the existence of progenitors with either combined 
granulocyte/macrophage and B cell (MB) potential or with combined granulocyte/ 
macrophage and T cell potential (MT) (Buza-Vidas et al., 2007; Katsura, 2002; Kawamoto et 
al., 2000; Kawamoto et al., 1998; Lu et al., 2002; Luc et al., 2007). However, there are 
currently no data indicating whether MPP, LMPP, MB or MT progenitors exist in human fetal 
life.  
 
 
3.2 Aim 
The aim of the experiments described in this chapter was firstly, to characterise the 
CD34+CD38- HSC/MPP compartment in normal second trimester FL and to determine 
whether LMPP were also present; and secondly to determine whether there were any changes 
in the HSC/MPP compartment in DS FL compared to normal FL. 
 
 
3.3 Experimental approach 
In order to characterise the HSC/ MPP compartment, FL samples from second trimester 
fetuses with (n = 6) and without (n = 11) DS were analysed. PCR and direct sequencing was 
performed as described in section 2.7, on CD34 cells from all DS FL samples to rule out pre 
existing mutations in exon 2 and exon 3 of GATA1 as well as JAK2R683 mutations that are 
known to be associated with DS-ALL. The approaches used to characterise the HSC/ MPP 
compartment were immunophenotyping by multiparameter flow cytometry (FC), clonogenic 
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assays to assess myeloid progenitor output, liquid culture to evaluate lymphoid differentiation 
and gene expression by RQ-PCR. A major limitation of my analysis was the very limited 
sample size and sample numbers of fetal tissues, available for these studies. 
 
3.4 Identification of HSC, MPP and LMPP in term cord blood 
Since HSC, MPP and LMPP have not previously been described in either normal human FL 
or DS FL and, at the time I started this work, there was only one paper (Majeti et al., 2007) 
describing HSC and MPP in human cord blood and cord blood LMPP were not fully 
characterised, one of the first steps in my project was to confirm their immunophenotypic 
approach for identifying HSC/ MPP in the CD34+CD38- compartment in normal cord blood 
and to investigate the presence of LMPP in the same compartment in normal cord blood.  
 
HSC, their immediate progeny, MPP and LMPP were reported by Majeti and colleagues to be 
readily distinguished by their patterns of CD45RA and CD90 expression. As I anticipated 
difficulties in working with very small numbers of FL cells, and because there were very few 
lineage positive cells in the cord blood and FL CD34+ compartment (Figure 3.1), I adapted 
the Majeti et al protocol and did not lineage deplete the cells prior to analysis. However, in 
most analyses cells were also stained with CD19, CD2 and CD14 in order to gate out B-, T- 
and monocyte-lineage cells respectively. HSC were defined as CD34+CD38-
/loCD90+CD45RA-; MPP as CD34+CD38-/loCD90-CD45RA- and LMPP as CD34+CD38-
/loCD45RA+ (Figure 3.2).                                                                             
                          
 
Figure 3.1 Lineage positive cells in CD34+CD38lo/- compartment in normal fetal liver 
Representative FC plots from immunomagnetically selected normal FL CD34+ cells, showing very 
low percentage of lineage positive cells (CD2/CD3/CD19/CD20/CD56/CD14/GlyA+) in the 
CD34+CD38- compartment. 
To confirm the multilineage differentiation capability of the cord blood HSC and MPP 
populations and to investigate the potential of the LMPP population, I flow sorted the same 
CD38
CD34
Lin+
CD34
FSC 
SSC 
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immunophenotypically-defined HSC, MPP and LMPP sub-populations from a normal term 
cord and plated them in methylcellulose semi-solid medium as described in section 2.4. The 
day 14 readout of myeloid colonies is depicted in Figure 3.3. As previously described by 
Majeti et al (Majeti et al., 2007), the highest clonogenicity was in the MPP fraction, which 
also had a more multilineage readout (erythroid, megakaryocyte and granulocyte-
macrophage); HSC had slightly lower clonogenicity and the predominant colony type was 
granulocyte-macrophage or myeloid blast colonies while the LMPP population had no 
detectable clonogenic activity (Majeti et al also plated cells from the CD34+CD38-
/loCD45RA+ compartment and found almost no clonogenic activity in this population 
although they did not go on to characterise this population further). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HSC
MPP LMPP
CD45RA 
CD90
Figure 3.2 Immunophenotypic analysis of the HSC/MPP compartment of normal  cord blood 
CD34+ cells were isolated from normal term cord blood using immunomagnetic beads (see 2.2) and  
analysed by flow cytometry. Representative data from 8 experiments.  HSC, MPP and LMPP formed  
20 3.± 1%, 52.8 ± 5.6% and 18.5 ± 2.1% of total CD34+CD38-/lo cells respectively. The proportion of HSC  
and MPP is consistent with previous data from Majeti et al (2007) as is the proportion of the cells in the  
CD34+CD38-/loCD45RA+ compartment subsequently shown to contain LMPP (Goardan 2010).  
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Figure 3.3 Clonogenicity of flow sorted normal term cord blood HSC, MPP and LMPP 
in methyl cellulose-containing myeloid colony assays. 
Sub-populations were flow sorted on the basis of immunophenotype: HSC- CD34+CD38-
/loCD90+CD45RA-; MPP-CD34+CD38-/loCD90-CD45RA- and LMPP- CD34+CD38-
/loCD45RA+) (n=3) and cultured in methyl cellulose with IL3, IL6, IL11, SCF, FLT3, GM-
CSF, TPO and EPO. Colonies were identified by light microscopy and counted at day 14. (n= 
4 ) 
* Erythroid blast colonies are described in section 3.5.2 
 
 
 
3.5 The HSC/ MPP/LMPP compartment in normal human second trimester fetal liver 
 
3.5.1 Immunophenotypic analysis of the CD34+CD38lo/- compartment of normal 
human FL 
The CD34+CD38-/lo compartment of second trimester human FL was analysed by flow 
cytometry to determine whether HSC, MPP and LMPP (defined as in 3.4 above) were present 
and their relative proportions.  The data are summarised in Table 3.1 and representative flow 
cytometric plots are shown in Figure 3.4. 
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% of CD34+ cells 
 
% of CD34+CD38-/lo 
HSC  
(CD34+CD38-/loCD90+CD45RA-)
 
2.4 ± 0.4 % 20 3.± 1% 
MPP  
(CD34+CD38-/loCD90-CD45RA-) 
  
5.9 ± 0.8% 52.8 ± 5.6% 
LMPP  
(CD34+CD38-/loCD45RA) 
 
2 ± 0.3% 18.5 ± 2.1% 
 
Table 3.1 Immunophenotypic analysis of the CD34+CD38-/lo compartment in normal 
human second trimester fetal liver (FL) 
CD34+ cells were isolated from normal second trimester FL (n=11) using immunomagnetic 
beads and analysed by flow cytometry to identify HSC, MPP and LMPP. Data are expressed 
as the mean+SEM.  
 
 
Using the definitions of Majeti et al (Majeti et al., 2007) and Goardon et al (Goardon, 2010), I 
found that HSC, MPP and LMPP are all present in normal human FL during the second 
trimester. MPP formed the largest subpopulation (almost 2.5-fold more than HSC and 3-fold 
more than LMPP) (Table 3.1; Figure 3.4).  The proportions of HSC, MPP and LMPP are 
similar to those I found in normal cord blood as well as those reported by Majeti et al (2007) 
in normal cord blood but differ from those reported in adult BM, which has a relatively higher 
proportion HSC and LMPP (Goardon, 2010).  
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Figure 3.4 Immunophenotypic analysis of the CD34+CD38-/lo compartment in normal 
human second trimester fetal liver (FL) 
CD34+ cells were analysed by flow cytometry, gated on CD34+CD38lo/- cells and the HSC, 
MPP and LMPP sub-populations identified as described above. Data shown here are 
representative of 11 second trimester FL samples and are summarised in Table 3.1  
 
 
3.5.2 Myeloid colony read out in clonogenic assays of the CD34+CD38lo/- compartment 
of normal human FL   
To investigate the myeloid potential of the immunophenotypically-defined HSC, MPP and 
LMPP in normal human FL, these populations were isolated from 5 second trimester FL 
samples by flow sorting and plated at 100 cells/well of a 24-well plate in methyl cellulose 
with IL3, IL6, IL11, SCF, FLT3, GM-CSF, TPO and EPO as described in section 2.4.   
 
CD90 
CD45RA
HSC
LMPP
MPP
CD34 
CD38
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The day 14 read out of myeloid colonies from normal FL HSC, MPP and LMPP is depicted in 
Figure 3.5.  The most clonogenic sub-population was MPP, as in cord blood (Figure 3.3 and 
(Majeti et al., 2007), which was more than twice as clonogenic (26.6 ± 3.7%) as HSC (12.6 ± 
3%) and, as expected, the clonogenicity of the CD34+CD38lo/-CD45RA+ sub-population 
(putative LMPP) in this myeloid colony assay system was very low (4.3 ± 1.4%) and confined 
to small numbers of CFU-G, GFU-M and CFU-GM consistent with their expected very 
limited myeloid potential.  
 
Interestingly, the colony read out of FL HSC was much more multilineage than previously 
reported for cord blood (Majeti et al, 2007) and more recently adult BM (Goardon, 2010); in 
contrast to cord blood and adult BM, almost 50% of colonies were erythroid or 
megakaryocytic (Figure 3.5). Similarly, FL MPP were markedly skewed towards the 
erythroid/megakaryocyte lineage, which formed more than 2/3 of the colonies compared to 
only 1/3 of colonies in cord blood MPP and considerably more than in adult BM (Goardon et 
al, 2010). In addition, since the clonogenicity of FL MPP was also higher than seen in cord 
blood, the actual numbers of erythroid and megakaryocyte colonies generated by FL MPP was 
~5-fold higher than in cord blood.   
 
I also noted the presence of large numbers of blast-like colonies in the FL HSC and MPP 
cultures (Figures 3.5 and 3.6) which were uncommon in normal cord blood cultures. These 
were particularly prominent in the HSC cultures where ~50% of the colonies were of blast 
like morphology.  There were two main types of blast cell colony, both of which were present 
in HSC and in MPP cultures: non-haemoglobinised blast cell colonies (designated myeloid 
blast colonies; Figure 3.6) and haemoglobinised blast cell colonies (designated erythroid blast 
colonies, with 2 different sub-types recognised- Figure 3.7).   
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Figure 3.5 Day 14 myeloid colony readout of sorted normal FL subpopulations.  
a) Clonogenicity of normal FL HSC, MPP and LMPP. (b) Clonogenic readout of normal FL 
HSC, MPP, and LMPP compared to normal FL myeloid progenitors: CMP (CD34+38+45RA-
123+), MEP (CD34+38+45RA-123- ) and GMP (CD34+38+45RA+123lo) after 14 days of 
culture in methyl cellulose with IL3, IL6, IL11, SCF, FLT3, GM-CSF, TPO and EPO. (n=5)  
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a) Myeloid blast colonies                  b) Cytospin of myeloid blast colony
           
                 
              x 10            x 20       
 
Figure 3.6 Normal human FL HSC and MPP give rise to myeloid blast cell colonies 
a) Myeloid blast cell colonies appeared on day 10-12 of culture and were characteristically 
small, round or oval, non-haemoglobinised colonies. b) Cytospin of plucked myeloid blast 
colony showing myeloid blast, and abnormal myelocyte and promyelocytes 
 
The greatest number of erythroid blast cell colonies was cultured from sorted normal FL 
MPP.  Sorted MPP gave rise to 2 types of erythroid blast colony in methyl cellulose which I 
designated as 'Type I' and 'Type II'. Type I colonies were large, macroscopically visible 
colonies composed of a dense cellular centre with a surrounding 'apron' of small, partially 
haemoglobinised erythroid cells; these colonies appeared after day 8 and continued to enlarge 
for up to 4 weeks; cytospins of plucked colonies showed that they were composed almost 
entirely of late and intermediate normoblasts with occasional proerythroblasts (Figure 3.7A). 
By contrast, Type II erythroid blast colonies were much smaller and tighter, appearing very 
late in culture (after day 14) and initially resembling myeloid blast colonies but gradually 
haemoglobinising; cytospins of type II colonies showed islands of cells consisting of central 
'nurse' macrophages with tightly adherent normoblasts and proerythroblasts, similar to 
previously described fetal haematopoietic islands (Isern et al., 2008; Palis, 2008; Sasaki et al., 
1993) (Figure 3.7B).  
 
The HSC sub-population gave rise only to type II colonies and neither type I nor type II 
colonies were ever cultured from the LMPP sub-population of normal FL. Taken together, 
these data suggest that type II erythroid 'blast' colonies are likely to derive from a very 
immature erythroid progenitor cell which may be unique to FL.  
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a) Type I large erythroid blast colonies     b) cytospin of Type I colony 
 
          
x 10 
c) Type II small erythroid blast colonies  d) cytospin of Type II colony    
            
         
x 10 
 
Figure 3.7 Erythroid blast colonies grown from the MPP and HSC sub-populations 
of normal human FL  
a) Very large type I erythroid blast cell colonies appeared on day 8 of culture and were 
composed of a dense cellular centre with a surrounding 'apron' of small, partially 
haemoglobinised erythroid cells.  b) Cytospins of plucked colonies showing late and 
intermediate normoblasts with occasional proerythroblasts. c) Small, round or oval, non-
haemoglobinised type II erythroid blast colonies appeared after day 14 of culture and initially 
resembled myeloid blast colonies before haemoglobinising. d) Cytospins of type II colonies 
showing islands of cells consisting of central 'nurse' macrophages with tightly adherent 
normoblasts and proerythroblasts. 
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3.5.3  Lymphoid potential of normal FL HSC, MPP and LMPP 
 
To confirm the multilineage differentiation capacity of cells within the 
immunophenotypically-defined HSC, MPP and LMPP in normal human FL, these populations 
were isolated from normal second trimester FL samples (n=3) by flow sorting and co-cultured 
at 100 cells/well in a 96-well plate pre-plated with MS5 murine stromal cells in alpha MEM 
with cytokines in a modification of a method described by Kouro et al (Kouro et al., 2005). 
Since I wanted to confirm the NK and GM/G/M as well as B lymphoid potential I added a 
cocktail of cytokines to support each lineage: IL2, IL7, Flt3, SCF, G-CSF and GM-CSF as 
described in section 2.5.2 in a modification of the methods used by Doulatov et al (Doulatov 
et al., 2010). Similarly sorted cells were cultured at 500/well in a 24 well plate pre plated with 
OP9-DL1 murine stromal cells in alpha MEM with Flt3 and IL7 to evaluate T cell 
differentiation potential as described in section 2.5.1. 
 
3.5.3.1 Generation of B cells and NK cells from normal FL HSC, MPP and LMPP 
 
Normal FL HSC, MPP and LMPP all gave rise to B cells after co-culture with MS5 stromal 
cells (Figure 3.8). The majority of the CD34-CD19+ cells generated did not express CD10 by 
flow cytometry (Figure 3.8, second row) strongly suggesting that CD19 is acquired before 
CD10 when normal FL CD34 cells are cultured in vitro which is consistent with the pattern of 
B cell maturation recently described in cord blood (Sanz et al., 2010).  
 
The timing of emergence of CD19+ B cells and the numbers of B cells generated varied in the 
3 different populations. The greatest number of CD19+ cells was generated by the LMPP 
population (Figures 3.8; 3.9). In addition, the majority of cells within the LMPP population 
demonstrated their ability to undergo B cell differentiation, only a small residual CD34+ 
population remaining after 14 days of culture (Figure 3.8, top row right plot) in comparison 
with the predominantly CD34+CD19- population at day 14 in HSC cultures (Figure 3.8, top 
row left) while MPP were intermediate between HSC and LMPP (Figure 3.8, top row centre).  
 
By day 14 of culture, 65.4 ± 4.6% of the cells in LMPP wells were CD34-19+, compared to 
11.1 ± 5% in MPP and 0.7 ± 0.5% in HSC (Table 3.2). Similarly CD34-CD19+ cells appeared 
earlier in the LMPP cultures compared to MPP and were latest in the HSC-initiated cultures. 
Together these data are consistent with a hierarchy of cells within the FL CD34+CD38lo/- 
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compartment consistent with HSC being most immature population followed by MPP and 
then LMPP.  
 
HSC, MPP and LMPP, also all gave rise to NK cells (CD34-CD19-CD56+CD3-) with the 
greatest numbers derived from the LMPP cultures (15.3 ± 8%) followed by MPP (3.1 ± 1.2%) 
and HSC (4.1 ± 0.2%)(Figure 3.8, third row), as expected since LMPP are lymphoid 'primed'.  
Finally, all 3 populations also gave rise to mature (CD11b+) myeloid cells, the greatest 
number, as expected, being derived after initiation with MPP (49.1%), which are 'myeloid 
primed' followed by HSC (15.1 ± 0.9%) and least in LMPP (8.7 ± 3.8%) (Figure 3.8, bottom 
row); a small number of CD14+ cells were also generated by all 3 populations consistent with 
their monocyte/ macrophage differentiation ability (Figure 3.8, bottom row). 
 
The results are summarised in Figure 3.9 which illustrates the position of HSC as the most 
immature of the 3 populations in the CD34+CD38lo/- compartment and the lineage priming 
of MPP and LMPP. 
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Figure 3.8  Generation of B cells and NK cells from normal FL HSC, MPP and LMPP  
Day 14 readout from normal FL HSC, MPP and LMPP on MS5 co-culture showing production of 
CD34-CD19+ B cells (red arrows), CD34-CD19-CD56+CD3- NK cells (blue arrows) and CD11b 
and/or CD14+ myeloid cells (black arrows). Residual CD34+ cells which have not undergone cell 
differentiation are marked with an orange star. Representative plots from one of 3 separate 
experiments are shown.  
CD34 
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CD56 
CD1Ib 
CD14 
HSC MPP LMPP 
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 B CELLS 
% CD34-CD19+
NK CELLS 
% CD34-19-CD56+
MYELOID CELLS 
% CD34-CD11b+and/CD14+
HSC (n=3) 
day 14 
 
0.7 ± 0.5% 
 
4.0 ± 0.2% 
 
15.2 ± 0.9% 
MPP (n=2) 
day 14 
 
11.1% 
 
3.1% 
 
49.1%  
LMPP (n=3) 
day 14 
 
65.4 ± 4.6% 
 
15.3 ± 8.9% 
 
8.6 ± 3.9% 
 
Table 3.2 Generation of B, NK and myeloid cells from normal fetal liver HSC, MPP and 
LMPP in MS5 stromal cell co-cultures 
Cells were harvested from the co-cultures at day 14, and analysed by flow cytometry as 
shown above. The data are expressed as % of human CD45+ cells detected in co culture on 
day 14.  
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Figure 3.9 Day 14 readout from MS5 co culture of human FL HSC, MPP and LMPP. 
Proportion of CD34+ cells, CD11b/CD14+ (myeloid) cells, CD34-CD19+ B cells and CD34-
CD19-CD56+CD3- NK cells in human CD45+ cells detected by flow cytometry after 14 days 
of co culture of FL HSC, MPP and LMPP on MS5 stroma with IL2, IL7, FLT3, SCF, G-CSF, 
GM-CSF.  
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3.5.3.2 Generation of T cells from normal FL HSC, MPP and LMPP 
 
Normal FL HSC, MPP and LMPP all gave rise to T cells (defined as CD7+CD2+CD4+ 
and/or CD8+) after co-culture with OP9-DL1 cells (Figure 3.10a and b; n= 3 experiments).  
After 14 days in OP9-DL1 co-cultures, the majority of cells (>95%) expressed CD7 consistent 
with early T cell differentiation (Figure 3.10a top row). As for B cell production, the timing of 
emergence of T cells and the numbers of T cells generated varied in the 3 different 
populations.  As expected, T cell differentiation occurred first in the LMPP-initiated cultures 
compared to both HSC- and MPP-initiated cultures with just over half (50 ± 9%;) of the 
LMPP-derived CD7+ cells expressing CD2 by day 14 and >60% (63.6 ± 10%) by day 21 
(Figure 3.10a top two rows; Table 3.3).  By day 21 the majority of the cells in culture had 
become CD8+, with a small proportion of CD4+CD8+ cells (Figure 3.10b). 
 
 
 
 % CD7+ % CD7+CD2+ % CD8+ or CD4+ % CD8+CD4+
HSC (n=3) 
day 14 
day 21 
 
79.5 ± 15% 
84.3 ± 9.3% 
 
26.5% 
57% 
 
31.7 ± 4.9% 
40 ± 13.2% 
 
3% 
8% 
MPP (n=5) 
day 14 
day 21 
 
97.8 ± 0.4% 
94.8 ± 1.9% 
 
31.4 ± 8.4% 
54.2 ± 9.3% 
 
34 ± 6.8% 
37.8 ± 6.1% 
 
3.5 ± 2% 
10.2 ± 4.8% 
LMPP (n=5) 
day 14 
day 21 
 
97.8 ± 0.7% 
93 ± 2.4% 
 
50 ± 9% 
63.6 ± 10% 
 
40.4 ± 4.9% 
44.3 ± 10.5% 
 
6.4 ± 3% 
22.7 ± 13.5% 
 
 
Table 3.3 T cell differentiation of normal FL HSC, MPP and LMPP on OP9-DL1 
Cells were harvested from the co-cultures at given time points, and analysed by flow 
cytometry as shown below. The data are expressed as % of human cells detected in co culture 
on day 14 and day 21. T cells were defined as being CD7+CD2+CD4+ and/ CD8+ 
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The difference in the numbers of T cells generated in vitro between LMPP-, MPP- and HSC-
initiated cultures was more dramatic, with by far the greatest number of CD4+ and CD8+ T 
cells generated from the LMPP population (Figure 3.10). In addition, the majority of cells 
within the LMPP population demonstrated their ability to undergo T cell differentiation, only 
a small residual CD34+ population remaining after 14 days of culture  in comparison with 
HSC cultures while MPP were intermediate between HSC and LMPP (Figure 3.10c). 
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b)                  HSC                 MPP                 LMPP 
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Figure 3.10: T lymphoid differentiation of normal FL HSC, MPP and LMPP on OP9-DL1 stromal cells 
Cultures were initiated with 100 flow-sorted human FL HSC, MPP or LMPP and analysed by flow cytometry 
after 14 and 21 days:  a) CD7+CD2+ lymphocytes (red arrow) (gated on CD45+ cells); b) CD4+ and/ CD 8+  
lymphocytes (blue arrow) and c) residual CD34+ cells. (Shown are representative plots from 3 samples tested).
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3.5.4 Gene expression in normal fetal liver HSC, MPP and LMPP 
 
Confirmation of the identity of the immunophenotypically-defined HSC, MPP and LMPP 
would require in vivo experiments to show their engraftment potential in xenograft models 
(Majeti et al., 2007) which was out with the scope of my PhD and would have required very 
large numbers of cells. An alternative approach I used was to determine their gene expression 
signature. Since very limited cell numbers precluded gene expression profiling using 
microarray technology, I initially used RT-PCR of a small number of selected transcription 
factors in flow-sorted HSC, MPP and LMPP. However, towards the end of my project I was 
able to gain access to the BioMark Real time PCR (qRT-PCR) system which allowed me to 
quantitate gene expression of ~50 genes in 50 cells (see section 2.7.3) thus allowing limited 
gene expression profiling of purified haematopoietic sub-populations from normal human FL 
and to compare this with the same, immunophenotypically-defined sub-populations from DS 
FL (the results in DS are described at the end of this chapter). 
 
3.5.4.1 RT-PCR of specific genes in sorted normal FL HSC, MPP and LMPP 
 
The genes I chose to investigate to look for evidence of lineage priming in the 3 sorted sub-
populations were GATA1 (HSC/MPP and erythroid/megakaryocytic progenitors); CEBPα 
(HSC/MPP and GMP); Pax5 (B cell progenitors) and Pre-TCRα (PTCRA; T cell progenitors). 
PU.1 was used as a control gene as I expected it to be expressed in all 3 populations . 
 
The expression of genes in the sorted populations (n=2 experiments); depicted by a positive 
band of the expected size in agarose gel by electrophoresis is summarised in Figure 3.11 and 
Table 3.4. The presence of cDNA in all samples was confirmed by positive amplification of 
β-actin. The pattern of gene expression in HSC/MPP/LMPP was similar to the predicted 
pattern from murine studies (Luc et al., 2007). HSC expressed PU.1, GATA1 and CEBPα but 
neither of the lymphoid genes; MPP had a similar gene expression pattern to HSC but higher 
GATA1 expression; and LMPP expressed only PU.1 and a very low level of PTCRA (the lack 
of expression of CEBPα was slightly unexpected but very few cells were sorted from this 
population).  
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       HSC  MPP          LMPP 
   
   
   
 
   
   
       
 
 
GENE HSC 
    CD34+38-45RA-90+ 
MPP 
CD34+38-45RA-90-
LMPP 
   CD34+38-45RA+ 
PU.1 + + + 
GATA1 +/- + - 
CEBPα + + - 
PAX5 - - - 
PTCRA - - +/- 
 
Table 3.4 Expression of lineage-associated haematopoietic transcription factor genes in 
human FL HSC, MPP and LMPP 
Gene expression was measured in flow sorted HSC, MPP and LMPP from normal human FL 
(n=2) by RT-PCR.  Populations in which a distinct band of the expected size was consistently 
seen on agar gel electrophoresis are marked +; populations in which a band of the expected 
size was consistently undetectable with +ve bands in the control lane and β-actin are marked -
; populations where the band was consistently very weak or results were variable are marked 
as +/-.  
β actin 
Figure 3.11: Expression of PU.1, 
GATA1, CEBPα, PTCRA, PAX5, 
and β-actin checked by RT-PCR for 
normal FL CD34 sub populations. 
Lane1: HSC cells; Lane2: MPP; 
Lane3: LMPP cells on 1.5% 
agarose gel. cDNA integrity was 
checked by expression of β actin- 
all subpopulations expressed β actin 
(n=2 normal FL samples) 
 PU.1 
GATA1 
CEBPα 
PAX5 
PTCRA 
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 3.5.4.2 Gene expression of normal FL HSC, MPP and LMPP by qRT-PCR using the 
nanofluidic BioMark 48.48 Dynamic Array and TaqMan Expression Assays  
 
To allow accurate comparison of gene expression between the sub-populations, and thereby 
determine the gene expression 'signatures' specific to each sub-population, I flow-sorted 50 
cells from the HSC, MPP and LMPP compartments in triplicate and processed them as 
described in section 2.7.2. Cells were sorted on the basis of the same immunophenotypes 
described above, i.e. HSC (CD34+CD38lo/-CD45RA-CD90+), MPP (CD34+CD38lo/-
CD45RA-CD90-) and LMPP (CD34+CD38lo/-CD45RA+).  
 
A list of the genes I studied is shown in Table 3.5. As well as investigating known 
transcription factor genes, I also investigated expression of several growth factor receptor 
genes, expression of a number of genes on chromosome 21 in order to compare with the 
expression pattern in DS FL sub-populations and also of a number of genes which had been 
identified by another PhD student in the lab as having differential expression on microarray of 
whole CD34+ cells. Expression of all genes was compared with the expression of GAPDH in 
the same cell population on the same assay run and calculated using the ΔCt method. The 
relative expression of all genes studied, is described in Appendix 3. 
 
 
3.5.4.2.1 Relative expression of genes in normal FL HSC  
 
Genes known to be crucial components of the HSC transcriptional regulatory code (reviewed 
in (Ottersbach et al., 2010), which are preferentially expressed in murine FL HSC and adult 
BM HSC (c-KIT, c-MPL, PU.1, ERG and GATA2) were highly expressed in human FL HSC 
compared to MPP and LMPP (Figure 3.12a). Normal FL HSC also co-expressed genes 
associated with erythroid/ megakaryocytic, and myeloid development consistent this 
population being already primed for multilineage potential as originally reported for murine 
HSC (Figures 3.12b and 3.12c).  
 
Expression of genes important for early megakaryocyte-erythroid development, such as EpoR, 
GATA1, FOG1 and ERAF1 (Figure 3.12b) were consistently found in FL HSC although at a 
fairly low level, with levels of the most mature erythroid marker, GYPA being barely 
detectable.  Similarly, the levels of expression of the myeloid-associated genes tested in the 
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HSC population (CEBPα, G-CSFR, GM-CSFR and CSF1R) was consistently detected but at 
low levels, apart from the levels of G-CSFR expression which were highest in the HSC 
population consistent with previous studies in murine and adult human HSC which suggest an 
important role for G-CSFR in HSC as well as in more mature granulocyte progenitors (Figure 
3.12c). 
 
Interestingly, genes known to be important for early B lymphoid development (IKAROS, 
IL7RΑ and E2A) were consistently expressed at low levels in the HSC population (Figure 
3.13a) while there was no detectable expression of genes reported to be necessary for more 
mature B cell progenitors and committed B cells (EBF1, PAX5 and CD19) (Figure 3.13b). 
This suggests that although normal FL HSC have some amount of lymphoid lineage priming, 
they show no evidence of B lineage commitment. Similarly the T cell specific gene, PTCRΑ, 
was not expressed in FL HSC (Figure 3.13c).  
 
The results of qRT-PCR for FL HSC were generally consistent with the findings of RT-PCR 
(Table 3.4) These results are also consistent with the in vitro data whereby HSC had 
multilineage potential giving rise to erythroid, megakaryocytic and myeloid colonies in 
methylcellulose cultures; mature B and NK cells in MS5 co culture and CD4 and/ CD8 
positive T cells in OP9-DL1 co-cultures. Overall, the HSC population, in comparison with the 
MPP and LMPP populations, exhibited an erythroid/myeloid priming bias with less lymphoid 
priming suggesting that this is the preferential priming in 2nd trimester normal human FL 
HSC. 
 
The expression of other genes studied by qRT-PCR, but not discussed in this section is 
depicted in Appendix 3. 
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Table 3.5 Genes studied by qRT-PCR using the nanofluidic BioMark 48.48 Dynamic 
Array and TaqMan Expression Assays in FL HSC, MPP and LMPP 
Transcription factors GATA1 
GATA2 
GATA3 
FOG1 
RUNX1 
PU.1 
CEBPα 
ERG 
 
Growth factor receptors c-MPL 
GM-CSFR 
G-CSFR 
CSF1R 
EpoR 
c-kit 
IL3Rα 
IGF1R 
IGF2R 
CRLF2 
Flt3 
IL7R 
 
Lymphoid genes Ikaros 
IL7RA 
PTCRA 
RAG1 
EBF1 
E2A 
PAX5 
CD19 
IgH@ 
MEF2C 
SHIP1 
 
Notch receptors and 
signaling 
Notch1 
DLL1 
HES1 
 
Chromosome 21 genes GABPα 
RUNX1 
DSCR1 
DYRK1a 
ERG 
DNMT3L 
 
Other GYPA 
CD7 
CXADR 
ERAF 
WEE2 
CDKN1C 
TGFB1 
 
House keeping ACTB 
GAPDH 
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3.5.4.2.2 Relative expression of genes in normal FL MPP  
 
Normal FL MPP showed a similar overall gene expression pattern to HSC but with important, 
distinct differences consistent with these cells being more differentiated than HSC. Thus, 
expression of genes normally preferentially expressed in HSC, which I also found to be highly 
expressed in FL HSC (c-KIT, c-MPL, PU.1, ERG and GATA2), was lower in MPP (Figure 
3.12a) consistent with down regulation of HSC regulatory genes as cells differentiate.  
 
Several of the genes important for early megakaryocyte and erythroid development such as 
EpoR, FOG1 and ERG were expressed at lower levels in MPP than in HSC, (Figure 3.12b). 
Interestingly, however, GATA1 was markedly up regulated in MPP which may explain the 
higher megakaryocyte-erythroid readout I found in FL MPP compared to HSC (Figure 3.4). 
Myeloid specific genes such as CEBPα and G-CSFR were expressed in lower levels; however 
GM-CSFR was up regulated in MPP (Figure 3.12c); this was reflected by a higher CFU-
GM/M readout from MPP in methylcellulose myeloid colony assays. 
 
Early B lymphoid progenitor genes, such as IKAROS and E2A, were expressed at higher 
levels in FL MPP than in the HSC; although, interestingly, IL7RA and EBF1 were not 
expressed in this population and neither were the more mature B cell progenitor and 
committed B cell genes, such as CD19 (Figure 3.13b). By contrast, low expression of PAX5, 
which was not detected in FL HSC, was seen in FL MPP suggesting that these cells do 
already have early B-lymphoid lineage priming and show some evidence of B lineage 
commitment.  
 
Although no detectable expression of the T cell progenitor gene, PTCRA was found in FL 
MPP, CD7 was expressed in MPP and at a higher level than in HSC although the significance 
of this for T-cell progenitor priming is unclear since CD7 was also found to be expressed on 
FL myeloid progenitors (section 3.5.3) (Figure 3.13c).  MPP also expressed significant levels 
of NOTCH1 which would be consistent with early T cell commitment, although this is not 
specific since NOTCH1 is also expressed in HSC and, at low levels, in myeloid progenitors 
(Figure 3.13c). Similarly GATA3, which is normally up regulated in T progenitors, was 
expressed in FL MPP but at lower levels than in HSC FL (Figure 3.13c) suggesting that while 
this would permit T cell differentiation; this is not likely to be a major pathway in FL MPP. 
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These results of the qRT-PCR for FL MPP were generally consistent with the findings of RT-
PCR (Table 3.3) except for PAX5 which was not detected by simple RT-PCR in normal FL 
MPP. These results are also consistent with the in vitro data whereby MPP had multilineage 
potential giving rise to erythroid, megakaryocytic and myeloid colonies in methylcellulose 
cultures; mature B and NK cells in MS5 co culture and CD4 and/ CD8 positive T cells in 
OP9-DL1 co-cultures. Furthermore the data are consistent with recent data in murine MPP 
which showed that expression of CEBPα, although promoting granulopoiesis, also permitted 
ongoing differentiation down erythroid/megakaryocyte and lymphoid lineages (Wolfler et al., 
2010). 
 
Overall, the MPP population had a very similar gene expression pattern to HSC with clear 
evidence of multilineage priming associated with erythroid/megakaryocytic, granulocyte-
monocyte and B and T lymphoid commitment. The main difference between FL MPP and 
HSC in terms of gene expression was the increased expression of rather more mature 
differentiated cells of these lineages, including GATA1, GlyA, GM-CSFR, PAX5 and CD7.  
 
The expression of other genes studied by qRT-PCR, but not discussed in this section is 
depicted in Appendix 3. 
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Figure 3.12  Relative expression of a) stem cell genes; b) erythroid/megakaryocyte genes 
and c) myeloid genes in normal FL HSC, MPP and LMPP compartments .  
Gene expression levels are shown relative to the expression of GAPDH and are the mean ± 
SEM of 3 normal FL samples from which 50 cells of each CD34+ sub-population (HSC, MPP 
and LMPP) were sorted in triplicate for analysis by qRT-PCR using the BioMark 48.48 
Dynamic Array and Taqman expression assays. 
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Figure 3.13  Relative expression of a) early lymphoid genes b) B progenitor and committed B cell 
genes and c) T lymphoid genes in normal FL HSC, MPP and LMPP compartments Gene 
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expression levels are shown relative to the expression of GAPDH and are the mean ± SEM of 
3 normal FL samples from which 50 cells of each CD34+ sub-population (HSC, MPP and 
LMPP) were sorted in triplicate for analysis by qRT-PCR  
 
3.5.4.2.3  Relative expression of genes in normal FL LMPP  
 
Compared to normal FL HSC and MPP the most notable differences in expression of the HSC 
transcription regulatory genes in FL LMPP were a marked up regulation in FLT3 and down 
regulation of both GATA1 and GATA2. Indeed, GATA1 was not expressed at all in FL LMPP 
(Figure 3.12a). These data are consistent with the patterns of gene expression reported in fetal 
and adult murine LMPP in which FLT3 expression is a robust marker of early lymphoid 
commitment. (Serwold et al., 2009).  In addition, the silencing of GATA1 is consistent with 
the lineage restriction of LMPP to prevent ongoing erythroid/megakaryocytic differentiation 
capacity at the same time as up regulating lymphoid specific genes. 
 
Consistent with the absence of GATA1 expression in normal FL LMPP, there was also 
silencing of the other principal genes important for early megakaryocyte-erythroid 
development including EpoR, FOG1 and GYPA (Figure 3.12b). In keeping with this, there 
was also no megakaryocytic or erythroid readout in methylcellulose myeloid colony assays 
from LMPP. 
 
Interestingly, the myeloid-specific genes, CEBPα, GM-CSFR and CSF1R were up regulated 
in normal FL LMPP at levels compared to MPP and slightly increased even compared to HSC 
(Figure 3.12c).  The increased granulocyte potential in this population was also seen in 
methylcellulose assays where CFU-G/GM/M were the only colonies grown and these were 
present in similar numbers to those cultured from HSC and MPP populations. These data, and 
the observation that myeloid blast cell colonies were never seen in LMPP clonogenic assays, 
are consistent with LMPP population being a more mature progenitor population than both 
MPP and HSC.  
 
As predicted from murine data, and from my LMPP MS5 stromal cell co-cultures, early B cell 
development genes, particularly EBF, IL7RA and CRLF2, were markedly up regulated in 
LMPP compared to HSC and MPP while E2A and IKAROS expression was maintained at 
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similar levels (Figure 3.13a).  By contrast, genes specific for more mature B cell progenitors/ 
committed B cells (PAX5 and CD19) were expressed but at extremely low levels consistent 
with the onset of the first steps of full B-lineage commitment in LMPP (Figure 3.13b). CD7 
was expressed by LMPP but might represent CD7 expression by myeloid cells within the 
LMPP compartment (see also section 3.5.3) since expression of the T cell-specific gene, 
PTCRΑ, could not be detected in FL LMPP and levels of expression of GATA3, which is 
normally up regulated in T progenitors, were lower in LMPP than in HSC and MPP (Figure 
3.13c). 
 
The results of the qRT-PCR of normal FL LMPP were largely consistent with the findings of 
RT-PCR (Table 3.4) except for PAX5 which was not detected by simple RT-PCR in normal 
FL LMPP. These results are also consistent with the in vitro megakaryocte-erythroid potential 
and limited myeloid potential of normal FL LMPP in methylcellulose cultures. LMPP very 
efficiently generated large numbers of mature B and NK cells in MS5 co culture and CD4 
and/ CD8 positive T cells in OP9 DL1 co cultures. Indeed, compared to HSC and MPP, the 
LMPP sub-population clearly had the greatest potential for lymphoid differentiation, while 
retaining some myeloid potential consistent with the immunophenotypically defined LMPP 
population (CD34+CD38lo/-CD45RA+) being a true LMPP. The expression of other genes 
studied by qRT-PCR, but not discussed in this section is depicted in Appendix 3. 
 
3.6 The HSC/ MPP/LMPP compartment in DS human fetal liver  
 
3.6.1 Immunophenotypic analysis of the CD34+CD38lo/- compartment 
 
There was a 3-fold increase in the frequency of cells in the HSC compartment in DS FL 
compared to normal FL while MPP frequency was reduced by about 50% compared to normal 
FL (Table 3.6; Figure 3.14). The frequency of cells in the LMPP fraction (CD34+CD38lo/-
CD45RA+) was similar in DS and normal FL (Figure 3.14). Therefore, there was a significant 
expansion in the HSC sub-population in DS FL (55.1 ± 6% of CD34 cells) compared to 
normal FL (6.5 ± 0.6 %) (p=0.008).  Since in DS FL, in contrast to normal FL, the frequency 
of HSC (6.5 ± 0.6% of total CD34 cells) was twice that of MPP (3.2 ± 0.5%) (Table 3.6; 
Figure 3.14b) this suggests that in DS there is both HSC expansion and a block to HSC 
differentiation into MPP. 
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 % of CD34+ cells 
 
% of CD34+CD38-/lo 
HSC  
(CD34+CD38-/loCD90+CD45RA-)
7.8 ± 0.9 % 55.1 ± 6% 
(Normal FL 20.3±1%) 
MPP  
CD34+CD38-/loCD90-CD45RA- 
3.7 ± 0.4% 20.6 ± 2.3% 
(Normal FL 52.8±5.6%) 
LMPP  
(CD34+CD38-/loCD45RA) 
3.2 ± 1.0% 21.7 ± 7.2% 
(Normal FL 18.5±2.1%) 
 
 
Table 3.6 Immunophenotypic analysis of the CD34+CD38-/lo compartment in DS FL 
CD34+ cells were isolated from DS second trimester FL (n=4) using immunomagnetic beads 
and analysed by flow cytometry. Data are expressed as the mean+SEM. Normal FL data are 
derived from Table 3.1. 
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Figure 3.14 Immunophenotypic analysis of the CD34+CD38-/lo compartment in DS second 
trimester FL 
a) DS FL CD34+ cells were analysed by flow cytometry and the HSC, MPP and LMPP sub-
populations identified as described above (representative plots; n=6). b) Frequency of HSC, MPP and 
LMPP in DS FL (n=6) compared to normal FL (n=11). Data are expressed as mean ± SEM. (**: p 
<0.01). 
 
 
3.6.2 Myeloid colony read out in clonogenic assays of the CD34+CD38lo/- compartment 
of DS FL   
 
To determine whether there were any differences in the erythroid/megakaryocytic and 
myeloid colony read out in DS FL compared to normal FL, flow sorted DS FL 
immunophenotypically-defined HSC, MPP and LMPP (n=4), were plated at 100 cells/well in 
24 well plates as above (section 3.5.2). The day 14 clonogenicity of these populations is 
depicted in Figure 3.15.  
 
DS FL HSC had almost 5-fold higher clonogenicity (61.7 ± 15%) than normal FL HSC (12.6± 
3 %) (Figure 3.15a). Clonogenicity data (n=3) from DS FL MPP suggest that they also have a 
higher clonogenicity (39.6± 11.8%) than normal FL MPP (26.6 ± 3.8%).  The LMPP sub-
population of DS FL also had higher clonogenicity (15.4 ± 8.9%) than normal FL LMPP (4.3 
p=0.008** 
p=0.05
P=0.73
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± 1.3%) in myeloid colony assay conditions (Figure 3.15a). This compares with clonogenicity 
of the same immunophenotypically defined LMPP population in normal FL.  
 
The higher clonogenicity of DS FL HSC, was mainly due to a marked increase (~3-fold) in 
the numbers of megakaryocyte, erythroid and erythroid blast colonies generated from the DS 
HSC but increased numbers of myeloid blast colonies were also seen (Figure 3.15b). A 
similar increase in erythroid and megakaryocyte colonies was seen in DS FL MPP (Figure 
3.15b). However, an interesting finding was the growth of erythroid colonies from the LMPP 
sub-population in certain DS FL samples (Figure 3.15c) which, in normal cord blood, adult 
BM and, as my studies have shown, in normal FL, is a lymphoid primed progenitor 
population and which, in normal FL, gives rise only to GM lineage colonies (see section 
3.5.2).  Furthermore, in normal FL LMPP the erythroid gene expression signature is not 
detected, presumably inhibited by the onset of expression of B lymphoid genes (see Figure 
3.12 and 3.13). 
 
As for normal FL, the DS FL CD34+CD38lo/- compartment gave rise to both type I and type II 
erythroid blast cell colonies in myeloid clonogenic assays. In contrast to normal FL, the 
erythroid blast cell colonies in DS FL were more numerous and were also found in the LMPP 
compartment as well as the HSC and MPP compartments (Figures 3.15 and 3.16). In addition, 
DS FL type I erythroid blast colonies were much larger in size than those generated from 
normal FL although the type II erythroid colonies were very similar (Figure 3.16).
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c) Lineage read out in DS FL (n=4) 
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Figure 3.15 Myeloid colony readout of sorted normal and DS FL HSC, MPP and LMPP 
a) Clonogenicity of normal (n=6) and DS (n=4) FL HSC, MPP and LMPP. (b) Clonogenic 
readout of DS FL HSC, MPP, and LMPP compared to normal FL after 14 days of culture in 
methyl cellulose with IL3, IL6, IL11, SCF, FLT3, GM-CSF, TPO and EPO. Data are 
expressed as mean ± SEM. 
 
a) Type I erythroid blast colonies 
       x 4 
Normal FL      DS FL 
 
b) Type II erythroid blast colonies 
     x 10 
Normal FL      DS FL 
 
Figure 3.16 Erythroid blast colonies generated from normal and DS FL CD34+CD38-/lo 
compartment  Morphological appearance a) Type I erythroid blast colonies and b) Type II 
erythroid blast colonies generated from normal and DS FL HSC, MPP and LMPP after 14 
days of culture in methylcellulose with cytokines as described in section 2.4 
 
3.6.3 Identification of a markedly expanded CD7+ population within the HSC/ MPP  
and myeloid progenitor compartments of DS FL 
 
As part of my work on characterising lymphoid development in FL (see chapter 4), I 
investigated CD7 expression on the different sub-populations within the CD34+CD38-/lo, as 
500 μm 500μm
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well as the CD34+CD38+, compartment since work by Hao et al (Hao et al., 2001) had 
previously shown that cord blood CLP were CD34+CD38-/loCD45RA+CD7+. Unexpectedly, 
I found an unusual pattern of CD7 expression on FL HSC, MPP and myeloid progenitor 
populations both in DS and normal FL compared to adult BM HSC and progenitors (Table 
3.7; Figure 3.17).  
In DS FL, 81.9 ± 5.9% of the CD34+CD38-/lo population was CD7+ compared with the 29.6 ± 
6.1% of CD34+CD38-/lo cells in normal FL (p≤0.009 ).  Surprisingly, the majority of CD7+ 
cells were in the CD45RA- fraction. Since CD7 is regarded as an early marker of T cell 
commitment, this suggested that this might represent an expanded T cell progenitor 
population in DS FL but the absence of CD45RA expression made this very unlikely.  
 
Alternatively, the expanded population in DS FL could have been an 'aberrant' CD7+ early 
myeloid population.  This was particularly interesting since one of the characteristic features 
of DS-AMKL is that a very high proportion of the myeloid blast cells are CD7+ (Creutzig et 
al., 1996; Lange et al., 1998; Langebrake et al., 2005; Massey et al., 2006) suggesting that the 
expanded, aberrant CD7+ myeloid population might contain leukaemia-initiating cells which 
then gave rise to the expanded MEP population we had previously identified.  
 
I therefore went on to investigate CD7 expression on the HSC, MPP and LMPP sub-
populations in the CD34+CD38-/lo compartment as well as the myeloid progenitor 
compartment in DS FL. CD7 was particularly highly expressed in the LMPP population of DS 
FL: 95% of LMPP were CD7+ compared to 69.6 ±6.8% of normal FL LMPP (p ≤0.05). CD7 
was also highly expressed on DS FL MPP (86.1%) compared to normal FL (46.9 ± 7.7%; p 
≤0.05) and HSC (69.9% vs. 49.2 ± 10.4%) (Figure 3.17).  
 
There was also a high frequency of CD7+ cells in the CD34+CD38+ compartment of DS FL 
(84 ± 1.1%) compared to normal FL (56.8 ± 6.2%) although this was not statistically 
significant (p<0.12; Table 3.7). Further analysis showed that CD7 was particularly expressed 
on MEP in DS FL: 91.1 ± 1.2% expressed CD7 compared to normal FL (70.7 ±13.3%; p 
≤0.05). However, the majority of CMP and GMP in DS and normal FL were also CD7+ 
(Table 3.7; Figure 3.18). 
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 % CD7+ 
DS FL (n=4) 
% CD7+ 
Normal FL (n=11) 
p value 
Total CD34+ cells 
CD34+CD38+ 
CD34+CD38-/lo 
 
84 ± 1.1% 
81.9 ± 5.9% 
 
56.8 ± 6.2% 
29.6 ± 6.1% 
 
≤0.12 
≤0.009* 
HSC  
CD34+CD38-/loCD90+CD45RA- 
 
69.9% (n=2) 
 
49.2 ± 10.4% 
 
≤0.67 
MPP  
CD34+CD38-/loCD90-CD45RA- 
 
86.1% (n=2) 
  
46.9 ± 7.7% 
 
≤0.05* 
LMPP  
CD34+CD38-/loCD45RA 
 
95% (n=2) 
 
69.6 ± 6.8% 
 
≤0.05* 
CMP  
CD34+CD38+CD123++CD45RA-
 
75.8 ± 4.7% 
 
65.5 ± 8.8% 
 
≤0.4 
MEP  
CD34+CD38+CD123lo/-CD45RA-
 
91.1 ± 1.2% 
 
70.7 ±13.3% 
 
≤0.05* 
GMP 
CD34+CD38+CD123+CD45RA+ 
 
85.2 ± 4.8% 
 
78.6 ± 5.3% 
 
≤0.4 
 
Table 3.7 CD7 expression on normal and DS FL CD34+ cells  
 
These data show that CD7 expression is increased in all myeloid cell-containing sub-
populations in DS FL and that CD7 on these populations in normal FL is much higher than in 
the equivalent immunophenotypically defined populations in cord blood and adult BM. 
Overall only 17% of CB CD34+ cells and ~ 12% of CB CD34+CD38-/lo cells were CD7+. In 
adult BM the proportion was even smaller, with only 3.5% of total CD34+ cells expressing 
CD7. Although it is possible that these results are explained by a non-specific increase in CD7 
gene/protein production, the variation in the frequency of CD7 expression suggests that it may 
either identify a unique function of CD7 in fetal haematopoietic stem/progenitor cells or that 
expression of CD7 delineates unique sub-populations of stem/progenitor cells present only in 
fetal life.  
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Figure 3.17 Expression of CD7 on HSC, MPP and LMPP cells in DS FL compared with normal FL.  
Representative flow cytometry plots from enriched FL CD34 cells. The level of expression of CD7 in HSC,  
MPP and LMPP is depicted in a) normal FL (n=11) and b) DS FL (n=6) respectively.   
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Figure 3.18 Expression of CD45RA and CD7 on myeloid progenitors in DS FL 
compared with normal FL  
Representative flow cytometry plots from enriched FL CD34 cells. CMP were defined as 
CD34+38+45RA-123+; MEP: CD34+38+45RA-123- and GMP: CD34+38+45RAlo123+. The 
level of expression of CD7 in each of the myeloid progenitor population is depicted in a) 
normal FL (n=11) and b) DS FL (n=6) respectively. 
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3.6.4 Lymphoid potential of DS FL HSC, MPP and LMPP 
 
The capacity for HSC, MPP and LMPP from DS FL to undergo normal lymphoid 
differentiation and generate B cells, T cells and NK cells was investigated as described in 
section 3.5.3 above (see also section 2.5.2 for detailed methodology).  
 
3.6.4.1 Generation of B cells and NK cells from DS FL HSC, MPP and LMPP 
  
Co-cultures of DS FL HSC, MPP or LMPP with MS5 stromal cells generated almost no 
mature B cells (CD19+) (Figure 3.19) in contrast to normal FL (Figure 3.8). The day 14 read 
out of MS5 co-cultures from DS FL HSC, MPP and LMPP also shows that under these 
lymphoid culture conditions there were very few haematopoietic cells detectable by flow 
cytometry and most of these were still CD34+ suggesting impaired survival, proliferation and 
differentiation of DS FL HSC, MPP and LMPP despite conditions which I have shown are 
permissive for B cell differentiation from normal FL CD34+ cells. There were detectable NK 
and myeloid cells after 14 days of MS5 co-culture from only one out of 4 DS FL HSC 
samples tested and none from DS MPP and LMPP, in contrast to normal FL (Table 3.8).  
 
 B CELLS 
% CD34-CD19+ 
NK CELLS 
% CD34-19-CD56+ 
MYELOID CELLS 
% CD34-CD11b+and/CD14+
HSC (n=4) 
day 14 
0 ± 0% 
Normal FL: 0.7 ± 0.5% 
5.4 ± 5.4% 
Normal FL: 4.0 ± 0.2% 
14 ± 14% 
Normal FL: 15.2 ± 0.9% 
MPP (n=2) 
day 14 
0% 
Normal FL: 11.1% 
0% 
Normal FL: 3.1% 
0% 
Normal FL: 49.1%  
LMPP (n=2) 
day 14 
0% 
Normal FL: 65.4 ± 4.6%
0% 
Normal FL: 15.3 ± 8.9%
0 % 
Normal FL: 8.6 ± 3.9% 
 
Table 3.8 Generation of B, NK and myeloid cells from DS fetal liver HSC, MPP and 
LMPP in MS5 stromal cell co-cultures 
Cells were harvested from the co-cultures at day 14, and analysed by flow cytometry as 
shown above. The data are expressed as % of live human CD45+ cells detected in co culture 
on day 14.  
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Figure 3.19  Generation of B cells, NK cells and myeloid cells from DS FL HSC, MPP 
and LMPP 
Day 14 readout from DS FL HSC, MPP and LMPP on MS5 co-culture showing lack of 
production of CD34-CD19+ B cells, CD34-CD19-CD56+CD3- NK cells and CD33/CD11b+ 
myeloid cells. Cells were stained with human CD45 Alexa 700, CD34 PE Cy7, CD19 APC, 
CD10 FITC, CD56 PE, CD3 PE Cy5, CD11b FITC, CD33 PE antibodies and analyzed by 
flow cytometry. The plots shown are representative of 4 experiments. 
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3.6.4.2     Generation of T cells from DS FL HSC, MPP and LMPP 
 
T cell differentiation experiments were performed on the sorted HSC/MPP compartment (i.e. 
all CD34+CD38lo/-CD45RA- cells) rather than individually sorted HSC and MPP populations 
because of limited cell numbers, as my main priority was to investigate B cell differentiation. 
DS FL HSC/MPP or LMPP populations (n=2 samples) were both able to give rise to T cells 
following co-culture with OP9-DL1 cells (Table 3.9, Figure 3.20).   
 
As with normal FL, DS FL LMPP showed greater T cell potential than HSC/MPP: T cell 
generation by DS FL LMPP was around 4-fold greater than T cell generation by HSC/ MPP. 
The day 14 and day 21 readout of OP9-DL1 co-cultures from DS FL HSC/ MPP and LMPP is 
shown in Table 3.9.  
 
 % CD7+ % CD7+CD2+ % CD8+ or CD4+ % CD8+CD4+
HSC/MPP 
 (n=2) 
day 14 
day 21 
 
 
94.5% (79.5 ± 15) 
99.8% (84.3 ± 9.3) 
 
 
25.9% (26.5) 
59.3% (57) 
 
 
37% (31.7 ± 4.9) 
26.3% (40 ± 13.2) 
 
 
1.1% (3) 
0.9% (8) 
LMPP (n=2) 
day 14 
day 21 
 
82.5% (97.8 ± 0.7) 
99.9% (93 ± 2.4) 
 
46.9% (50 ± 9) 
26.3% (63.6 ± 10%)
 
53% (40.4 ± 4.9) 
36.3%(44.3 ± 10.5)
 
1.1% (6.4 ± 3) 
8.8% (22.7±13)
 
Table 3.9 T cell differentiation of DS FL HSC/MPP and LMPP on OP9-DL1 
Cells were harvested from co-cultures of DS FL HSC/MPP and LMPP on OP9-DL1 stroma at 
given time points, and analysed by flow cytometry as shown below. The data are expressed as 
% of human cells detected in co culture on day 14 and day 21 (mean of 2 experiments). T 
cells were defined as being CD7+CD2+CD4+ and/ CD8+. Figures in brackets represent 
results from corresponding normal FL populations. 
 
Although DS FL HSC/MPP and LMPP seemed to have comparable frequencies of 
CD7+CD2+ CD4 and/CD8+ cells produced in OP9-DL1 culture, the frequency of 
CD4+CD8+ double positive (DP) T cells was lower than normal FL. The absolute numbers of 
T cells produced was however lower in DS FL subpopulations (Figure 3.21 and 3.22) 
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a)     HSC/ MPP    LMPP 
                      
                               
 
 
b)     HSC/ MPP    LMPP 
                    
               
 
 
Figure 3.20  T lymphoid differentiation of DS FL HSC, MPP and LMPP on OP9-DL1 
stroma: a) CD7+CD2+; and b) CD4+ and/ CD 8+ T lymphocytes generated after 14 and 21 
days in OP9-DL1 co-culture of HSC/MPP and LMPP from DS FL (representative plot from 2 
samples tested). 
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Figure 3.21 Generation of T cells from normal and DS fetal liver LMPP in OP9-DL1 
stromal cell co-cultures 
500 LMPP cells were used to initiate OP9-DL1 co-cultures. A fraction of cells were removed 
from the co-cultures at the indicated times, and analysed by flow cytometry as shown above. 
Absolute counts were determined using CountBright Absolute counting beads (see section 
2.5). (n=2) 
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Figure 3.22 Generation of T cells from normal and DS fetal liver HSC/ MPP in OP9-
DL1 stromal cell co-cultures 
500 HSC/MPP cells were used to initiate OP9-DL1 cultures. A fraction of cells were removed 
from the co-cultures at the indicated times, and analysed by flow cytometry as shown above. 
Absolute counts were determined using CountBright Absolute  counting beads (see section 
2.5). (n=2) 
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3.6.5 Gene expression in DS FL HSC, MPP and LMPP 
 
I tested the expression of selected genes and haematopoietic transcription factors in the 
immunophenotypically defined HSC, MPP and LMPP from DS FL as described in 3.5.4, by 
simple RT-PCR and subsequently the BioMark Real time PCR (qRT-PCR) system. The aim 
of these studies was to investigate whether there were any detectable differences in levels of 
gene expression and lineage priming between DS FL HSC, MPP and LMPP and their normal 
counterparts which could help explain the perturbed fetal haematopoiesis in DS and/or the 
high frequency of AMKL and ALL in this condition.  
 
 
3.6.5.1      RT-PCR of selected genes in DS FL HSC/ MPP and LMPP 
 
Expression of the same profile of lineage-associated transcription factors assessed in normal 
FL HSC and LMPP, was also investigated in these sub-populations from DS FL: GATA1 
(HSC/MPP and erythroid/megakaryocytic progenitors); CEBPα (HSC/MPP and GMP); Pax5 
(B cell progenitors), PTCRΑ (T cell progenitors) and PU.1 as a control gene. RNA was 
extracted from flow-sorted HSC and LMPP from two DS FL samples and subjected to RT-
PCR as described in section 2.7.1 (MPP were not studied using RT-PCR as cells were 
reserved for more extensive gene expression studies using the BioMark qRT-PCR system. 
The presence of cDNA in all samples was confirmed by positive amplification of β-actin. A 
representative agarose gel is shown in Figure 3.23 and the results are summarised in Table 
3.10.  
 
There were no differences in the expression of the 2 lymphoid genes (PAX5 and PTCRΑ, 
neither of which had detectable expression in DS or normal FL HSC or LMPP (Table 3.10). 
However, of potential interest, I did find differences in the apparent level of expression of 
GATA1 and CEBPα in DS FL compared to normal FL. Specifically, GATA1 was expressed 
more strongly in DS FL HSC compared to normal FL HSC and CEBPα expression was 
undetectable in DS FL HSC whereas it was expressed in normal FL HSC (both by RT-PCR 
and qRT-PCR). This could indicate that there is stronger megakaryocyte-erythroid priming at 
the expense of myeloid priming in DS FL HSC. However, a caveat is that I also did not detect 
CEBPα in normal (or DS) FL LMPP whereas this was clearly detectable in normal FL LMPP 
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by qRT-PCR (Figure 3.12).  It is also interesting to note that GATA1 was not expressed in DS 
FL LMPP despite data from the clonogenic assays demonstrating that this sub-population has 
some erythroid lineage capacity in DS FL. 
                HSC         LMPP 
               
           
           
         
           
           
 
  GENE              HSC 
  CD34+38-45RA-90+ 
             LMPP 
     CD34+38-45RA+ 
 Normal FL DS FL Normal FL DS FL 
PU.1     +     +     +     + 
GATA1    +/-     +     -     - 
CEBPα     +     -     -     - 
PAX5     -     -     -     - 
PTCRA     -     -    +/-     - 
 
Table 3.10 Gene expression by RT-PCR in flow sorted HSC and LMPP from DS FL 
Gene expression was measured by RT-PCR on sorted populations from DS FL (n=2). The 
results are compared with those obtained in normal FL (data from Table 3.4).  Populations in 
which a distinct band of the expected size was consistently seen on agar gel electrophoresis 
are marked +; populations in which a band of the expected size was consistently undetectable 
with bands in the control lane and β-actin are marked -; populations where the band was 
consistently very weak or results were variable are marked as +/-.  
β actin 
Figure 3.23: Expression of PU.1, GATA1, 
CEBPα, PTCRA, PAX5, and β-actin checked 
by RT-PCR for DS FL CD34 sub 
populations. Lane1: HSC cells; Lane2: 
LMPP cells on 1.5% agarose gel. cDNA 
integrity was checked by expression of β 
actin- all subpopulations expressed β actin 
(n=2 DS FL samples) 
 PU.1 
GATA1 
CEBPα 
PAX5 
PTCRA 
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3.6.5.2      Fluidigm real time PCR of selected genes in normal and DS FL HSC, MPP 
and LMPP 
 
DS FL HSC, MPP and LMPP had a similar pattern of expression to normal FL of HSC 
regulatory genes (c-KIT, c-MPL, PU.1, ERG and GATA2) which were all highly expressed in 
DS FL HSC and, as in normal FL, progressively downregulated as cells differentiated from 
MPP to LMPP (Figure 3.24a).  There were, however, some potentially interesting differences 
in the relative expression of some of these genes: FLT3 expression was relatively low in DS 
FL HSC, MPP and LMPP (Figure 3.24b), possibly in association with impaired B lymphoid 
development in DS. 
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Figure 3.24 Relative expression of stem cell genes in DS and normal FL HSC, MPP and 
LMPP (Note: y axis scales are different in a) and b))  
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Gene expression levels are shown relative to the expression of GAPDH and are the mean ± 
SEM of 3 normal FL and 3 DS FL samples from which 50 cells of each CD34+ sub 
population (HSC, MPP and LMPP) were sorted in triplicate for analysis by qRT-PCR. 
 
DS FL HSC and MPP, like normal FL HSC/MPP, co-expressed genes associated with 
erythroid/ megakaryocytic, myeloid and early lymphoid development. However, the pattern of 
lineage priming was distinctly different in DS FL HSC and MPP. In particular, GATA1 
appeared to be expressed at higher levels in DS FL HSC and was accompanied by high levels 
of GATA2, although not significantly more than in normal FL (Figure 3.25). Together these 
data suggest increased erythroid or erythroid-megakaryocyte priming of DS FL HSC, 
although FOG1, EPOR and GYPA were not expressed at higher levels in DS FL (see chapter 
5) and Appendix 3 (Figures A4, B3, F1); but the data need to be confirmed by analysing more 
samples. 
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Figure 3.25 Relative expression of a) GATA1 and b) GATA2 in DS FL HSC, MPP and 
LMPP compared to normal FL.  
Gene expression levels are shown relative to the expression of GAPDH and are the mean ± 
SEM of 3 normal FL and 3 DS FL samples from which 50 cells of each CD34+ sub 
population (HSC, MPP and LMPP) were sorted in triplicate for analysis by qRT-PCR  
 
Most of the myeloid-associated genes I tested were expressed in the DS FL HSC/MPP LMPP 
compartment (CEBPα, GM-CSFR and CSF1R) (Figure 3.26; G-CSFR is shown in Appendix 
3). The only consistent difference was the lower level of CEBPα expression in DS FL HSC 
and LMPP (Figure 3.26) consistent with the results of RT-PCR, the reduction in GMP in the 
DS FL CD34+CD38+ compartment and the differences in colony profile seen in myeloid 
clonogenic assays, whereby DS FL HSC gave rise to mainly CFU-M as opposed to CFU-M, 
CFU-GM and CFU-G seen in normal FL cultures. 
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Figure 3.26 Relative expression of CEBPα, GM-CSFR and CSF1R in a) DS FL HSC, 
MPP and LMPP and b) normal FL.  (Note: y axis scales are different in a) and b)) 
Gene expression levels are shown relative to the expression of GAPDH and are the mean ± 
SEM of 3 normal FL and 3 DS FL samples from which 50 cells of each CD34+ sub 
population (HSC, MPP and LMPP) were sorted in triplicate for analysis by qRT-PCR  
 
Finally, expression of FLT3 and IL7RA, which are believed to be the initial determinants of 
lymphoid lineage restriction (Sigvardsson et al, 2010), was markedly reduced in DS FL HSC, 
MPP and LMPP compared to normal FL (Figure 3.24 and Figure 3.27).    
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Figure 3.27 Relative expression of a) FLT3and b) IL7RΑ in DS FL HSC, MPP and 
LMPP compared to normal FL 
Gene expression levels are shown relative to the expression of GAPDH and are the mean ± 
SEM of 3 normal FL and 3 DS FL samples from which 50 cells of each CD34+ sub 
population (HSC, MPP and LMPP) were sorted in triplicate for analysis by qRT-PCR  
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Expression of genes on chromosome 21 
There was no consistent increase in the level of any of the genes on chromosome 21 in DS FL 
HSC, MPP or LMPP (ERG, RUNX1, DSCR1, DYRK1A and GABPA) compared to their 
counterparts in normal FL apart from RUNX1 which was slightly increased in DS FL HSC 
(Figure 3.28). There were differences in the levels of expression of some of the chromosome 
21 genes in other subpopulations of DS FL and these are discussed in chapters 4 and 5 and the 
data are all shown in Appendix 3.  
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Figure 3.28 Relative expression of RUNX1 in DS FL HSC, MPP and LMPP compared to 
normal FL  
Gene expression levels are expressed relative to the expression of GAPDH. Data is shown as 
mean ± SEM of 3 normal FL and 3 DS FL samples from which 50 cells of each CD34+ sub 
population (HSC, MPP and LMPP) were sorted in triplicate for analysis by qRT-PCR 
 
3.7  Summary and discussion 
 
The aim of these experiments was firstly, to characterise the HSC/MPP compartment in 
normal second trimester FL and to determine whether LMPP were also present; and secondly 
to determine whether there were any changes in the HSC/MPP compartment in DS FL 
compared to normal FL.   
 
Since there have been no previous descriptions of the HSC compartment in normal human FL, 
I started by adapting the immunophenotypic criteria used to define HSC, MPP and LMPP in 
cord blood and adult BM (Goardon, 2010; Majeti et al., 2007).  Using this approach I have 
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confirmed that HSC, MPP and LMPP are all found in normal second trimester FL where they 
form 2.4± 0.4%; 5.9± 0.8% and 2± 0.3% respectively of the whole CD34+ population. 
Consistent with their immunophenotypic definition, HSC and MPP both had full multilineage 
potential, giving megakaryocyte-erythroid and myeloid readouts in semi-solid clonogenic 
assays; and mature B, NK and T cells in MS5 and OP9 stromal co-culture systems.   
 
Although I did not formally confirm their hierarchical relationship, both the clonogenic 
profile and gene expression studies were consistent with MPP being more mature than HSC, 
with relatively lower expression of stem cell genes and up regulation of megakaryocyte-
erythroid and lymphoid specific genes in the MPP compared to the HSC.  As reported for 
murine data (Mansson et al., 2007), and more recently in human adult BM (Goardon, 2010), 
normal FL LMPP had no megakaryocyte-erythroid potential in vitro, but retained limited 
myeloid potential (mainly CFU-M) and produced B, NK and T cells very efficiently in 
stromal co-culture systems, confirming that they are lymphoid primed. The in vitro data was 
supported by qPCR results which showed that stem cells genes were further down regulated; 
megakaryocyte-erythroid genes were silenced and lymphoid-specific genes were up regulated 
in LMPP consistent with LMPP being more mature stage of the HSC differentiation hierarchy 
than HSC and MPP.  
 
My results have for the first time demonstrated that human FL HSC, MPP and LMPP can be 
identified using the same criteria used for human cord blood and ABM (Majeti et al., 2007). 
Formal proof of this would require transplantation studies in a xenograft model, which are 
currently being performed as part of another project by a post-doc in the lab. Similar to cord 
blood HSC and MPP, normal FL HSC and MPP have a multilineage readout although, unlike 
cord blood, FL MPP are much more clonogenic than FL HSC in the second trimester. This 
property, and that fact that both HSC and MPP in normal FL were markedly skewed towards 
the erythroid/megakaryocyte lineage, may reflect the very high demand for increasing red cell 
and platelet production during this period of very rapid fetal growth, at a time before full 
haematopoiesis is established in the BM and there may be little physiological necessity for a 
large reserve of long-lived HSC in the FL, a transient haematopoietic site.  
 
I have also demonstrated for the first time that FL HSC and MPP produced B, NK and T cells 
in lymphoid co-culture systems. No such data are available for corresponding human cord 
blood or adult BM populations; however there are data to show that human cord blood 
 133
CD34+38- cells can give rise to B and T cells in vitro (La Motte-Mohs et al., 2005). My 
results showed that FL LMPP had limited myeloid potential in colony assays (similar to cord 
blood LMPP) and efficiently produced B, NK and T cells in lymphoid co-culture systems 
confirming that these are 'lymphoid primed' MPP. Similar lymphoid culture assay results have 
been described for adult BM LMPP (Goardon, 2010).  Taken together, my data show, that 
despite a longstanding belief that B-lymphopoiesis occurs in fetal BM, there is clear evidence 
of a distinct, immunophenotypically-defined, strongly primed, lymphoid progenitor 
population, able to give rise to mature B, T and NK cells at least in vitro, in normal FL during 
the second trimester. 
 
My second aim, to determine whether there were any changes in the HSC/MPP compartment 
in DS FL compared to normal FL, arose as a result of recent data from our lab which had 
shown that there were distinct abnormalities in the myeloid progenitor compartment in DS FL 
(Tunstall-Pedoe et al., 2008). I hypothesised that T21 would also perturb the earlier MPP and 
HSC compartments. Using a number of approaches, my data have confirmed that there are 
several important differences in the size, composition and function of the HSC compartment 
in DS FL.  
 
First, I found that the HSC compartment was around 3-fold larger in DS FL compared to 
normal FL with HSC, MPP and LMPP forming 6.5± 0.6%; 3.2± 0.5% and 1.9± 0.9% 
respectively of all CD34+ cells; there was a commensurate reduction in MPP in DS FL 
suggesting that there may also be a block to normal HSC differentiation in DS FL. In addition, 
I found a large, 'aberrant' CD7+ population of HSC and progenitors in DS FL: CD7 was 
highly expressed on HSC, MPP, LMPP, CMP, MEP and GMP, with the highest levels on 
LMPP and MEP.  Thirdly, DS FL HSC, MPP and LMPP were all much more clonogenic than 
their counterparts in normal FL HSC and MPP. Consistent with the marked megakaryocyte-
erythroid bias noted in the myeloid progenitor compartment, a similar bias was seen in HSC 
and MPP, although the ability to produce CFU-GM and myeloid blast cell colonies was 
preserved at normal levels. Furthermore, despite being CD45RA+, DS FL LMPP retained the 
capacity to generate erythroid colonies in direct contrast to normal FL LMPP which had lost 
all megakaryocyte-erythroid lineage potential. Taken together, these data help to explain the 
high numbers of colonies of all myeloid lineages grown from DS FL CD34+ cells reported in 
the original work from our lab despite reduced numbers of CMP and GMP (Tunstall-Pedoe et 
al, 2008) since many of the colonies must have derived from the HSC/MPP/LMPP 
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compartment rather than the mature myeloid progenitor compartment. In addition, my data 
support the hypothesis that T21 itself perturbs FL haematopoiesis and extend the role of T21 
to include significant effects on the HSC/MPP/LMPP compartment, as well as on more 
mature myeloid progenitors.  
 
Gene expression data provided some clues to the molecular basis for the haematological 
abnormalities in DS FL HSC. Expression of both GATA1 and GATA2 appeared to be 
increased, consistent with the megakaryocyte-erythroid bias observed in clonogenic assays. 
This increase was accompanied by a reduction in the expression of B-lymphoid genes in DS 
FL HSC and LMPP suggesting defective lymphoid priming and of CEBPα suggesting 
impaired granulocyte differentiation capacity.  However, the role of Hsa 21 in mediating these 
changes is so far unclear since none of these genes is expressed on chromosome 21 or targeted 
by one of the 5 miRs on Hsa21. There has been longstanding interest in the possible 
contribution of RUNX1 to DS-AMKL since mutations in RUNX1 are well recognised in AML, 
including those with T21 (Osato et al., 1999; Preudhomme et al., 2000). There is also 
evidence that RUNX1 cooperates with GATA1 during megakaryocyte differentiation (Elagib et 
al., 2003).. On the other hand, RUNX1 expression is not increased in DS-AMKL (Bourquin et 
al., 2006) and mouse models of T21 indicate that RUNX1 is not required for the development 
of MPD (Gjertson et al., 1999; Kirsammer et al., 2008). 
 
As well as the abnormalities in myeloid function of the HSC/MPP compartment in DS FL, I 
also found that unlike the corresponding normal FL populations, DS FL HSC/MPP and LMPP 
did not generate B or NK cells in MS5 co-culture suggesting specifically impaired B-
lymphoid differentiation and proliferation since T cell differentiation, though not optimal 
compared to normal FL, was much less affected. qRT-PCR results demonstrate much lower 
expression of early lymphoid and B lymphoid specific genes when compared to normal FL, 
which may explain the lymphoid defect seen.  
 
In conclusion, all of the immunophenotypically defined HSC and multipotent progenitor 
populations previously described in murine fetal and adult haematopoietic tissues were also 
seen in normal human second trimester FL. Flow cytometry, colony assays and gene 
expression studies suggest that FL HSC/MPP may be preferentially 'myeloid primed' but they 
are still able to generate mature cells of all of the principal lymphoid lineages.  Studies in DS 
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FL HSC/MPP/LMPP indicate that T21 also perturbs their normal proliferation and 
differentiation and causes a pronounced megakaryocyte/ erythroid differentiation bias which 
may partially, or completely, block normal lymphoid differentiation, particularly of the B 
lineage. The experiments in the next chapter investigated this further by characterising B 
progenitors in normal and DS FL and BM. 
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CHAPTER 4  
 
CHARACTERISATION OF THE LYMPHOID PROGENITOR 
COMPARTMENT IN NORMAL AND DS FETAL LIVER AND 
BONE MARROW 
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4.1 Background 
 
4.1.1 DS and acute lymphoblastic leukaemia (ALL) 
As discussed in chapter 1, children with DS have an increased risk of ALL as well as 
AMKL (Hasle et al., 2000). ALL in children with DS has several clinical, biological and 
molecular features distinct from non-DS ALL (Forestier et al., 2008; Izraeli, 2010; 
Whitlock, 2006): virtually all cases are B lineage, there is a lower incidence of 
favourable/unfavourable chromosomal translocations and they have a high prevalence 
(~18%) of JAK2 pseudokinase domain mutations (Bercovich et al., 2008; Kearney et al., 
2009) and increased CRLF2 expression (Hertzberg et al., 2010; Russell et al., 2009). 
These data directly implicate T21 as crucial for ALL pathogenesis and raise the 
possibility that T21 might perturb lymphopoiesis as well as myelopoiesis.  
 
4.1.2 DS and immune abnormalities 
Several lines of evidence suggest that T21 itself affects lymphocyte development and 
function.  Children with DS are known to be lymphopenic, with a progressive decline in 
B and T cell lymphocyte numbers during childhood (de Hingh et al., 2005; Douglas, 
2005). Variable degrees of immunoglobulin deficiency have also been reported (Loh et 
al., 1990) and children with DS also have increased susceptibility to infections and 
autoimmune disorders (Garrison et al., 2005; Gillespie et al., 2006; Karlsson et al., 1998).    
However, the cellular and molecular basis for immune deficiency in DS and the 
relationship between abnormalities in lymphocyte development and acute leukaemia in 
DS are unknown.  
 
4.1.3 Normal fetal lymphopoiesis 
As discussed in chapter 1, human fetal lymphopoiesis is poorly understood and most of the 
data derive from murine studies (Bhandoola et al., 2007; Bunting, 2009; Kawamoto et al., 
1998; Kondo et al., 1997; Lu et al., 2002; Serwold et al., 2009) and from small observational 
studies relying on very limited flow cytometry and immunohistochemistry of fetal liver and 
bone marrow sections (Bofill et al., 1985; Hofman et al., 1984; Reynaud et al., 2003; Uckun, 
1990; Uckun and Ledbetter, 1988). Understanding normal fetal lymphopoiesis has been made 
more difficult by the use of different purification and immunophenotyping strategies by 
different groups as well as ongoing controversy surrounding alternative routes of lymphoid 
progenitor differentiation described by different groups (Bunting, 2009).  My studies have 
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focused on fetal B cell development because of the striking association of DS with B cell 
immune deficiency and B-ALL, rather than T-ALL. To explain the strategy I used for 
investigating human FL lymphopoiesis, I will briefly outline the main principles for 
identifying and classifying fetal B lymphoid progenitors. 
 
As shown in chapter 3, B cell potential is detectable from the earliest stage of haematopoietic 
differentiation.  My data show that in human FL all of the populations in the CD34+CD38lo/- 
compartment are able to give rise to B cells, T cells and NK cells, with progressively 
increased lymphoid output (together with progressively restricted differentiation potential 
down other lineages) as cells mature from HSC to MPP to LMPP. However, what has 
generated most controversy is the differentiation hierarchy downstream of LMPP where 
debate surrounds the existence, or not, of a purely lymphoid progenitor cell lacking any 
myeloid progeny, designated a 'common lymphoid progenitor' (CLP) (see Figure 4.1). 
 
Apparent CLP able to give rise only to B cells, T cells and NK cells were originally defined in 
mouse BM as CD34+/CD38-/lo/Lin-IL7R+/CD90-/Sca1lo/c-kitlo by (Kondo et al., 1997) and 
more recently confirmed by Weissman's group who added Flk2 (also known as Flt3) 
positivity to distinguish CLP (Flk2+) from MPP (Flk2-) (Serwold et al., 2009). Cells with the 
same differentiation ability have also been described in human adult BM, fetal BM and cord 
blood although the immunophenotypic profiles used by the investigators to define CLP were 
different: Galy et al defined CLP in human adult and fetal BM as CD34+lin-CD38+CD10+ 
(Galy et al., 1995) while Hao and Hoebeke used the definition CD34+CD38-CD7+ for CLP in 
human cord blood (Hao et al., 2001; Hoebeke et al., 2007).  
 
However, in contrast to these findings, other investigators have found that all ‘common 
lymphoid progenitors’ (i.e. those able to give rise to B cells, T cells and NK cells) also retain 
some myeloid activity, at least under some experimental conditions, and suggest that some, if 
not all, B progenitors and T progenitors arise from MPP and LMPP (Bell and Bhandoola, 
2008; Benz et al., 2008; Bhandoola et al., 2007; Boehm and Bleul, 2006; Pelayo et al., 2005; 
Wada et al., 2008); others go further and report that there is no evidence for the existence of 
'true CLP' with uniquely lymphoid potential in either mouse or human FL or in adult mouse 
BM (Mebius et al., 2001).  One of the first questions I therefore had to address in my work 
was whether or not a true CLP could be identified in second trimester human FL.  
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Downstream of CLP (or LMPP), commitment to the B cell lineage occurs along with loss of 
T cell and NK cell potential- these cells are known as committed B progenitors (CBP).  In 
adult BM, CBP, which are all CD34+, are believed to sequentially acquire CD10 and then 
CD19 such that three types of CBP with increasing maturity (ProB1, ProB2 and Pre-PreB) 
can be identified on the basis of their surface marker expression as summarised in Figure 4.1 
and Table 4.1. Whether these different B progenitor stages exist in human FL is unclear and 
indeed recent data in cord blood suggest that B progenitor maturation may have a uniquely 
'fetal' pattern in which B progenitors first acquire CD19 and then become CD10+ rather than 
the maturation pattern described in adult BM (Davi et al., 1997; Hystad et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Schematic representation of human B cell differentiation 
LMPP: lymphoid primed multipotent progenitor (has mainly lymphoid but also some myeloid 
potential); CLP: common lymphoid progenitor (purely lymphoid: B/T/NK potential); ELP: 
early lymphoid progenitor (more mature than CLP: B/T/NK lymphoid potential); CBP: 
committed B progenitor (purely B lymphoid potential). In black are lymphoid progenitor 
populations that have been described in cord blood, or adult BM. In red is the corresponding 
nomenclature that I have used to describe B progenitor populations that I looked for/ found in 
human fetal liver and fetal bone marrow. 
 
4.2 Aim 
 
The aim of the experiments described in this chapter was firstly, to characterise lymphoid 
progenitors, particularly B progenitors, in normal second trimester FL and to determine 
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whether CLP were also present; secondly to determine whether there were any changes in the 
B progenitor compartment in DS FL compared to normal FL; and finally, to determine 
whether there were any changes in the B progenitor compartment in fetal BM in DS. 
 
4.3 Experimental approach 
The human fetal samples studied were all from the second trimester and DS FL (n=6) and 
fetal BM (n=4) samples were compared to normal FL (n=10) and fetal BM (n=6) samples of 
this gestation in order to identify whether there were any differences due to T21. To develop 
the analytical techniques used to study lymphoid development in fetal tissues, I first studied 
human term cord blood. The approaches used to characterise the lymphoid compartment were 
immunophenotyping by flow cytometry, clonogenic assays to evaluate residual myeloid 
potential, liquid culture to evaluate lymphoid differentiation and gene expression by RT-PCR 
and qRT-PCR using the nanofluidic BioMark 48.48 dynamic array and TaqMan expression 
assays of flow-sorted lymphoid progenitor populations. A major limitation of my analysis was 
the very limited sample size and sample numbers of fetal tissues available for these studies. 
 
Progenitor name 
 
Abbreviation 
used 
 
Immunophenotype 
Common lymphoid progenitor CLP CD34+CD38lo/-CD45RA+CD7+ 
Early B lymphoid progenitor EBP CD34+CD127+CD10-CD19- 
 
Committed B lymphoid progenitor 1 CBP1 CD34+CD10+CD19- 
 
Committed B lymphoid progenitor 2 CBP2 CD34+CD10+CD19+ 
 
Committed B lymphoid progenitor 3 CBP3 CD34+CD10-CD19+ 
 
 
Table 4.1   Immunophenotype of human common lymphoid and committed B lymphoid 
progenitors 
 
4.4 Identification of 'CLP' and B progenitors in cord blood 
 
As mentioned above, within the committed B progenitor (CBP) compartment, which all 
express CD34, there is a hierarchy of B progenitor differentiation as progenitors gain CD10 
expression followed by CD19 expression and then lose expression of CD10. I have used the 
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terms CBP1, CBP2 and CBP3 to denote these progenitors which broadly equate to the Pro-
B1, Pro-B2 and Pre-Pre B stages of B cell development described in adult BM.  The reason I 
used this terminology was that during my project, a carefully executed study clearly showed 
the existence of an alternative developmental pathway of B lymphopoiesis in cord blood in 
which B progenitors acquired CD19 before CD10 (Sanz et al., 2010) and indeed 
CD34+CD19+CD10- cells may represent Pre-Pro B cells rather than ‘Pre-Pre B cells’.  
 
I established normal ranges for these progenitors in normal cord blood (CB) (using the 
immunophenotypic profiles shown in Table 4.1) before beginning the analyses in fetal tissues.  
Representative flow cytometry plots are shown in Figure 4.2 and a summary of the data from 
the analysis of 10 normal term cords is shown in Table 4.2. 
 
 
 
 
a) Putative common lymphoid progenitor (CLP: CD34+CD38lo/-CD45RA+CD7+) 
         
 
CLP 
CD38 CD7
CD34 CD45RA
CD34 CD34 FSC 
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b) Early lymphoid progenitor (ELP: CD34+CD127+CD10-CD19-) 
        
 
  
 c) Committed B progenitor (CBP: Pro-B1: CD34+CD10+CD19-; Pro-B2: 
CD34+CD10+CD19+) 
 
                  
 
 
 
d) Committed B progenitor (CBP3/ “Pre-Pre B”: CD34+CD19+CD10-)  
        
 
Figure 4.2: Immunophenotypic analysis of a) common, b) early lymphoid progenitors and c), d) 
committed B progenitors in human term cord blood (CB). CD34+ cells were isolated from normal 
CB by immunomagnetic beads (see 2.2), labeled with CD34 PerCP/ PE Cy7, CD38 Pacific Blue, CD7 
PE, CD127 PE, CD19 APC and CD10 FITC antibodies and analyzed by flow cytometry. 
Representative data from 10 experiments (data summarised in Table 4.2). The proportion of 
immunophenotyic CLP is consistent with Hao et al (Hao et al., 2001) 
ELP
CBP1: Pro-B1 CBP2: Pro-B2
CBP3: Pre-Pre B
CD127 CD10
CD19CD34 
CD10
CD19CD34 
CD10 
CD10
CD19
CD34 
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Progenitor Immunophenotype % of CD34+ cells  
CLP CD34+38lo/-45RA+7+ 0.12+ 0.05  
ELP CD34+127+10-19- 0.9+ 0.24 
CBP1 (ProB1) CD34+10+19- 3.6+ 1.0 
CBP2 (ProB2) CD34+10+19+ 3.5+ 1.3 
CBP3 (‘Pre pre B’) CD34+10-19+ 0.34+ 0.1 
 
Table 4.2  CLP and B lymphoid progenitors in normal cord blood 
The data shown are the mean + SEM of 10 normal CB samples. 
 
 
4.5 The lymphoid progenitor compartment in normal fetal liver 
 
4.5.1 Immunophenotypic analysis of the lymphoid compartment of normal human FL 
The CD34+ compartment of second trimester human FL was analyzed by flow cytometry to 
determine whether CLP, ELP and CBP (defined as in 4.4 above) were present and their 
relative proportions.  The data are summarised in Table 4.3 and representative flow 
cytometric plots are shown in Figure 4.3 and Figure 4.4.  
Progenitor Immunophenotype % of CD34+ cells  
CLP CD34+38lo/-45RA+7+ 0.75+ 0.2  
ELP CD34+127+10-19- 3.1+ 0.8 
CBP1 (ProB1) CD34+10+19- 1.0+ 0.2 
CBP2 (ProB2) CD34+10+19+ 7.2+ 1.0 
CBP3 (Pre-Pre B) CD34+10-19+ 3.6+ 0.5 
 
Table 4.3 CLP and B lymphoid progenitors in normal human FL 
Data shown are the mean +SEM of 10 normal second trimester FL samples 
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 a) CLP  
 
 
             
 
 
b) ELP  
 
   
 
 
 
Figure 4.3 Immunophenotypic analysis of a) common lymphoid progenitors (CLP) and 
b) early lymphoid progenitors (ELP) in normal second trimester human FL.  
CD34+ cells were isolated from normal FL by immunomagnetic beads, labeled with CD34 
PerCP/ PE Cy7, CD38 Pacific Blue, CD7 PE, CD127 PE, CD19 APC and CD10 FITC 
antibodies and analyzed by flow cytometry. Representative data from 10 experiments.  
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c) CBP1 (Pro-B1) and CBP2 (Pro-B2)  
  
   
 
 
d) CBP3 (Pre-Pre B) 
 
     
   
Figure 4.4 Immunophenotypic analysis of committed B progenitors in normal second 
trimester human FL.  
CD34+ cells were isolated from normal FL by immunomagnetic beads (see 2.2), labeled with 
CD34 PerCP/ PE Cy7, CD38 Pacific Blue, CD7 PE, CD127 PE, CD19 APC and CD10 FITC 
antibodies and analyzed by flow cytometry. Representative data from 10 experiments.  
 
 
Immunophenotypically-defined CLP were present in all the FL samples I investigated (n=10). 
This is the first demonstration of CLP in normal human FL.  The numbers of CLP were low, 
ranging from 0.03-1.7% of normal FL CD34+ cells (mean 0.75+0.2%) which was 
significantly higher (p≤ 0.03) than in CB (0.12+ 0.05%) (see also Figure 4.5).  There are also 
no data about ELP in human FL.  However, ELP were detectable in all normal FL samples I 
analyzed with a range from 0.4 - 7% of total CD34+ cells and a mean frequency around 4-fold 
CD10
CD19
CD10 
CD34 
CD10
CD19
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CD19 
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greater than the frequency of CLP in FL consistent with their position in the lymphoid 
differentiation hierarchy downstream of CLP. Again, the frequency of ELP was significantly 
higher in normal FL compared to CB (3.1+ 0.8  vs. 0.9+ 0.24; p≤ 0.03) (Figure 4.5). 
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Figure 4.5 Lymphoid progenitors in normal FL compared with term CB  
 
Frequency of CLP (common lymphoid progenitors); ELP (early lymphoid progenitors); and 
CBP (committed B progenitors) in normal FL CD34+ cells compared with CB CD34+ cells. 
Data are expressed as mean (±SEM) of flow cytometric analysis of CD34+ cells from normal 
human second trimester FL (n=10) and term CB (n=10). The inverted commas around CLP 
reflect the fact that data later in this chapter showed that this population appeared to have 
some residual myeloid activity and therefore this immunophenotypically defined population 
might not be a purely lymphoid progenitor in human FL. (* p <0.05; ** p <0.01) 
 
CBP have previously been reported in human fetal BM and CD10+ cells, which were largely 
CD19-, and which are most likely to represent CBP, have also been reported in human FL 
(Uckun, 1990). In keeping with this, I also found all three types of CBP in normal FL. The 
majority of normal FL CBP were CD10+CD19+ (CBP2) and they formed a substantial 
proportion of normal FL CD34+ cells (7.2+1%), with a frequency of around twice that found 
in CB (p≤ 0.03) (Figure 4.5).  The second most abundant form of B progenitor in normal FL 
was CD19+CD10- CBP3 (3.6+ 0.5% of CD34+ cells) and very interestingly these were found 
**
*
*
*
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at a much higher frequency than in CB (0.34+ 0.1%; p <0.0002) (Figure 4.5).  The CBP1 
population, which may contain a mixture of types of lymphoid progenitor since it does not 
express surface CD19, formed only 1.0 +0.2% of CD34+ cells in normal FL, compared to 
3.6+ 1.0% in normal CB (p≤ 0.05) (Figure 4.5). CBP are not defined on the basis of their 
CD38 expression; however there were no CD19+ or CD10+ cells detectable in the CD34+ 
CD38lo/- fraction of normal FL. 
 
 
4.5.2   Differentiation of normal FL CLP, ELP and CBP into mature lymphocytes 
 
To confirm the lymphoid differentiation capacity of cells within the immunophenotypically-
defined CLP, ELP and CBP in normal human FL, these populations were isolated from 
normal second trimester FL samples by flow sorting and co-cultured at 100 cells/well in 96-
well plates pre-plated with MS5 murine stromal cells in alpha MEM with cytokines.  
 
Since I wanted to confirm the NK and GM/G/M as well as B lymphoid potential I added a 
cocktail of cytokines to support each lineage: IL2, IL7, FLT3, SCF, G-CSF and GM-CSF as 
described in section 2.5.2 and modified from Doulatov et al (Doulatov et al., 2010).  
 
In order to determine the ability of CLP, ELP to produce T cells and to confirm the B cell 
specificity of each of the three CBP populations, each population was also flow-sorted and 
cultured at 500 cells/well in 24 well plates pre-plated with OP9-DL1 murine stromal cells in 
alpha MEM with Flt3 and IL7 as described in section 2.5.1.  
 
 
4.5.2.1 Generation of B cells and NK cells from normal FL CLP, ELP and CBP 
 
Normal FL CLP and ELP gave rise to B cells after co-culture with MS5 stromal cells (Figure 
4.6). The vast majority of the CD34-CD19+ cells generated did not express CD10 initially by 
flow cytometry strongly suggesting that CD19 is acquired before CD10 when normal FL 
CD34 cells are cultured in vitro which is consistent with the alternative pattern of B cell 
maturation recently described in CB (Sanz et al., 2010).  
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CLP and ELP also gave rise to NK cells (CD34-CD56+CD2-) and myeloid cells (CD11b+ 
CD14+/-) consistent with their earlier position in the differentiation hierarchy.  Interestingly, 
ELP appeared to have greater myeloid potential than CLP in this co-culture system despite the 
fact that ELP are CD38+ and have previously been placed downstream of CLP. These data 
indicate that in normal FL, lymphoid progenitors appear to retain myeloid and NK potential at 
least as far as the CBP stage of differentiation and that there may be no purely lymphoid 
progenitors detectable within the CD34+CD38lo/- compartment in human FL.  
 
As expected, normal FL CBP gave also rise to B cells after co-culture with MS5 stromal cells 
(Figure 4.7).  Interestingly, the majority of the CD34-CD19+ cells were CD10+ by day 14 
consistent with the 'fetal' pattern of B cell differentiation described in CB by Sanz and 
colleagues and with my in vitro results in chapter 3. Thus, CBP1 (CD34+10+19- ) acquired 
CD19 in vitro, while CBP2 retained both CD10 and CD19 as they lost CD34 expression 
during maturation to Pre-B cells (CD34-CD10+CD19+). These data, together with my 
immunophenotypic data showing a predominance of CBP2 in normal FL, provide further 
evidence that the normal pattern of fetal B progenitor development involves sequential 
acquisition of CD19 followed by CD10.  Furthermore, even with prolonged co-culture on 
MS5, CD19+10+ cells did not lose their CD10 expression.  
 
None of the CBP had any myeloid potential in MS5 co-cultures. However, CBP1, but not 
CBP2 or CBP3, had limited NK cell potential. This suggests either that CBP1 might be a true 
'CLP' (consistent with the CD34+CD38+CD10+ population in adult BM and fetal BM 
designated as CLP by Galy et al, 1995) or that the CBP1 population which is defined simply 
as CD34+CD10+CD19-, might be a mixed population of committed B progenitors, NK 
progenitors and T progenitors.   
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                  CLP                  ELP 
         
 
         
         
 
           
 
Figure 4.6 Generation of B cells and NK cells from normal FL CLP and ELP 
Day 14 readout from normal FL CLP (left panel) and ELP (right panel) on MS5 co culture 
showing production of CD34-CD19+ B cells (red arrows) and CD19+10+ B cells (pink 
arrows), CD34-CD19-CD56+CD3- NK cells (blue arrows) and CD11b and/ CD14+ myeloid 
cells (black arrows). Cells harvested after 14 days of culture were stained with human CD45 
Alexa 700 antibody and hCD45 cells further analyzed by flow cytometry. Representative 
plots from 3 experiments.  
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Figure 4.7 Generation of B cells and NK cells from normal FL CBP 
Day 14 readout from normal FL CBP on MS5 co culture showing production of CD34-
CD19+ B cells (red arrows) from CBP1, CBP2 and CBP3, CD34-CD19-CD56+CD3- NK 
cells (blue arrow) were only generated by the CBP1 population. Cells harvested after 14 days 
of culture were stained with human CD45 Alexa 700, CD34 PE Cy7, CD19 APC, CD10 
FITC, CD56 PE, CD3 PE Cy5 antibodies and hCD45 cells analyzed by flow cytometry. 
Representative plots from 3 experiments. 
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4.5.2.2 Generation of T cells from normal FL LMPP, ELP and CBP 
 
Normal FL CLP and ELP gave rise to T cells (defined as CD7+CD2+CD4+ and/or CD8+) 
after co-culture with OP9-DL1 cells (Figure 4.8). CBP1 had some T cell potential as well, but 
CBP2 and CBP3 did not give rise to T cells after co-culture with OP9-DL1 cells.  
 
The timing of emergence of T cells and the numbers of T cells generated varied in CLP, ELP 
and CBP1. The greatest number of CD4+ and CD8+ T cells was generated by the CLP 
population (Figure 4.8a and b). However, the majority of cells within the CBP1 population 
demonstrated their ability to undergo T cell differentiation quickly, with only a small residual 
CD34+ population remaining after 14 days of culture in comparison with CLP cultures 
(Figure 4.8c) while ELP were intermediate between CLP and CBP1 (Figure 4.8c). Similarly 
CD4+ and CD8+ cells appeared earlier in the CBP1 cultures confirming that CBP1 are 
already lymphoid committed and that CLP and ELP are more immature populations. There 
were no discernable haematopoietic cells remaining in culture by day 21 in CBP1 cultures, 
suggesting that these cells mainly differentiate in culture with limited proliferation.  
 
The T cell yield of 500 flow sorted normal FL CLP, ELP and CBP1 after 14 and 21 days of 
OP9-DL1 co-culture is summarised in Table 4.4). Data from limited experiments suggests that 
T cell generation by CLP was greater than T cell generation by ELP. Although CBP1 
produced T cells, the cell numbers generated were very low and there were no human cells 
detectable in culture by day 21 (Table 4.4). This may suggest that only a fraction of the 500 
CBP1 cells plated have T cell potential. 
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a) CD7+2+        CLP                  ELP                  CBP1 
                    
           
 
b) CD4+ and/or CD8+             
            
        
 
c) Residual CD34+ cells           
            
 
 
 
CD2 
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Figure 4.8: T lymphoid differentiation of normal FL CLP, ELP and CBP on OP9-DL1 stromal cells  
Cultures were initiated with 500 flow-sorted human FL HSC, MPP or LMPP and analysed by flow cytometry 
after 14 and 21 days:  a) CD7+CD2+ lymphocytes (red arrow) (gated on CD45+ cells); b) CD4+ and/ CD 8+  
lymphocytes (blue arrow) and c) residual CD34+ cells. (Shown are plots from one sample tested). 
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 % CD7+ % CD7+CD2+ % CD8+ or CD4+ % CD8+CD4+
LMPP (n=5) 
day 14 
day 21 
 
97.8 ± 0.7% 
93 ± 2.4% 
 
50 ± 9% 
63.6 ± 10% 
 
40.4 ± 4.9% 
44.3 ± 10.5% 
 
6.4 ± 3% 
22.7 ± 13.5% 
ELP (n=2) 
day 14 
day 21 
 
95.2% 
96% 
 
42.5% 
61.9% 
 
53% 
73% 
 
11.8% 
12.2% 
CBP1 (n=1) 
day 14 
day 21 
 
57% 
 
 
66.1% 
 
77% 
 
23.4% 
 
Table 4.4 T cell differentiation of normal FL LMPP, EBP and CBP1 on OP9-DL1 
Cells were harvested from the co-cultures at given time points, and analysed by flow 
cytometry as shown below. The data are expressed as % of human cells detected in co culture 
on day 14 and day 21. T cells were defined as being CD7+CD2+CD4+ and/ CD8+ 
 
 
4.5.3 Myeloid clonogenic assays from normal FL lymphoid progenitors 
 
To determine whether or not CLP had any residual myeloid differentiation capacity (and 
thereby to try to identify a true 'CLP'), flow-sorted CLP were plated in myeloid culture 
conditions (section 2.4) in methylcellulose. Since the immunophenotypic CLP population 
(CD34+CD38lo/-CD45RA+CD7+) is present in normal FL at a very low frequency (0.75% of 
CD34+ cells) sufficient cells were available from only 2 samples. In these samples I found 
that normal FL CLP both had a small amount of myeloid potential in vitro, giving rise to 1 
and 3 GM colonies per 100 cells plated respectively (Table 4.5) suggesting that the 
immunophenotypic definition of a common lymphoid progenitor as described for cord blood 
(Hao et al., 2001; Hoebeke et al., 2007) did not identify a true CLP in human FL.  Therefore, 
in order to try to identify the immunophenotype of true CLP in FL, I decided to check the 
myeloid potential of the other immunophenotypically defined early and committed B 
lymphoid progenitors.  
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Flow-sorted ELP and CBP from normal FL (n=4) were plated at 100 cells/well under myeloid 
conditions (section 2.4) and colonies counted after 14 days. ELP (CD34+CD127+CD10-
CD19-) gave rise to a very small number of myeloid and erythroid colonies while CBP1 gave 
rise to an even smaller number of myeloid colonies (1%) (Full lineage potential of the sorted 
lymphoid progenitor populations is summarised in Table 4.5). No megakaryocyte colonies 
were grown from ELP and CBP sorted populations. Neither CBP2 nor CBP3 produced 
colonies in myeloid assays, confirming that these populations are lymphoid lineage 
committed.  These data may mean that a true 'common' lymphoid progenitor able to give rise 
to all B, T and NK cells but without any myeloid potential does not exist in significant 
numbers in normal FL. However, this conclusion would need to be tested in a much larger 
number of samples, with very rigorous cell sorting and then confirmed at the single cell level.
  
 
Cells types 
generated in vitro 
CLP ELP CBP1 CBP2 CBP3 
 
Granulocytic  
(mean %  of cells 
producing CFU-G/GM) 
 
     2 
 
     2   
 
      1 
 
 
     0 
 
     0 
Erythroid 
( mean % cells 
producing BFU-e) 
   
     0 
 
    3 
 
     0 
      
      0 
     
      0 
B cells 
CD19+  
   +++   ++     + + ++ 
T cells 
CD2+  
    ++ 
 
     +      + 
 
0 0 
NK cells 
CD56+  
    +      ++      + 0 0 
 
 
Table 4.5  Summary of lymphoid and myeloid cell generation from normal FL early and 
committed B progenitors 
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Flow-sorted progenitors from each of the immunophenotypically-defined lymphoid progenitor 
populations were assessed for their myeloid differentiation ability (G/GM/G/erythroid/MK) in 
methylcellulose clonogenic assays. Ability to produce mature B cells (CD34-CD19+) and NK 
cells (CD34-CD56-) was assessed in MS5 stromal co-cultures and to produce mature T cells 
(CD34-CD7+2+4+/8+) in OP9-DL1 co-cultures as described above. Populations scored as 0 
produced no cells of the specified lymphoid lineage while those scoring ++, + or + had high, 
medium and modest output respectively (data summarised from Figures 4.7, 4.8, 4.9 and 
4.10). 
 
 
 
4.5.4 Gene expression in normal FL lymphoid progenitors 
 
To further characterise the normal FL lymphoid compartment and confirm their identity, I 
flow sorted ELP and CBP and tested the expression of a similar panel of selected genes to 
those studied in chapter 3, including the principal transcription factors known to be important 
in normal lymphoid, particularly B cell, development. I did not further study CLP as 
originally defined (CD34+CD38lo/-CD45RA+CD7+) for several reasons: 1. this 
immunophenotype forms 70% of the LMPP population which I studied in chapter 3 which 
makes it logistically extremely difficult to obtain sufficient cell numbers to study CLP (0.75% 
of FL CD34+ cells); 2. Aberrant expression of CD7 in the DS CD34+CD38lo/- meant that 
comparisons between normal FL CD7+ 'CLP' and DS FL 'CLP' impossible to interpret; and 3. 
I had already shown myeloid output from this immunophenotypic population.  
 
As an initial screening, I performed simple RT-PCR for specific genes as described in 2.7.1 
However as the cell numbers were limited, I subsequently used the BioMark Real time PCR 
(qRT-PCR) system which allowed me to quantify gene expression of a larger number of genes 
in very small numbers of cells (10- 50 cells) as described in 2.7.3 thus allowing me to 
compare the patterns of gene expression in normal FL with the same, immunophenotypically-
defined sub-populations from DS FL (the results in DS are described at the end of this 
chapter). 
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4.5.4.1  RT-PCR of specific genes in sorted normal FL ELP and CBP 
 
The expression of genes in the sorted populations (n=2); depicted by a positive band of the 
expected size in agarose gel by electrophoresis is summarised in Table 4.6. The patterns of 
expression in LMPP (data from chapter 3) are shown for comparison. The presence of cDNA 
in all samples was confirmed by positive amplification of β-actin. The pattern of gene 
expression in ELP and CBP was similar to the predicted pattern from murine studies 
(Cobaleda et al., 2007; Northrup and Allman, 2008) although, as cell numbers were very 
limited, it was not always possible to amplify cDNA to confirm the presence/ absence of 
expression of genes of interest and I therefore had to rely mainly on the qRT-PCR studies 
(section 4.5.4.2) to establish gene expression patterns in the lymphoid populations. Thus, EBF 
was expressed in ELP and all CBP while PAX5 was only weakly expressed in ELP and CBP1 
becoming more highly expressed in the more mature CD19+ CBP2 and CBP3, as expected.  
In addition, no detectable expression of GATA1 and CEBPα was consistent with down 
regulation of erythroid/megakaryocyte and myeloid differentiation programs respectively 
(Table 4.6). 
 
  GENE LMPP/ CLP 
34+38-45RA+ 
       ELP 
34+127+10-19- 
   CBP1 
34+10+19- 
   CBP2 
34+10+19+ 
   CBP3 
34+10-19+
GATA1       -         - NT NT NT 
CEBPα       -         - NT NT NT 
IL7Ra     +/-         NT NT NT NT 
EBF       -         +     +     +     + 
PAX5       -        +/ -     +/ -     +     + 
Table 4.6  Expression of lineage-associated haematopoietic transcription factor genes in 
human FL ELP and CBP: Gene expression was measured in flow sorted ELP, CBP1, CBP2 
and CBP3 from normal human FL (n=2) by RT-PCR.  Populations in which a distinct band of 
the expected size was consistently seen on agar gel electrophoresis are marked +; populations 
in which a band of the expected size was consistently undetectable bands in the control lane 
and β-actin are marked -; populations where the band was consistently very weak or results 
were variable are marked as +/-. NT = not tested. Results in LMPP are shown for comparison. 
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4.5.4.2  Gene expression of normal FL committed B progenitors (CBP) and early 
lymphoid progenitors (ELP) by qRT-PCR using the nanofluidic BioMark 48.48 
Dynamic Array and TaqMan Expression Assays  
 
To allow accurate comparison of gene expression between the sub-populations, and thereby 
determine the gene expression 'signatures' specific to each sub-population, I flow-sorted 50 
cells from the ELP, CBP1, CBP2 and CBP3 compartments in triplicate and processed them as 
described in section 2.7.3. Cells were sorted on the basis of the same immunophenotypes 
described above, i.e. ELP (CD34+CD127+CD10-CD19-), CBP1 (CD34+CD10+CD19-), 
CBP2 (CD34+CD10+CD19+) and CBP3 (CD34+CD10-CD19+).  
 
4.5.4.2.1 Relative expression of genes in normal FL ELP  
As predicted from murine data, and from my ELP MS5 stromal cell co-cultures, all of the 
early B cell development genes I tested, were expressed in ELP (Figure 4.9). There was clear 
evidence of further B cell commitment in ELP compared to LMPP with up regulation of EBF 
compared to its expression level in LMPP; up regulation of PAX5 which was undetectable in 
LMPP; and even very low levels of expression of CD19 (Figure 4.9b). Interestingly, E2A was 
expressed at similar levels to LMPP and was only markedly up regulated at the CBP stage 
while IKAROS expression was maintained at similar levels throughout B cell differentiation 
from LMPP through to CBP3.  (Figure 4.9a).  Expression of IL7RA was very high in ELP (as 
expected since they were selected on the basis of CD127 expression) (Figure 4.9a) and since 
CRLF2, with which IL7R dimerises, was also expressed at moderately high levels (Figure 
4.9c) this suggests that FL ELP may express functional TSLP (thymic stromal lymphopoietin) 
receptors (Fujio et al., 2000; Rochman and Leonard, 2008; Ziegler and Liu, 2006).   
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a) 
b) 
c) 
Figure 4.9: Relative expression of a) Early lymphoid genes, b) B lymphoid genes; and c) CRLF2 in normal FL 
early and committed B progenitors   
Gene expression levels are shown relative to GAPDH and are the mean ± SEM of 3 normal FL and 3 DS FL samples 
from which 50 cells of each CD34+ sub-population (LMPP, ELP, CBP) were sorted in triplicate for analysis by qRT-PCR
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Since FL ELP were able to give rise to T cells in OP9-DL1 co-cultures, I also investigated 
their expression of T cell-associated genes (Figure 4.10). Although no there was no detectable 
expression of the T cell progenitor gene (PTCRA) in ELP, CD7 was expressed as was 
NOTCH1 which would be consistent with early T cell commitment, although this is not 
specific since both genes are also expressed at low levels in myeloid progenitors and 
NOTCH1 is expressed by B progenitors (Figure 4.10). On the other hand, GATA3, which is 
normally up regulated in T progenitors, was barely expressed in ELP suggesting that T cell 
differentiation capacity is likely to be minimal in FL ELP. 
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Figure 4.10  Relative expression of T lymphoid genes in normal FL early and committed 
B progenitors  Gene expression levels are shown relative to GAPDH and are the mean ± SEM of 3 
normal FL and 3 DS FL samples from which 50 cells of each CD34+ sub-population (LMPP, ELP, 
CBP1 CBP2 and CBP3) were sorted in triplicate for analysis by qRT-PCR.  
 
I also investigated the expression of myeloid and megakaryocyte/erythroid-associated genes 
(Figure 4.11) since I had observed small numbers of myeloid and erythroid colonies in 
methylcellulose cultures of FL ELP. All of the myeloid-associated genes tested (CEBPα, G-
CSFR, GM-CSFR and CSF1R) were expressed at very low levels, presumably sufficient to 
explain the low numbers of G/GM colonies generated from ELP grown under myeloid 
conditions (Figure 4.11a). Levels of genes important for early megakaryocyte and erythroid 
development (GATA1, GATA2, EpoR and FOG1) were also expressed although at very low 
levels (Figure 4.11b). It is not clear whether this, as for the occasional erythroid colony grown 
from this population, represents true erythroid lineage differentiation capability in the ELP 
population, or whether this immunophenotype includes a small number of CD127+ myeloid 
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and/or erythroid progenitors (e.g. HSC and LMPP both expressed the IL7RA gene by qRT-
PCR). Unfortunately, there was no time to investigate this possibility further.  
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a) 
b) 
c) 
Figure 4.11: Relative expression of a) myeloid gene; b) erythroid/megakaryocyte genes; and  
c) stem cell genes in normal FL early and committed B progenitors compared to GAPDH 
Gene expression levels are shown relative to GAPDH and are the mean ± SEM of 3 normal FL and 3 DS FL samples 
from which 50 cells of each CD34+ sub-population (LMPP, ELP, CBP) were sorted in triplicate for analysis by qRT-PCR
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Finally, I looked at the expression pattern of stem-cell associated genes in ELP and found, as I 
expected, that genes known to be crucial components of the HSC transcriptional regulatory 
code were either markedly down regulated compared to HSC and LMPP (C-KIT) or had been 
completely silenced (c-MPL) (Figure 4.11c).  Interestingly, PU1 was expressed at low levels 
in ELP compared to both CBP and HSC, MPP and LMPP.  
 
Overall, the results of qRT-PCR for FL ELP were generally consistent with the findings of 
RT-PCR (Table 4.6) and the in vitro data. The expression of other genes studied by qRT-PCR, 
but not discussed in this section, is depicted in Appendix 3. 
 
4.5.4.2.2 Relative expression of genes in FL committed B progenitors (CBP) 
CBP expressed all genes necessary for both early and more mature B cell development 
(Figure 4.9). Expression of E2A, EBF, PAX5 and CD19 was up regulated in CBP compared to 
ELP and LMPP while IKAROS expression was maintained at very similar levels to those 
found in ELP, LMPP and HSC (Figure 4.9a and b).  Expression of E2A peaked slightly earlier 
(CBP1; Pro-B1) than peak expression of EBF, PAX5 and CD19 (CBP2; Pro-B2) (Figure 
4.9b).  Expression of IL7RA (Figure 4.9a) increased progressively from CBP1 to CBP2 to its 
highest levels in CBP3 (pre-Pre B) whereas CRLF2 expression, which was detectable in all 
CBP, peaked in CBP2 suggesting that similar to ELP, CBP (especially CBP2) may be able to 
form functional TSLP receptors (Figure 4.9c).  The peak expression of the majority of B cell 
genes in CBP2 raises the possibility, as discussed above, of FL CBP3 (CD10-CD19+) being a 
more immature B progenitor than CBP2 (CD10+CB19+), i.e. that B progenitors acquire 
CD19 expression prior to CD10 expression, and that CBP3 should more logically be 
designated as pre-Pro B cells similar to the pre-Pro B cell recently reported in CB (Sanz et al., 
2010).  
 
To confirm the B cell-specificity of CBP, I also investigated the expression of T cell-
associated genes (Figure 4.10). There was no detectable expression of the T-cell specific gene 
PTCRA in FL CBP2 and CBP3 which also had no detectable expression of CD7 and GATA3 
(Figure 4.10). Since these genes are known to be highly expressed adult T progenitors and 
silenced in B progenitors (Laiosa et al., 2006), these data further support the designation of 
CBP2 and CBP3 as committed uniquely to the B lineage. By contrast, normal FL CBP1 
expressed GATA3 and NOTCH1 levels higher than those detected in LMPP and expression of 
PTCRA was also just detectable (Figure 4.11) consistent with residual T cell potential, as also 
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shown from the OP9-DL1 co-culture data and consistent with published data that suggests 
that CD34+10+19- cells may represent a common lymphoid progenitor or that it contains a 
mixture of early B and T progenitors (Katsura, 2002; Kawamoto et al., 2000; Kawamoto et 
al., 1998; Lu et al., 2002). 
 
I also investigated their expression of myeloid-associated genes (Figure 4.11) since I had 
observed an occasional CFU-GM in methylcellulose cultures of FL CBP1. Most of the 
myeloid-associated genes tested (G-CSFR, GM-CSFR and CSF1R) were not expressed in 
CBP or had just detectable expression except in CBP1 which expressed low levels of G-CSF 
and fairly high levels of CSF1R (Figure 4.11a) which probably explains the residual myeloid 
activity detected in CBP1 cultures.. Interestingly, low levels of CEBPα continued to be 
expressed even in progenitors with purely B cell output (Figure 4.11a). Levels of the genes 
important for early megakaryocyte and erythroid development such as GATA1, GATA2, and c-
MPL were barely detectable in FL CBP (Figure 4.11b and 4.11c).  To my surprise, FL CBP1 
appeared to express high levels of EpoR and FOG1, although CBP1 never gave rise to 
erythroid colonies (Figure 4.11b).  
 
Finally, expression of most of the stem-cell associated genes in CBP was markedly down 
regulated compared to HSC and LMPP (c-KIT, FLT3) or had been completely silenced (c-
MPL) although PU1 continued to expressed at fairly highly high levels (Figure 4.11c).   
 
The expression of other genes studied by qRT-PCR, but not discussed in this section is 
depicted in Appendix 3. 
 
These results of the qRT-PCR for FL CBP were consistent with the RT-PCR results (Table 
4.6), myeloid colony assays and lymphoid stromal co-culture assays.  The qRT-PCR and in 
vitro data suggest that the normal FL CBP1 population (defined by the immunophenotype 
CD34+CD10+CD19-) is unlikely to be a single progenitor population but instead is most 
likely to be a mixed progenitor population, which includes B progenitors, T progenitors and 
possible a small number of multilineage myeloid progenitors similar or identical to CMP +/- 
MEP.   
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4.6 The lymphoid progenitor compartment in DS human fetal liver  
 
4.6.1 Immunophenotypic analysis of the lymphoid compartment of DS human FL 
In comparison to normal second trimester FL, DS human FL CD34 compartment had similar 
proportions of CLP and ELP (Table 4.6). However, the frequency of CBP was markedly 
reduced in DS FL. In particular, DS FL showed a significant reduction in CBP2 (2.7 ± 1.3% 
of total CD34+ cells; p<0.03) compared to CBP2 in normal FL (7.2+1%) (Table 4.7; Figure 
4.12). In addition the number of CBP3 was also reduced in DS FL compared to normal FL 
(0.3 ± 0.1% vs. 3.6 +0.5%; p<0.0002) (Table 4.7; Figure 4.12). Representative flow 
cytometry plots are shown in Figures 4.13 and 4.14. 
 
 
Table 4.7 CLP and B lymphoid progenitors in second trimester DS FL 
Data shown are the mean +SEM of 6 DS FL samples and 10 normal second trimester FL 
samples. * p <0.05; ** p <0.01 
Progenitor Immunophenotype % of DS FL CD34+
 cells  
(mean + SEM; n=6)
% of normal FL  
CD34+ cells  
(mean + SEM; n=10)
p value 
 
CLP 
 
CD34+38lo/-45RA+7+
 
1.3 ± 0.3 
 
0.75 ± 0.2  
 
≤ 0.12     
 
ELP 
 
CD34+127+10-19- 
 
1.98 ± 0.5 
 
3.1 ± 0.8 
 
≤ 0.42    
 
CBP1 (ProB1) 
 
CD34+10+19- 
 
0.7 ± 0.2 
 
1.0 ± 0.2 
 
≤ 0.42    
 
CBP2 (ProB2) 
 
CD34+10+19+ 
 
2.7 ± 1.3 
 
7.2 ± 1.0 
 
≤ 0.03*    
 
CBP3(‘Pre pre B’)
 
CD34+10-19+ 
 
0.3 ± 0.1 
 
3.6 ± 0.5 
 
≤ 0.0002** 
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Figure 4.12 Lymphoid progenitors in normal and DS FL  
Frequency of CLP: common lymphoid progenitors; ELP: early lymphoid progenitors; CBP: 
committed B progenitors in normal and DS FL CD34 cells. Data are expressed as mean 
(±SEM) of CD34+ cells from normal FL (n=10) and DS FL (n=6). (* p ≤0.05, ** p ≤0.01) 
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a) CLP 
 
              
 
b) ELP 
 
    
 
 
 
Figure 4.13  Immunophenotypic analysis of a) common lymphoid progenitors (CLP) and 
b) early lymphoid progenitors (ELP) in DS second trimester human FL.  
 
CD34+ cells were isolated from DS FL by immunomagnetic beads, labeled with CD34 
PerCP/ PE Cy7, CD38 Pacific Blue, CD7 PE, CD127 PE, CD19 APC and CD10 FITC 
antibodies and analyzed by flow cytometry. Representative data from 4 experiments.  
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a) Committed B progenitors: CBP1 and CBP2   
 
 
       
 
 
 
b) Committed B progenitors: CBP3 
 
       
   
 
 
Figure 4.14 Immunophenotypic analysis of committed B progenitors in DS second 
trimester human FL: a) CBP1 and CBP2; b) CBP3. 
 CD34+ cells were isolated from second trimester DS FL by immunomagnetic beads (see 2.2), 
labeled with CD34 PerCP/ PE Cy7, CD38 Pacific Blue, CD7 PE, CD127 PE, CD19 APC and 
CD10 FITC antibodies and analyzed by flow cytometry. Representative data from 4 
experiments are shown. Normal FL CBP3 are shown for comparison in the right hand panel of 
Figure 4.14b. 
 
 
CD10
CD19
CD10 
CD34 
CD10
CD19
CBP1: Pro-B1 CBP2: Pro-B2 
CD34 
CD19 
CBP3: pre-Pre B 
Normal FL 
CD19
CD10 
 167
4.6.2  Lymphoid potential of DS FL ELP and CBP 
 
To confirm the lymphoid differentiation capacity of cells within the immunophenotypically-
defined ELP and CBP compartments in DS FL, these populations were isolated from DS FL 
samples by flow sorting and co-cultured with MS5 stromal cells to measure B and NK cell 
differentiation as described above. Unfortunately, the severe reduction in lymphoid 
progenitors in DS FL meant that insufficient numbers of cells were available to test their T 
cell differentiation potential. 
 
4.6.2.1 Generation of B cells and NK cells from DS FL ELP and CBP 
In keeping with the marked reduction of B progenitors that I found in DS FL, compared to 
normal FL; I found that the production of B cells from ELP and CBP was severely impaired 
in DS FL.  No B cells, NK cells or myeloid cells were detected in ELP co-cultures at any time 
points up to 14 days (Figure 4.15) in contrast to the results obtained in normal FL MS5 co-
cultures ( compare with Figure 4.6). 
   
                  
 
Figure 4.15  DS FL early lymphoid progenitors (ELP) fail to generate B cells in MS5 co-
cultures 
Day 14 readout from DS FL ELP on MS5 co-culture showing no live (DAPI+) human 
haematopoietic cells (CD45+). All live cells are the MS5 murine stromal cells which do not 
express human CD45. Data are representative of 2 experiments.  
 
CBP2 and CBP3 also failed to generate CD34-CD19+ B cells (unlike normal FL- shown in 
Figure 4.7) and as expected there was no generation of NK or myeloid cells either. The only 
lymphoid progenitor population in DS FL which was able to generate mature B cells was 
CBP1 which produced a small number of CD34-19+10- cells on day 12 (Figure 4.16)    
   
SSC 
FSC DAPI human CD45 
 168
 CBP1       CBP2     CBP3 
                
 
               
 
                
 
      
 
 
Figure 4.16 Severely impaired generation of B cells (and NK cells) from DS FL CBP 
Readout from DS FL CBP on MS5 co-culture showing transient production of CD34-CD19+ 
B cells only from the CBP1 sub-population (on day 12) but no live (DAPI+) human 
haematopoietic cells (CD45+) on day 14. Data are representative of 2 experiments.  
 
FSC 
SSC 
DAPI 
SSC 
human CD45 
SSC 
CD34 
CD19 
 169
4.6.3 Myeloid clonogenic assays from DS FL lymphoid progenitors 
 
Since I had previously found (chapter 3) that DS FL LMPP gave rise to some erythroid 
colonies (in contrast to normal FL LMPP), I decided to investigate the myeloid potential of 
DS FL ELP and CBP. Flow-sorted ELP (CD34+CD127+CD10-CD19-) and CBP1 
(CD34+10+19-) from DS FL (n=2) were plated at 100 cells/well under myeloid conditions 
(section 2.4) and colonies counted after 14 days (insufficient CBP2 and CBP3 were available 
to test their myeloid potential in vitro).  
 
DS FL CBP1 generated no myeloid colonies in methylcellulose in contrast to normal FL 
which gave rise to occasional myeloid colonies (Figure 4.17).  
 
DS FL ELP, however, had markedly increased clonogenicity in myeloid colony assays. The 
colony readout was also extremely abnormal, with predominantly megakaryocyte and 
erythroid colonies as well as a small number of CFU-GEMM and myeloid blast colonies 
(Figure 4.17).  The colony read out for DS FL ELP closely resembled that for DS FL CMP 
(also shown in Figure 4.17 for comparison). Since the qRT-PCR gene expression profile of 
normal FL ELP also suggested that the immunophenotypically-defined ELP population 
(CD34+CD127+10-19-) might contain a small number of CMP and/or MEP, it is possible that 
my results in DS FL ELP might reflect an expansion of a CD34+CD127+ myeloid progenitor 
population in DS FL further reducing the number of B progenitors contained within this 
population in DS FL.  Alternatively the data may indicate a failure to properly down regulate 
the myeloid/erythroid differentiation program in DS FL ELP. 
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Figure 4.17  Myeloid colony readout of flow-sorted a) DS FL lymphoid and myeloid 
progenitor subpopulations compared with b) normal FL    
Clonogenic readout of a) DS FL LMPP, ELP and CBP compared to corresponding FL 
myeloid progenitors (CMP, MEP and GMP) and to the same progenitor populations in normal 
FL (b) to show the increase in myeloid colonies in DS FL ELP compared to normal FL ELP 
and the similarity in the colony read out between DS FL ELP and CMP/MEP. Colony readout 
was done after 14 days of culture in methyl cellulose with IL3, IL6, IL11, SCF, FLT3, GM-
CSF, TPO and EPO. Results are the mean of 4 experiments (normal FL) and n=2 (ELP, DS 
FL) or n=4 (LMPP/CMP/MEP/GMP DS FL).  
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4.6.4 Gene expression of DS FL lymphoid progenitors 
 
To further characterise the DS FL lymphoid compartment and to gain insight into the 
mechanism of the severe impairment of B progenitor development in DS FL, I flow sorted 
ELP and CBP and tested the expression of a similar panel of selected genes to those studied in 
chapter 3, including the principal transcription factors known to be important in normal 
lymphoid, particularly B cell, development. As for normal FL, I first performed simple RT-
PCR for specific genes as described in 2.7.1 and subsequently used the BioMark Real time 
PCR (qRT-PCR) system, as described in section 2.7.2.  
 
 
4.6.4.1  RT-PCR of specific genes in sorted DS FL LMPP, ELP and CBP 
 
The expression of genes in the sorted populations (n=2) is summarised in Table 4.8. The 
pattern of expression in LMPP (data from chapter 3) is shown for comparison. The presence 
of cDNA in all samples was confirmed by positive amplification of β-actin. As cell numbers 
were very limited, it was not always possible to amplify cDNA to confirm the 
presence/absence of expression of genes of interest and I therefore relied mainly on the qRT-
PCR studies (section 4.6.4.2) to establish gene expression patterns in the lymphoid 
populations.  There was no detectable expression of GATA1 and CEBPα by simple RT-PCR 
in ELP (Table 4.8) despite the erythroid/megakaryocyte colony read out shown in Figure 
4.17).  However, interestingly, DS FL ELP did not express detectable amounts of PAX5 and 
had barely detectable levels in CBP3 (Table 4.8), unlike normal FL (see Table 4.6). 
Nevertheless, PAX5 expression was detected in DS FL CBP1 and CBP2 suggesting that the 
severe impairment in B progenitor development is not the result of an absence of PAX5 
expression.   
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  GENE LMPP/ CLP 
34+38-45RA+ 
       ELP 
34+127+10-19- 
   CBP1 
34+10-19- 
   CBP2 
34+10+19+ 
   CBP3 
34+10-19+
GATA1 
 
      -         - NT NT NT 
CEBPα 
 
      -         - NT NT NT 
PAX5 
 
      -         -     +     +     +/- 
 
 
Table 4.8  Expression of lineage-associated haematopoietic transcription factor genes in 
DS FL ELP and CBP 
Gene expression was measured in flow sorted ELP, CBP1, CBP2 and CBP3 from DS FL 
(n=3) by RT-PCR.  Populations in which a distinct band of the expected size was consistently 
seen on agar gel electrophoresis are marked +; populations in which a band of the expected 
size was consistently undetectable with bands in the control lane and β-actin are marked -; 
populations where the band was consistently very weak or results were variable are marked as 
+/-. NT = not tested. Results in LMPP are shown for comparison. 
 
 
 
4.6.4.2  Gene expression of DS FL committed B progenitors (CBP) and early lymphoid 
progenitors (ELP) by qRT-PCR using the nanofluidic BioMark 48.48 Dynamic Array 
and TaqMan Expression Assays  
 
Gene expression of flow sorted DS FL early lymphoid progenitors and committed B lymphoid 
progenitors was determined by qRT-PCR as described in section 2.7.2. In view of the marked 
reduction in B progenitors in DS FL, it was not always possible to get enough cells to perform 
triplicate analysis. The expression of other genes studied by qRT-PCR, but not discussed in 
this section, is depicted in Appendix 3. 
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Genes important for early lymphoid development (IKAROS, IL7RA and E2A) appeared to be 
expressed at much lower levels in DS FL B lymphoid progenitors when compared to normal 
FL; however this needs to be confirmed in more samples. (Figure 4.18). In addition, EBF and 
PAX5, B lymphoid specific genes normally expressed slightly later in B progenitor 
differentiation, were also expressed at lower levels in DS FL (Figure 4.18) suggesting a 
failure to upregulate the B lymphoid programme in DS FL progenitors. Interestingly, two of 
the genes I tested from Hsa21 may be upregulated in DS FL B lymphoid progenitors- GABPA 
was minimally increased in all committed B progenitors, while DYRK1A appeared to be 
increased in CBP2 (Figure 4.19). Both genes have been implicated in normal B cell 
development (Gallo et al., 2008; Xue et al., 2007), although their role in fetal B progenitor 
development and ALL is unknown.  
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Figure 4.18  Relative expression of a) Early lymphoid genes, b) B lymphoid genes in DS FL  
compared to normal FL early and committed B progenitors   
Gene expression levels are shown relative to GAPDH and are the mean ± SEM of 3 normal FL and 3 DS FL  
samples from which 50 cells of each CD34+ sub-population (LMPP, ELP, CBP) were sorted in triplicate for  
analysis by qRT-PCR 
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Figure 4.19  Relative expression of a) GABPA and b) DYRK1A in DS FL compared to 
normal early and committed B progenitors  
Gene expression levels are shown relative to GAPDH and are the mean ± SEM of 3 normal 
FL and 3 DS FL samples from which 50 cells of each CD34+ sub population (LMPP, ELP, 
CBP) were sorted in triplicate for analysis by qRT-PCR. 
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4.7  Characterisation of the lymphoid progenitor compartment in DS fetal BM 
 
The identification of a major block to B progenitor differentiation in DS FL suggests that T21 
perturbs FL lymphopoiesis. To investigate the hypothesis that T21 also perturbs 
haematopoiesis in fetal BM, which may be more important as a site of leukaemia initiation in 
ALL in DS since this is not a disease which presents until after the age of 12 months, I 
analyzed BM samples from second trimester fetuses with and without DS.  
 
 
4.7.1 Identification of CLP and B progenitors in CB and adult BM 
 
Since lymphoid progenitors have not previously been characterised in either normal human 
fetal BM or DS fetal BM, I first used the same immunophenotypic criteria used to define B 
progenitors in human CB and adult BM. The CB data are described in section 4.4; 
representative flow cytometry plots from the analysis of 2 adult BM samples are shown in 
Figures 4.20 and 4.21. Normal adult BM had a much higher proportion of B progenitors 
compared to CB; especially CBP2 which made up almost 84% of total CBP in adult BM 
(Table 4.9).  
 
 
Progenitor Immunophenotype Adult BM (n=2) 
% CD34+ cells  
CB (n=10) 
% CD34+ cells  
CLP CD34+38lo/-45RA+7+ 0.2  
(2.3% of CD34+CD38- cells)
0.12+ 0.05  
(6.8% of CD34+CD38- cells)
ELP CD34+127+10-19- 1.06 0.9+ 0.24 
CBP1 (ProB1) CD34+10+19- 1.98 3.6+ 1.0 
CBP2 (ProB2) CD34+10+19+ 25.6 3.5+ 1.3 
CBP3 (Pre pre B CD34+10-19+ 2.4 0.34+ 0.1 
 
Table 4.9 Summary of CLP and B lymphoid progenitors in adult BM compared with CB 
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a) Adult BM common lymphoid progenitors (CLP) 
 
                    
 
 
b) Adult BM early lymphoid progenitor (ELP) 
 
       
 
  
Figure 4.20: Immunophenotypic analysis of a) common and b) early lymphoid 
progenitors in human adult bone marrow (BM). CD34+ cells were isolated from normal 
BM by immunomagnetic beads (see 2.2), labeled with CD34 PE Cy7, CD38 Pacific Blue, 
CD7 PE, CD127 PE, CD19 APC and CD10 FITC antibodies and analyzed by flow cytometry. 
Representative data from 2 experiments.  
CLP
ELP
CD38 CD7
CD34 CD45RA
CD127 CD10
CD19CD34 
SSC SSC
FSC DAPI CD34
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a) CBP1 and CBP2 
 
 
                           
 
 
 
 
 
b) CBP3 
                  
 
 
 
Figure 4.21: Immunophenotypic analysis of committed B progenitors in normal adult 
BM.  
CD34+ cells were isolated from normal adult BM by immunomagnetic beads (see 2.2), 
labeled with CD34 PE Cy7, CD38 Pacific Blue, CD7 PE, CD127 PE, CD19 APC and CD10 
FITC antibodies and analyzed by flow cytometry. Representative data from 2 experiments.  
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CBP3: Pre Pre B
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4.7.2 The lymphoid progenitor compartment in normal fetal BM 
 
The CD34+ compartment of second trimester human fetal BM was analyzed by flow 
cytometry to determine whether immunophenotypically-defined CLP, ELP and CBP were 
present and their relative proportions.  The data are summarised in Table 4.10 and Figure 4.22 
and representative flow cytometric plots are shown in Figure 4.23. 
 
 
Progenitor Immunophenotype Fetal BM (n=4) 
% CD34+ cells  
Adult BM (n=2) 
% CD 34+ cells 
CLP 
 
CD34+38lo/-45RA+7+ 0.14 ± 0.06 0.2  
 ELP 
 
CD34+127+10-19- 4.5 ±0.67 1.06 
CBP1 (ProB1) 
 
CD34+10+19- 0.9 ± 0.15 1.98 
CBP2 (ProB2) 
 
CD34+10+19+ 13.9 ± 3.3 25.6 
CBP3  
(‘Pre pre B’) 
CD34+10-19+ 35.5 ± 2.9 2.4 
 
Table 4.10 Summary of CLP and B progenitors in normal second trimester fetal BM 
compared to adult BM  
 
 
Immunophenotypically-defined CLP were present in very low frequency in fetal BM, ranging 
from 0-0.27% of CD34+ cells (Table 4.10; Figure 4.22). There are no data about ELP in 
human fetal BM.  ELP were detectable in all normal FBM samples I analysed, with a 
frequency ranging from 2.8 -5.8% of total CD34+ cells.  Interestingly, although the frequency 
of CLP and of ELP was comparable in adult BM and fetal BM, there were more CBP in fetal 
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BM (50.4 ± 2.2% of total CD34 cells vs. 29.9% in adult BM). The main difference between 
fetal and adult BM was the proportion of CBP3 which was much higher in fetal BM (35.5 ± 
2.9% of total CD34+ cells) compared to adult BM (2.4%) (Table 4.10; Figures 4.22 and 4.23).  
Indeed, the majority of fetal BM CBP were CBP3, which made up ~70% of the committed B 
progenitors in contrast to adult BM, where CBP2 formed majority of the committed B 
progenitors (~84%) suggesting that there are intrinsic differences in B cell development 
pathways in fetal and adult BM. 
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Figure 4.22 Lymphoid progenitors in normal fetal BM   
Frequency of CLP: common lymphoid progenitors; ELP: early lymphoid progenitors; and 
CBP: committed B progenitors in normal fetal BM CD34 cells (n=4) compared to normal 
adult BM (n=2). 
ELPCLP CBP1 CBP2 CBP3 
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a) CLP 
         
          
b) ELP 
         
 
c) Committed B progenitors: CBP1 and CBP2 
 
         
 
d) Committed B progenitors: CBP3 
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Figure 4.23 Normal fetal BM CLP, ELP and committed B progenitors   
CD34+ cells were isolated from normal fetal BM by immunomagnetic beads (see 2.2), labeled 
with CD34 PerCP/PE Cy7, CD38 Pacific Blue, CD7 PE, CD127 PE, CD19 APC and CD10 
FITC antibodies and analysed by flow cytometry. Representative data from 4 experiments.  
 
 
4.7.3 The lymphoid progenitor compartment in DS fetal BM 
 
The CD34+ compartment of second trimester DS fetal BM was analyzed by flow cytometry to 
determine whether CLP, ELP and CBP (defined as in 4.4 above) were present and their 
relative proportions.  In particular, my aim was to determine whether the reduction in B 
progenitors which I observed in DS FL, was also evident in DS fetal BM. The data are 
summarised in Table 4.11 and Figure 4.26 and representative flow cytometric plots are shown 
in Figure 4.24 and Figure 4.25. 
 
 
Table 4.11 Summary of CLP and B progenitors in DS fetal BM compared to normal 
fetal BM   
Progenitor Immunophenotype DS FBM (n=4) 
% CD34+ cells 
Normal fetal BM 
(n=4)  
% CD34+ cells 
 p value 
CLP CD34+38lo/-45RA+7+ 0.12 ± 0.03 0.14 ± 0.06 ≤ 0.9143 
ELP CD34+127+10-19- 2.2 ± 0.5 4.5 ±0.67 ≤ 0.05*  
CBP1 (ProB1) CD34+10+19- 4.2 ± 0.5 0.9 ± 0.15 ≤ 0.02*  
CBP2 (ProB2) 
 
CD34+10+19+ 12.6 ± 3.8 13.9 ± 3.3 ≤ 0.88   
CBP3 (pre-Pre B) 
 
CD34+10-19+ 2.2 ± 0.6 35.5 ± 2.9 ≤ 0.02*  
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a) Common lymphoid progenitors (CLP) in DS fetal BM  
 
                         
            
 
b) Early lymphoid progenitors (ELP) in DS fetal BM 
 
           
 
 
Figure 4.24 Immunophenotypic analysis of a) common and b) early lymphoid 
progenitors in DS fetal BM. CD34+ cells were isolated by immunomagnetic beads, labeled 
with CD34 PerCP/ PE Cy7, CD38 Pacific Blue, CD7 PE, CD127 PE, CD19 APC and CD10 
FITC antibodies and analyzed by flow cytometry. Representative data from 4 experiments.  
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a) Committed B progenitors: CBP1 and CBP2 
 
 
                   
 
 
b) Committed B progenitors: CBP3 
                   
   
Figure 4.25 Immunophenotypic analysis of committed B progenitors in DS fetal BM.  
CD34+ cells were isolated from DS fetal BM by immunomagnetic beads, labeled with CD34 
PerCP/ PE Cy7, CD38 Pacific Blue, CD7 PE, CD127 PE, CD19 APC and CD10 FITC 
antibodies and analyzed by flow cytometry. Representative data from 4 experiments.  
 
 
In comparison to normal second trimester fetal BM, DS fetal BM had similar proportions of 
CLP; a slightly reduced frequency of ELP (p<0.05) and a markedly reduced frequency of 
committed B progenitors, particularly CBP3 (2.2 ± 0.6% vs. 35.5 ± 2.9% of CD34+ cells; DS 
vs. normal; p<0.02) (Table 4.11; Figures 4.23-4.25). In addition, the frequency of CBP1 in 
DS fetal BM was increased compared to normal fetal BM (4.2 ± 0.5% vs. 0.9 ± 0.15%; 
p<0.02) suggesting a block to B progenitor differentiation at the CBP2/3 stage of 
differentiation (summarised in Figure 4.26).  
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Figure 4.26  Lymphoid progenitors in normal and DS fetal BM  
Frequency of CLP: common lymphoid progenitors; ELP: early lymphoid progenitors; and 
CBP: committed B progenitors in normal and DS fetal BM CD34 cells. Data are expressed as 
mean (±SEM) of flow cytometric  analysis of CD34+ cells from normal fetal BM (n=4) and 
DS fetal BM (n=4). (* p ≤ 0.05) 
CLP ELP CBP1 CBP2 CBP3 
* *
*
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4.8 Summary and discussion 
 
 
4.8.1  B lymphopoiesis is active in normal second trimester fetal liver 
 
Lymphopoiesis, especially B lymphopoiesis, in human fetuses is poorly understood with 
many gaps in knowledge compared to fetal and adult mice and adult human BM.  Although B 
progenitors have been reported in human fetal BM, until the studies described above, the 
extent to which the full profile of normal B lymphopoiesis occurred in human FL was 
unknown.  Thus, the only data were from immunohistochemistry studies suggesting the 
presence of IgM+/ CD10 + B progenitors in human FL, but it was not clear whether these 
cells were actually generated within the FL or had merely circulated there from other sites 
such as the AGM, BM or spleen. 
 
My studies have shown for the first time that, using the immunophenotypic criteria used to 
define early and committed B progenitors in CB and adult BM (Davi et al., 1997; Hao et al., 
2001; Hoebeke et al., 2007; Reynaud et al., 2003; Ryan et al., 1997), all of the previously 
described B progenitors can also be identified in normal second trimester FL and that they are 
present in proportions consistent with a hierarchy of progenitor differentiation from CLP 
(0.75 ± 0.2%) to ELP (3.1 ± 0.8%) to CBP (11.7 ± 1.4%). This strongly suggests that B 
lymphopoiesis is likely to be actively occurring in normal FL rather than the progenitors 
'passing through' in the circulation.   
 
 
4.8.2  True, purely lymphoid 'CLP' could not be identified in normal fetal liver 
 
Using the immunophenotypic criteria used to define CLP in human CB and in mouse fetal 
BM (Serwold et al., 2009), I failed to identify a true 'common lymphoid' progenitor without 
myeloid potential in human FL. Although normal FL CLP and ELP both gave rise to B, NK 
and T cells in MS5 and OP9 stromal co-culture systems, they also gave rise to small numbers 
of myeloid colonies in methylcellulose and expressed several myeloid-specific genes, albeit at 
low levels.  The in vitro read out and gene expression pattern of 'CLP' was, in fact, so close to 
that of the LMPP population, that it seems likely that the immunophenotypic CLP definition 
which I used (CD34+CD38lo/-CD45RA+CD7+) simply identified a non-distinct subset of 
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LMPP which could not be separated from it.  The gene expression pattern by qRT-PCR 
indicated that ELP were more mature than CLP, despite the fact that ELP produced occasional 
erythroid colonies, in that stem cell-specific genes were down regulated and lymphoid genes 
were up regulated. Therefore it is possible that the flow-sorted ELP population, which is only 
positively identified on the basis of CD34 and CD127 expression, may have contained an 
occasional CMP or MEP.  
 
Finally, it is possible that the CBP1 population contains true CLP since both the in vitro 
assays and gene expression studies strongly suggested that this was likely to consist of a 
mixture of progenitors of several lineages rather than a single multilineage progenitor.  This 
would be consistent with previous data in human adult and fetal BM which suggested that 
CLP were CD34+lin-CD38+CD10+  (Galy et al., 1995)  On the other hand, progenitors with 
various potentials, including M/E/T/B, M/E, M/T/B, M/T, and M/B, (M: myeloid; E: 
erythroid; T: T cell; B: B cell) as well as monopotent progenitors have been described in 
mouse FL (Katsura, 2002; Kawamoto et al., 2000; Kawamoto et al., 1998; Lu et al., 2002). 
However, as in my data, CLP with purely T/B/ NK cell differentiation capacity were never 
found, even when the immunophenotypic fraction corresponding to mouse BM CLP was 
examined.(Mebius et al., 2001).  
 
 
4.8.3  A unique fetal B progenitor differentiation scheme is evident in fetal liver and 
bone marrow 
 
The most notable feature of normal FL B lymphopoiesis was the predominance of CBP3, B 
progenitors which co-expressed CD34 and CD19 but did not express CD10. Although CBP3 
were also seen in CB, they were present at a very low frequency (0.34 ± 0.1%) which was 10-
fold lower than in FL.  This population has not been previously described in human adult BM, 
where B progenitors have been shown to mature from CD34+10+19+ (Pro B2 cells)  to 
CD34-CD10+CD19+  (Pre B cells), i.e. to lose CD34 expression before CD10 expression,  
My studies show that normal FL CBP3, which are CD19+ but CD10-, acquire CD10 during 
their maturation in vitro before losing CD34 strongly suggesting that in FL, CBP3 do not arise 
from CBP2 but in fact that CBP2 arise from CBP3 (see proposed model depicted in Figure 
4.27). This hypothesis is also supported by the qRT-PCR data which show lower expression 
of B cell specific genes, such as PAX5 and CD19, in CBP3 compared to CBP2. The presence 
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of CBP3 in normal FL suggests a unique alternative pathway for B lymphoid development in 
fetal life whereby CD34+ B progenitors (ELP) first acquire CD19 (CD34+CD19+CD10-; 
CBP3) and then acquire CD10 (i.e. CD34+CD19+CD10+; CBP2). This would re-define 
CBP3 as pre-Pro B cells rather than pre- Pre B cells. This pathway has very recently also been 
described as an alternative earlier pathway of B cell differentiation in vitro  in CB (Sanz et al 
2010); however, my data would suggest that this is the predominant pathway for B cell 
production in fetal life.  
 
 A revised B cell development pathway in normal human FL is depicted in Figure 4.27. 
 
Figure 4.27     Revised B cell differentiation pathway in human FL 
Schematic representation of revised B lymphopoietic pathway in fetal life: Black arrows 
represent conventional adult human BM B cell differentiation hierarchy. Red arrows represent 
suggested fetal pathway of B cell differentiation. Solid and dotted arrows represent the 
suggested predominant and secondary pathways respectively. 
Key: LMPP, lymphoid primed multipotent progenitor; ELP, early lymphoid progenitor; EBP, 
early B progenitor; ETP, early T progenitor  
 
 
4.8.4  B lymphopoiesis in human fetal BM 
 
The main site of fetal lymphopoiesis, especially B lymphopoiesis, reported in the mouse is the 
BM. CLP were originally defined as a CD34+/CD38-/lo/Lin-IL7R+/CD90-/Sca1lo/c-kitlo 
population in mouse BM (Kondo et al., 1997). Very recently, Weissman's group used Flk2 
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positivity to more reliably distinguish CLP (IL7R+/Flk2+/Sca1lo/c-kitlo) from MPP (IL7R-
/Flk2-/Sca1hi/c-kithi) (Serwold et al., 2009). As previously mentioned, cells with the same 
differentiation ability as mouse fetal BM CLP have also been described in human adult BM, 
fetal BM and CB (Galy et al., 1995) (Hao et al., 2001; Hoebeke et al., 2007) and using the 
criteria used by Hao and Hoebeke, I was able to identify CLP in human fetal BM; however 
the numbers were extremely small (0.13 ± 0.06% of total CD34+ cells) and insufficient to 
confirm their identity by testing their lymphoid and myeloid differentiation potential and gene 
expression. 
 
I also found ELP and CBP in normal fetal BM as previously reported in limited studies of 
second trimester BM (Reynaud et al., 2003; Ryan et al., 1997; Uckun, 1990; Uckun and 
Ledbetter, 1988). However, there are very few data and the time course of establishment of B 
lymphopoiesis in human fetal BM is unclear (Bofill et al., 1985; Dorshkind and Montecino-
Rodriguez, 2007; Hofman et al., 1984). I have shown the relative frequencies of CBP1, CBP2 
and CBP3 to each other for the first time and also the very high frequency of lymphoid 
progenitors in BM of this gestation relative to non-lymphoid progenitors- B progenitors 
represented >50% of the total CD34+ population with, in contrast to FL, a very high 
proportion of CBP3 (CD34+CD19+CD10-) compared to CBP2. Since this immunophenotype 
may give rise to, or arise from the previously reported 'leukaemia-associated 
immunophenotype' (LAIP) (Hong et al., 2008), it is possible that this population in fetal BM 
provides the preleukaemic substrate for childhood common ALL unrelated to DS. This may 
be of particular relevance in understanding the origins of childhood ALL, especially infant-
ALL. 
 
4.8.5  Fetal B lymphopoiesis in severely impaired in DS 
 
As children with DS have a higher incidence of B ALL than children without DS (Hasle et al., 
2000), I hypothesised that T21 would perturb B lymphopoiesis in fetal life. Using both 
multiparameter flow cytometry and progenitor cultures I have shown that B progenitor 
development is severely impaired in vivo and in vitro strongly suggesting an intrinsic defect in 
B cell development in DS FL.  Furthermore, lymphoid progenitor development appeared to be 
qualitatively abnormal in that DS FL CLP and ELP populations both had markedly increased 
myeloid and erythroid + megakaryocytic potential. This suggests either that early lymphoid 
progenitors in DS FL fail to down regulate their myeloid/erythroid gene expression program 
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sufficiently to allow normal B progenitor differentiation and/ or that T21 causes a failure of 
the normal up regulation of B progenitor genes thereby producing a block to lymphoid 
differentiation.  
 
Gene expression data from sorted B progenitors, as well as early lymphoid progenitors and 
HSC/MPP/LMPP, support this interpretation of the functional data. Genes crucial for early 
lymphoid specification (FLT3 and IL7RA) were expressed at lower levels in DS FL early 
lymphoid progenitors while EBF was barely detectable in early and committed B progenitors 
and PAX5 was reduced in mature CBP. In addition, genes normally active in 
megakaryocyte/erythroid progenitors but silenced in lymphoid progenitors (particularly 
GATA2 and GATA1) continued to be expressed at low levels in DS early and committed 
lymphoid progenitors.  The molecular mechanism of impaired B cell development was not 
clear from my studies.  However, it is interesting that, two Hsa21 genes crucial for normal B 
cell development may be abnormally expressed in DS FL lymphoid progenitors- GABPA and 
DYRK1A.  This needs further exploration by examining more samples and is further discussed 
in chapter 6. 
 
One caveat to the significance of aberrant erythroid gene expression in DS FL is that although 
gene expression and myeloid colony assay data for the CBP1 population in DS FL (sorted as 
CD34+CD10+CD19-) showed expression of a number of erythroid-specific genes, including 
EPOR and GYPA, this was also seen in normal FL CBP1. This suggests that this population 
needs further work to resolve what is likely to be a mixture of B and T progenitors as well as 
possibly some myeloid progenitors which continue to express low levels of surface CD10 
and/or CD127. 
 
My data add to clinical studies in children with DS with and without ALL which suggest that 
T21 itself affects lymphocyte development and function in post-natal life and therefore would 
be predicted to perturb B lymphopoiesis in the BM (de Hingh et al., 2005; Douglas, 2005) 
Consistent with this I found that there was a marked reduction in committed B progenitors in 
DS fetal BM, especially of CBP3 (CD34+10-19+), compared to normal fetal BM. There was 
also a 4-fold increase in the frequency of CD34+CD10+CD19- cells (CBP1) in DS fetal BM 
suggesting that the reduction in CBP3 is at least in part due to a B progenitor differentiation 
block. It is possible that, in response to this differentiation block, fetal B progenitor 
differentiation in DS follows the 'conventional' adult BM B lymphopoiesis pathway (in which 
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CBP2 predominate over CBP3) (Figure 4.27).  Further investigation of this hypothesis would 
require both in vitro differentiation assays and in vivo studies in a xenograft model such as 
NSG mice (McDermott et al., 2010).  
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4.8.6 Conclusion 
 
In conclusion, I have characterised the lymphoid compartment in normal human FL and fetal 
BM for the first time and demonstrated that lymphoid progenitors at all stages of maturation 
are present in human fetal life and that B lymphopoiesis is particularly active in fetal BM 
where B progenitors constitute >50% of the total CD34 cells. My data also suggest that an 
alternative pathway for B lymphopoiesis exists in fetal life whereby CD19 is acquired before 
CD10.  Furthermore, I have shown that in DS, there is a marked reduction of B lymphopoiesis 
in FL and fetal BM, together with a block in B cell differentiation, at the CBP stage. Indeed 
DS fetal BM B progenitors seem to be more akin to adult BM B progenitors (Figure 4.28), 
suggesting that T21 may alter the developmental pathway taken by early lymphoid 
progenitors. Understanding the mechanism by which T21 exerts its effects on B progenitor 
development is likely to provide insight into the pathogenesis both of ALL and immune 
deficiency in DS. 
Figure 4.28  Comparison of the relative frequency of different stages of committed B progenitors
in maturation (CBP1, CBP2 and CBP3) in normal fetal BM, DS fetal BM and adult BM 
Relative proportions of CBP1, CBP2 and CBP3 are expressed as a % of total CBP based on 4  
experiments in normal and DS fetal BM and 2 normal adult BM.   
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CHAPTER 5  
 
CHARACTERISATION OF THE MYELOID PROGENITOR 
COMPARTMENT IN DS FETAL LIVER AND DS FETAL 
BONE MARROW 
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 5.1 Background  
 
5.1.1 The myeloid progenitor compartment in normal and DS fetal liver  
 
Previous work in our lab showed by flow cytometry that there was an expansion of MEP in 
DS fetal liver (FL) compared to normal FL and that CMP and GMP were commensurately 
reduced (Tunstall-Pedoe et al., 2008). Furthermore DS FL CD34+ cells were found to have 
increased clonogenicity although, somewhat surprisingly given the flow cytometry data, these 
assays showed that DS FL cells gave rise to increased numbers of all clonogenic myeloid 
cells, i.e. CFU-GM and CFU-GEMM as well as increased numbers of megakaryocyte and 
erythroid colonies (Tunstall-Pedoe et al., 2008).  
 
Crucially, these experiments were performed by immunophenotyping whole mononuclear 
cells and culturing clonogenic cells from whole CD34+ cells rather than purified sub-
populations.  Thus, although this identified perturbation of the myeloid progenitor 
compartment, the myeloid progenitors themselves were not evaluated and characterised 
leaving it unclear whether T21 exerted its effects only on the more immature CD34+ sub-
populations or whether it had any direct effects also on myeloid progenitor growth and 
differentiation. Interestingly, the work in chapter 3 and 4 showed that the HSC, MPP and ELP 
sub-populations in normal and DS FL, as well as the LMPP sub-population in DS FL, gave 
rise to large numbers of erythroid +/- megakaryocyte colonies and therefore it was possible 
that the increased clonogenicity reported in the earlier study (Tunstall-Pedoe et al., 2008) 
derived from these immature sub-populations rather than from any intrinsic abnormalities in 
the myeloid progenitor compartment itself. To address this, I first analysed myeloid 
progenitors in purified CD34+ cells (rather than MNC) to allow more detailed analysis of 
each progenitor population both in normal FL, as this had not previously been reported, and 
DS FL and then flow-sorted CMP, MEP and GMP from normal and DS FL to study their 
clonogenic potential and gene expression pattern. 
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5.1.2 The myeloid progenitor compartment in normal and DS fetal bone marrow 
 
One of the interesting findings from the initial study of DS fetal haematopoiesis (Tunstall-
Pedoe et al., 2008), was that the myeloid progenitor profile in DS fetal BM, in contrast to DS 
FL, appeared to be normal.  These data were complementary to work in various mouse 
models of abnormal GATA1 expression and T21 (Kirsammer et al., 2008; Li et al., 2005).  Li 
et al, in a GATA1 knock in transgenic mouse model engineered to express only GATA1s, 
suggested that there was a 'time window' in development during which AGM and FL 
haematopoietic progenitors are uniquely sensitive to changes in the pattern of GATA1 
expression (Li et al, 2005).  Furthermore, Crispino's group showed that Ts65Dn mice, the 
most widely used mouse model of DS since they are trisomic for many genes in the human 
DSCR, also develop a megakaryocyte myeloproliferative syndrome; although this does not 
occur until the mice are adults and is not associated with AMKL (Kirsammer et al., 2008).  
 
The absence of an abnormal progenitor population in DS fetal BM also provided a possible 
explanation for the narrow clinical 'time window' in humans during which TMD and DS-
AMKL present (Hasle et al., 2008; Klusmann et al., 2008; Massey et al., 2006; Muramatsu et 
al., 2008). In addition, the data suggested that FL CD34+ cells in DS have intrinsically 
different growth characteristics compared to DS BM CD34+ cells and their normal 
counterparts, and/or that the different FL and BM microenvironments played an important 
role in DS-associated leukaemogenesis.  Since the question of whether or not DS fetal BM 
CD34+ cells have any intrinsic abnormalities was not addressed in the earlier study (Tunstall-
Pedoe et al., 2008), I decided to investigate the myeloid progenitor compartment in DS fetal 
BM in more detail using purified CD34+ cells and myeloid progenitor sub-populations.  
 
 
5.2 Aim 
 
The aim of the experiments described in this chapter was firstly, to further investigate the 
effects of T21 on fetal haematopoiesis by characterising the myeloid progenitor compartment 
in normal and DS second trimester FL and fetal BM; and secondly, by studying CB, to 
investigate whether perturbation of fetal haematopoiesis in DS was confined to the second 
trimester of fetal life or persisted until birth. 
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5.3 Experimental approach 
 
CD34+ cells were isolated from FL and fetal BM samples from second trimester fetuses and 
from CB samples from babies with and without DS by immunomagnetic beads and analysed 
using multiparameter flow cytometry and clonogenic assays to assess myeloid progenitor 
output. FL myeloid progenitor sub-populations were further assessed by studying gene 
expression by qRT-PCR. Myeloid progenitors analysed in normal FL (n=10), fetal BM (n=3) 
and CB (n=10) samples were compared with DS FL (n=5), DS fetal BM (n=4) and DS CB 
(n=3) samples. A major limitation of my analysis was the very limited sample size and sample 
numbers of fetal tissues available for these studies.  
 
5.4 The myeloid progenitor compartment in normal human second trimester FL 
 
5.4.1 Immunophenotypic analysis of the normal FL myeloid progenitor compartment 
 
The CD34+CD38+ compartment of second trimester human FL was analysed by flow 
cytometry to determine the relative proportions of CMP, MEP and GMP (defined as in 3.6).  
The data are summarised in Table 5.1 and representative flow cytometric plots are shown in 
Figure 5.1. 
 
 % of CD34+ cells % of CD34+CD38+ 
MEP  
(CD34+CD38+ CD45RA-CD123-) 
16.1 ± 2.3% 21.5 ± 2.8% 
CMP 
 (CD34+CD38+ CD45RA-CD123lo) 
23.6 ± 2.7% 32.2 ± 3.2% 
GMP  
(CD34+CD38+CD45RA+CD123lo) 
12.3 ± 1% 16.6 ± 1.4% 
 
Table 5.1 Immunophenotypic analysis of the CD34+CD38+ compartment in normal 
human second trimester fetal liver (FL) 
CD34+ cells were isolated from normal second trimester FL (n=11) using immunomagnetic 
beads and analysed by flow cytometry. Data are expressed as the mean+SEM. 
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Using the definitions of Manz et al (Manz et al., 2002) and Tunstall-Pedoe et al (Tunstall-
Pedoe et al., 2008), I found that the majority of myeloid progenitors in normal second 
trimester FL were CMP, followed by MEP (Table 5.1; Figure 5.1). These data contrast with 
adult BM, in which MEP have a lower frequency than both CMP and GMP (Manz et al 2002; 
see also Table 5.4) and are consistent with the expected skewing towards megakaryocyte-
erythroid potential in FL compared to adult life.  Since the CD34+ cells were not lineage-
depleted, I checked for surface expression of B and T lineage markers (CD19 and CD2 
respectively) which confirmed that fewer than 1% of CMP/MEP were positive while 1-2.5% 
of GMP appeared to express very low levels of CD19 and CD2 (Figure 5.2).  
 
 
            
 
           
 
Figure 5.1 Representative FACS plots of myeloid progenitors in normal FL  
Normal FL CD34+ cells were analysed by flow cytometry, gated on CD34+CD38+ cells and 
the CMP, MEP and GMP sub-populations identified as described above. Data shown here are 
representative of 11 normal FL samples. 
 
CD34
CD38
FSC 
SSC 
CD45RA
CD123 GMP
MEP 
CMP 
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      CMP                   MEP        GMP 
         
 
Figure 5.2   Expression of B and T lineage markers on normal FL myeloid progenitor 
populations  
CD34+ cells were stained with CD19 (B lineage) and CD2 (T lineage) to determine the 
specificity of immunophenotypic definition of CMP, MEP and GMP using CD34, CD38, 
CD123 and CD45RA in non lineage-depleted FL CD34+ cells. These plots are derived from 
the CMP, MEP and GMP gates depicted in Figure 5.1. CD2-CD19- CMP, MEP and GMP 
depicted by the blue arrows were sorted for all assays. Data shown here are representative of 
11 normal FL samples.  
 
 
5.4.2 Myeloid colony read out of flow sorted normal FL myeloid progenitors  
 
To investigate the myeloid potential of the immunophenotypically-defined CMP, MEP and 
GMP in normal human FL, I isolated these populations from 6 second trimester FL samples 
by flow sorting and plated each population at 100 cells/well in a 24-well plate in methyl 
cellulose with SCF, Flt3, IL3, IL6, IL11, GM-CSF, TPO and EPO as described in section 2.4. 
CD19+/ CD2+ cells were gated out during the sort to exclude any B and T progenitors 
respectively. 
 
The clonogenicity of normal FL CMP and MEP was around ~25% which is slightly more than 
previously found when the whole FL CD34+ population was plated (Tunstall-Pedoe et al, 
2008) possible reflecting the lack of clonogenic cells in most of the lymphoid progenitors 
contained within unfractionated CD34+ cells (Figure 5.3). Interestingly, the clonogenicity of 
the GMP population was more than 50% less than the CMP or MEP population (Figure 5.3a).   
CD19
CD2 
 198
       
0
5
10
15
20
25
30
35
CMP MEP GMP
C
O
LO
N
IE
S/
 1
00
 C
EL
LS
 P
LA
TE
D
 
 
b) 
     
0
10
20
30
CMP MEP GMP
co
lo
ny
 c
ou
nt
/ 1
00
 c
el
ls
 p
la
te
d
CFU GEMM
BFU-E
Erythroid blast small
Erythr/ mixed blast large
CFU-Mk/E
CFU-GM/G/M
myeloid blast
 
 
Figure 5.3 Day 14 myeloid colony readout of sorted normal FL subpopulations.  
a) Clonogenicity of flow sorted normal FL CMP, MEP and GMP (n=6). (b) Clonogenic 
readout of normal FL CMP (CD34+38+45RA-123+), MEP (CD34+38+45RA-123-) and GMP 
(CD34+38+45RA+123lo) after 100 cells from each population were cultured for 14 days in 
methyl cellulose with IL3, IL6, IL11, SCF, FLT3, GM-CSF, TPO and EPO. The data are 
expressed as mean + SEM.   
 
a) 
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Consistent with their immunophenotype, CMP gave rise to erythroid, megakaryocytic and 
G/M colonies; GMP gave rise solely to CFU-GM/G/M; and the MEP subpopulation gave rise 
almost entirely to megakaryocyte-erythroid or erythroid colonies with only occasional GM 
colonies (Figure 5.3b). As noted in the sorted normal FL HSC and MPP populations, two 
types of erythroid blast colonies (type I and II) were grown from CMP and MEP (see section 
3.5.2).  
 
 
5.4.3 Gene expression in normal fetal liver CMP, MEP and GMP 
 
In order to determine the gene expression signature of human FL myeloid progenitors, I 
initially used RT-PCR of a small number of selected transcription factors in flow-sorted FL 
CMP, MEP and GMP. Subsequently I used the BioMark Real time PCR (qRT-PCR) system 
which allowed me to quantitate gene expression (see section 2.7.2) by each of the purified 
myeloid progenitor sub-populations from normal human FL and to compare this with the 
same, immunophenotypically-defined sub-populations from DS FL. 
 
5.4.3.1 RT-PCR of specific genes in sorted normal FL CMP, MEP and GMP 
 
The genes I chose, in order to look for evidence of lineage-specific priming in the 3 sorted 
sub-populations were GATA1 (erythroid/megakaryocytic progenitors); CEBPα (myeloid); 
Pax5 (B cell progenitors) and Pre-TCRα (PTCRA; T cell progenitors) (Manz et al., 2002).  
 
The expression of genes in the sorted populations (n=3 experiments); depicted by a positive 
band of the expected size in agarose gel by electrophoresis is summarised in Figure 5.4 and 
Table 5.2. The presence of cDNA in all samples was confirmed by positive amplification of 
β-actin. The pattern of gene expression in myeloid progenitors was similar to the predicted 
pattern from previous studies (Manz et al., 2002). CMP expressed PU.1, GATA1, CEBPα and 
had faint expression of PAX5 but not PTCRα; MEP had a similar gene expression pattern to 
CMP but no PU.1 expression; and GMP expressed PU.1 and CEBPα,  but not GATA1 and 
had faint expression of PAX5 and a very low level of PTCRα. This suggests either that there 
was contamination of the sorted GMP population with B and T progenitors, although by 
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gating out the CD19+ and CD2+ cells this is unlikely, or that immunophenotypically defined 
GMP (CD34+CD38+CD45RA+CD123lo) may contain progenitors with M/T and/or M/B 
potential as previously described in mice (Buza-Vidas et al., 2007; Katsura, 2002; Kawamoto 
et al., 2000; Kawamoto et al., 1998; Lu et al., 2002; Luc et al., 2007). 
 
 
 
 
              CMP         MEP    GMP 
           
           
         
           
           
       
 
Figure 5.4: Expression of GATA1, CEBPα, PTCRA, PAX5, and β-actin checked by 
RT-PCR for normal FL myeloid progenitors.  
Lane1: CMP cells; Lane2: MEP; Lane3: GMP cells on 1.5% agarose gel. cDNA 
integrity was checked by expression of β actin- all subpopulations expressed β actin. 
(n=3 normal FL samples) 
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GENE               CMP  
   CD34+38+45RA-123lo 
            MEP 
CD34+38+45RA-123- 
           GMP 
   CD34+38+45RA+123lo
PU.1 + - + 
GATA1 + + - 
CEBPα + + + 
PAX5 +/- +/- + 
PTCRA - - +/- 
 
Table 5.2 Expression of lineage-associated haematopoietic transcription factor genes in 
human FL CMP, MEP and GMP 
Gene expression was measured in flow-sorted CMP, MEP AND GMP from normal human FL 
(n=3) by RT-PCR.  Populations in which a distinct band of the expected size was consistently 
seen on agar gel electrophoresis are marked +; populations in which a band of the expected 
size was consistently undetectable bands in the control lane and β-actin are marked -; 
populations where the band was consistently very weak or results were variable are marked as 
+/-.  
 
 
5.4.3.2 Gene expression of normal FL CMP, MEP and GMP by qRT-PCR using the 
nanofluidic BioMark 48.48 Dynamic Array and TaqMan Expression Assays  
 
To allow accurate comparison of gene expression between the sub-populations, and thereby 
determine the gene expression 'signatures' specific to each sub-population, I flow-sorted 50 
cells from the CMP, MEP and GMP compartments in triplicate and processed them as 
described in section 2.7.3. Cells were sorted on the basis of the same immunophenotypes 
described above, i.e. CMP- CD34+CD38+CD45RA-CD123lo(CD2-CD19-), MEP- 
CD34+CD3+CD45RA-CD123-(CD2-CD19-); and GMP- 
 CD34+CD38+CD45RA+CD123lo(CD2-CD19-) 
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5.4.3.2.1   Relative expression of genes in normal FL CMP 
 
Genes important for early megakaryocyte-erythroid development, such as EpoR, GATA1, 
GATA2 and FOG1, were expressed in FL CMP, although at a fairly low level, with levels of 
EpoR being barely detectable and the most mature erythroid marker, GYPA, was not 
detectable in FL CMP (Figure 5.5a).  The relative expression of these genes was almost 
identical to that seen in normal FL MPP (Figure 3.12b; Figure 5.5a), which like CMP also 
express IL3Rα, suggesting that CMP may be a more mature developmental stage of MPP 
differing only by their level of CD38 expression (MPP CD38lo/- and CMP CD38+). Consistent 
with this, CMP continued to express HSC regulatory genes (c-kit, c-MPL, PU.1, ERG and 
GATA2) at similar levels to those found in MPP (Figure 5.5b).  
 
Similarly, myeloid-associated genes (CEBPα, G-CSFR, GM-CSFR and CSF1R) were 
detected but at low levels, apart from the levels of G-CSFR expression which were highest in 
the CMP when compared to MEP and GMP (Figure 5.6).  Interestingly, expression of this 
group of genes was also very similar to normal FL MPP (Figure 3.12c; Figure 5.6). In fact 
expression of G-CSFR, CSF1R and CEBPα were also slightly greater in the CMP than MPP 
population consistent with CMP being more mature than MPP (Figure 5.6).  
 
Genes known to be important for early lymphoid development (IKAROS and E2A) were 
expressed at low levels in the CMP population (Figure 5.7a) while there was no detectable 
expression of genes reported to be necessary for more mature B cell progenitors and 
committed B cells (EBF1, PAX5 and CD19) (Figure 5.7b). Similarly, although early T 
lymphoid genes (GATA3 and NOTCH1) were expressed in FL CMP, the T cell specific gene, 
PTCRα, was not expressed (Figure 5.7c). Once again, the pattern of gene expression, in this 
case of B and T lymphoid genes, was almost identical to that seen in MPP apart from slightly 
higher levels of IKAROS expression and a low level of detectable PAX5 in MPP (Figure 
3.13b; Figure 5.7) consistent with earlier maturation stage and commensurately less lineage 
restriction.  
 
The expression of other genes studied by qRT-PCR, but not discussed in this section, is 
depicted in Appendix 3. 
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The results of qRT-PCR for FL CMP were generally consistent with the findings of RT-PCR 
(Table 5.2) and also consistent with the in vitro data whereby CMP had multilineage potential 
giving rise to erythroid, megakaryocytic and myeloid colonies in methylcellulose cultures. 
Overall, the CMP population exhibited erythroid/myeloid priming but expressed lower levels 
of specific megakaryocyte-erythroid genes and myeloid genes in comparison with the MEP 
and GMP populations respectively. Most interestingly, the pattern of gene expression for 
more than 30/x genes tested was almost identical in normal FL CMP to that in normal FL 
MPP (chapter 3) with evidence of CMP being slightly more mature and lineage restricted 
(Figures 5.5 -5.7). This suggests a model of haematopoietic differentiation in human FL 
similar to that described in mice (Lai and Kondo, 2006), whereby in MPP, upregulation of 
myeloid-associated genes, without upregulation of erythroid genes (indeed slight 
downregulation), leads to maturation to CMP which is accompanied by increased expression 
of CD38 protein on the cell surface. 
.  
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Figure 5.5  Relative expression of a) eythroid genes b) HSC regulatory genes in normal 
FL CMP, MEP and GMP; MPP is shown for comparison with CMP (see text).  
Gene expression levels are shown relative to GAPDH and are the mean ± SEM of 3 normal 
FL samples from which 50 cells of each CD34+ sub population (CMP, MEP and GMP) were 
sorted in triplicate for analysis by qRT-PCR  
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Figure 5.6  Relative expression of myeloid genes in normal FL CMP, MEP and GMP; 
MPP is shown for comparison with CMP (see text).  
Gene expression levels are shown relative to GAPDH and are the mean ± SEM of 3 normal 
FL samples from which 50 cells of each CD34+ sub population (CMP, MEP and GMP) were 
sorted in triplicate for analysis by qRT-PCR 
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5.4.3.2.2   Relative expression of genes in normal FL MEP  
a) 
b) 
c) 
Figure 5.7  Relative expression of a) early lymphoid genes b) B progenitor and committed B cell genes  
and c) T lymphoid genes in normal FL CMP, MEP and GMP; MPP is shown for comparison with CMP  
Gene expression levels are shown relative to GAPDH and are the mean ± SEM of 3 normal FL samples from which 
50 cells of each CD34+ sub-population (CMP, MEP and GMP) were sorted in triplicate for analysis by qRT-PCR. 
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5.4.3.2.2   Relative expression of genes in normal FL MEP  
 
The most striking finding from the gene expression studies in normal FL MEP was the 
marked upregulation of all of the erythroid lineage genes, specifically GATA1, GATA2, 
FOG1, EpoR, GYPA and ERAF (Figure 5.5a). Indeed, GATA1, GATA2 and GYPA were 
expressed at the their highest level in the MEP sub-population compared to any other sub-
population in normal human FL, while expression of the remaining erythroid genes, FOG1, 
EpoR and ERAF were only higher than MEP in the HSC population), further supporting the 
strong erythroid lineage priming in FL HSC.  
 
In addition to upregulation of erythroid genes, there was also downregulation of many of the 
HSC 'signature genes', including c-MPL, ERG, c-KIT and PU1 (Figure 5.5b) compared to 
CMP and MPP consistent with these cells being more differentiated/committed than CMP.  
 
As expected,  myeloid specific genes such as CEBPα,  CSF1R, GM-CSFR and G-CSFR were 
markedly down regulated in MEP (Figure 5.6), as were lymphoid genes (Figure 5.7); although 
low levels of IKAROS expression were detected, the level of expression was lower in MEP 
than in any other sub-population studied.  The expression of other genes studied by qRT-PCR, 
but not discussed in this section, is depicted in Appendix 3. 
 
Thus, qRT-PCR for FL MEP was generally consistent with the RT-PCR results (Table 5.2) 
and the in vitro data showing almost exclusively megakaryocyte-erythroid potential in 
clonogenic assays.  
 
5.4.3.2.3   Relative expression of genes in normal FL GMP  
 
Genes required for granulocyte and monocyte development, specifically, CEBPα  and 
CSF1R, were all upregulated in GMP consistent with their CFUG/M/GM read out in 
clonogenic assays. GCSFR and GM-CSFR were in fact slightly downregulated in GMP 
compared to CMP (Figure 5.6) and expressed at levels considerably lower than in HSC/MPP 
supporting the conventional model of haematopoiesis differentiation with GMP being more 
differentiated than CMP.  Interestingly, the changes in levels of expression of these myeloid 
genes in GMP compared with CMP were relatively modest and what was more evident in 
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comparing GMP with CMP, was the switching off of erythroid genes: GATA1, GATA2 and 
FOG1 were barely detectable and mature erythroid genes (EpoR and GYPA) were not 
expressed at all in GMP (Figure 5.5). In addition, expression of the HSC 'signature' genes, c-
MPL, ERG, c-KIT and PU.1, was downregulated in GMP compared to the more immature 
CMP and MPP (Figure 5.5b). 
 
Interestingly, FLT3 was considerably upregulated in GMP compared to CMP and both early B 
lymphoid progenitor genes, such as IKAROS, E2A and IL7RA, and low levels of PAX5, EBF1 
and CD19 were expressed in normal FL GMP despite gating out CD19+ cells during flow 
sorting of this population (Figure 5.7). These data suggest that FL GMP have some B-
lymphoid lineage priming and would also be consistent with the presence of GM/B bipotential 
progenitors, as previously reported in mice (Buza-Vidas et al., 2007), within the 
immunophenotypically-defined GMP population. Similarly, T progenitor genes (NOTCH1, 
GATA3, and CD7) were also expressed in FL GMP at a low level (Figure 5.7c), despite gating 
out CD2+ cells, consistent with T lineage priming of GMP and/or GM-T bipotential 
progenitors (Buza-Vidas et al., 2007).  
 
The results of the qRT-PCR for FL GMP were generally consistent with the findings of RT-
PCR (Table 5.2) and the in vitro clonogenic data showing exclusively CFU-G/GM/M colonies 
in methylcellulose cultures.  In addition, sorted normal FL GMP gave rise to mature B cells 
and CD4 and/ CD8 positive T cells in stromal co-cultures (Appendix 4) further supporting the 
presence of progenitors with G/M/B and G/M/T potential within the immunophenotypically 
defined GMP population (CD34+CD38+CD45RA+CD123loCD19-CD2-).  
 
The expression of lymphoid lineage genes in normal FL GMP also led me to compare their 
gene expression signature with LMPP from the same samples (Figure 5.8). Similar to the link 
between MPP and CMP, the gene expression signature in GMP was almost identical to that in 
LMPP apart from slightly higher levels of expression of genes associated with the HSC 
compartment (FLT3, PU1, C-MPL, ERG, GCSFR and GM-CSFR) and, interestingly, 
markedly increased expression of IL3RA and CRLF2, in LMPP compared to GMP. This 
suggests a model of haematopoietic differentiation in human FL similar to that described in 
mice (Mansson et al., 2007) whereby in LMPP, upregulation of granulocyte and monocyte 
genes, together with downregulation of HSC regulatory genes, leads to maturation to GMP 
and is accompanied by increased expression of CD38 protein on the cell surface. 
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Figure 5.8  Relative expression of a) stem cell genes b) myeloid genes and c)  lymphoid 
genes in normal FL LMPP and GMP (see text)  
Expression of selected genes relative to GAPDH in sorted normal FL LMPP and GMP. Data 
are expressed as mean ± SEM of 3 experiments. Data in LMPP were previously presented in 
chapter 3 and are from the same 3 FL samples flow sorted and analysed at the same time at 
the GMP. 
 
 
 
5.5 The myeloid progenitor compartment in DS human second trimester FL 
 
5.5.1 Immunophenotypic analysis of myeloid progenitors in DS fetal liver 
 
Analysis of the CD34+CD38+ compartment of second trimester DS FL by flow cytometry 
showed a 2.5-fold increase in the proportion of MEP, a 30% decrease in CMP and a 50% 
decrease in GMP compared to normal second trimester FL (Figure 5.9; Table 5.3). As with 
normal FL myeloid progenitors, there was minimal contamination with B/ T lineage cells 
(CD2+/ CD19+) in the DS myeloid progenitor populations (Figure 5.9). 
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 % of CD34+  
cells 
% of CD34+CD38+ 
cells 
p value 
DS vs.  
normal FL 
MEP  
CD34+CD38+ CD45RA-CD123-) 
40 ± 6.7% 56.1 ± 8.4% 
Normal FL 21.5 ± 2.8% 
 
p= 0.0074**
CMP 
 (CD34+CD38+ CD45RA-CD123lo
15.2 ± 3.6% 22 ± 5.5% 
Normal FL 32.2 ± 3.7% 
 
p= 0.227 
GMP  
(CD34+CD38+CD45RA+CD123lo)
6 ± 2.5% 8.6 ± 3.3% 
Normal FL 16.6 ± 1.5% 
 
p= 0.05 
 
Table 5.3 Immunophenotypic analysis of the myeloid progenitor compartment in DS FL 
CD34+ cells were isolated from DS second trimester FL (n=6) using immunomagnetic beads 
and analysed by flow cytometry. Data are expressed as the mean+SEM. Normal FL data are 
derived from Table 5.1.  * p<0.05; ** p< 0.01 
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b) 
      CMP                   MEP        GMP 
               
 
 
Figure 5.9 Representative FACS plots of myeloid progenitors in DS FL: a) DS FL CD34+ 
cells were analysed by flow cytometry, gated on CD34+CD38+ cells and the CMP, MEP and 
GMP sub-populations identified as described above. b) CD2 + CD19+ cells were present in 
very small numbers and were detected only in the GMP population. CD2-CD19- CMP, MEP 
and GMP depicted by the blue arrows were sorted for all assays. Data shown here are 
representative of 6 DS fetal liver samples.  
 
 
 
 
5.5.2 Myeloid colony read out in clonogenic assays of the myeloid progenitor 
compartment of DS FL   
 
Flow sorted MEP from DS FL (n=4) showed increased clonogenicity compared to normal 
second trimester FL (62.3 ± 9.9 vs. 24.8 ± 6.2%) as did CMP from DS FL (64.3 ± 16.8 vs. 24 
± 6.9%) (Figure 5.10) despite being present in slightly lower numbers by flow cytometry. By 
contrast, DS FL GMP had similar clonogenicity when compared to normal FL GMP (7.6 ± 
4.1 vs. 9.7 ± 1.7%) (Figure 5.10) 
 
 
 
 
CD19
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Figure 5.10 Day 14 myeloid colony numbers from sorted normal and DS FL myeloid 
progenitors.  
Clonogenicity of normal and DS FL CMP (CD34+38+45RA-123+), MEP (CD34+38+45RA-
123-) and GMP (CD34+38+45RA+123lo) after 100 cells from each population were cultured 
for 14 days in methyl cellulose with IL3, IL6, IL11, SCF, FLT3, GM-CSF, TPO and EPO . 
The data are expressed as mean ± SEM. There was a significant increase in MEP 
clonogenicity in DS FL compared to normal FL (p≤ 0.05). (n=6) for normal FL and (n=4) for 
DS FL. 
 
 
The higher clonogenicity of DS FL CMP and MEP compared to normal FL, was mainly due 
to a marked increase (~3-fold) in the numbers of megakaryocyte, megakaryocyte-erythroid 
and Type II erythroid blast colonies generated from the DS CMP and MEP (Figure 5.11). In 
contrast to normal FL, the type II erythroid blast cell colonies in DS FL were more numerous 
and DS FL type I erythroid blast colonies were much larger in size than those generated from 
normal FL (examples are shown in Figure 3.16). 
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b) Normal FL 
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Figure 5.11 Myeloid colony readout of sorted myeloid progenitors from DS FL (a) 
compared with normal FL (b)  
Day 14 clonogenic readout of DS FL CMP, MEP and GMP (n=4) compared to normal FL 
(n=6) after 100 cells from each population were cultured for 14 days in methyl cellulose with 
IL3, IL6, IL11, SCF, FLT3, GM-CSF, TPO and EPO. The data are expressed as mean + SEM.  
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5.5.3 Gene expression of DS FL myeloid progenitors by qRT-PCR  
 
The expression of selected genes and haematopoietic transcription factors in the 
immunophenotypically defined CMP, MEP and GMP from DS FL was tested using the 
BioMark Real time PCR (qRT-PCR) system, as described in section 2.7.2, to look for 
differences in gene expression between DS FL CMP, MEP, GMP and their normal 
counterparts which might help explain the perturbed fetal myelopoiesis in DS FL.  
 
There was a relative increase in the level of expression of all of the erythroid/megakaryocyte 
genes tested, apart from ERG and c-MPL, in DS FL CMP: GATA1, GATA2, FOG1, EPOR, 
GYPA and ERAF were all expressed at higher levels than normal FL CMP (Figure 5.12). This 
is consistent with the myeloid colony assay data and suggests an erythroid/megakaryocytic 
bias as also noted in the HSC compartment. In addition, consistent with the 
erythroid/megakaryocyte bias of the CMP population in DS FL, expression of the myeloid-
associated genes (CEBPα, G-CSFR, GM-CSFR and CSF1R) and of FLT3 was reduced 
compared to normal FL CMP (Figure 5.13).   
 
In contrast to the differences in gene expression in DS FL CMP, there were fewer differences 
noted in the DS FL MEP population despite increased MEP being the most notable 
characteristic of perturbed fetal haematopoiesis in DS. Although there was upregulation of the 
erythroid/megakaryocyte genes (GATA1, GATA2, FOG1, EPOR, GYPA and ERAF) compared 
to HSC/MPP, levels of expression of these genes were not higher in DS FL MEP compared to 
normal FL MEP (Figure 5.12). Interestingly, the only genes which appeared to show an 
increased level of expression in DS FL MEP compared to normal FL MEP were RUNX1, 
MEF2c, JAK3, PU1, GATA3 and CDKN1C (Figure 5.14). The increased expression of PU1 
was surprising since it would normally be downregulated in MEP; however, this might be one 
reason for the reduced expression of GATA1 in DS MEP compared to normal FL MEP since 
GATA1 normally antagonises PU.1 (Warren and Rothenberg, 2003). However sample 
numbers were inadequate to draw any firm conclusions from these observations. 
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Figure 5.12 Relative expression of erythroid/megakaryocyte genes DS FL CMP, MEP 
and GMP compared to normal FL.  
Gene expression levels are shown relative to the expression of GAPDH and are the mean ± 
SEM of 3 normal FL and 3 DS FL samples from which 50 cells of each sub-population (CMP, 
MEP and GMP) were sorted in triplicate for analysis by qRT-PCR 
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Figure 5.13 Relative expression of myeloid genes in DS FL CMP, MEP and GMP 
compared to normal FL.  
Gene expression levels are shown relative to the expression of GAPDH and are the mean ± 
SEM of 3 normal FL and 3 DS FL samples from which 50 cells of each sub-population (CMP, 
MEP and GMP) were sorted in triplicate for analysis by qRT-PCR  
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Figure 5.14 Genes over expressed in DS FL MEP compared to normal FL MEP  
Gene expression levels are shown relative to the expression of GAPDH and are the mean ± 
SEM of 3 normal FL and 3 DS FL MEP sub-population from which 50 cells were sorted in 
triplicate for analysis by qRT-PCR 
 
The pattern of gene expression in DS FL GMP was similar to that in normal FL GMP. There 
was, however, a reduction in the levels of expression of the majority of myeloid-associated 
genes, particularly of CEBPα, and a failure to upregulate FLT3, as seen in the LMPP 
population (Figure 5.13). Interestingly, levels of expression of PU1, which is known to be 
essential for normal myelopoiesis (DeKoter et al., 1998) were also higher in DS FL GMP 
compared to normal FL GMP suggesting that this may contribute to the changes in levels of 
expression of these myeloid genes in DS FL GMP.  
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There were no consistent increases in the level of expression of any of the Hsa21 genes I 
tested in DS FL committed myeloid progenitors (Figure 5.15).  Interestingly, levels of 
expression of ERG in DS FL MEP were the same as those in normal FL MEP; given that 
expression levels of the majority of genes were actually lower than in comparable normal FL 
progenitor populations, it is possible that ERG is relatively over-expressed and might 
contribute to the megakaryocyte bias seen in the clonogenic assays of DS FL MEP. 
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Figure 5.15 Relative expression of selected genes on chromosome 21 in DS FL CMP, 
MEP and GMP compared to normal FL. 
Gene expression levels are shown relative to the expression of GAPDH and are the mean ± 
SEM of 3 normal FL and 3 DS FL samples from which 50 cells of each sub-population (CMP, 
MEP and GMP) were sorted in triplicate for analysis by qRT-PCR  
 
 
5.6 Characterising the myeloid progenitor compartment in DS fetal BM 
 
As mentioned above (5.1), work in our lab on DS fetal BM had previously found no 
difference in MEP, CMP and GMP compared to normal fetal BM when whole marrow 
mononuclear cells were analysed by flow cytometry (Tunstall-Pedoe et al., 2008). This 
suggested that the abnormalities in haematopoiesis in DS might be confined to FL myeloid 
progenitors due to cell intrinsic differences in the progenitors and/or the role of different FL 
and BM microenvironments.  I therefore decided to investigate the myeloid progenitor 
compartment in DS fetal BM in more detail using purified CD34+ cells and myeloid 
progenitor sub-populations and to compare this with normal BM 
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5.6.1 Myeloid progenitors in normal fetal and adult BM 
 
5.6.1.1 Immunophenotypic analysis of the myeloid compartment of normal human fetal 
and adult BM 
 
The CD34+ compartment of normal second trimester human fetal BM (n=3) and normal adult 
BM (healthy BM donors; n=2) was analysed by flow cytometry to determine the relative 
proportions of CMP, MEP and GMP as described above.  
 
Fetal BM had markedly reduced CMP and MEP when compared to adult BM whereas GMP 
were present in similar numbers (Table 5.4; Figure 5.16). A likely explanation for this is that 
the liver is the main site of haematopoiesis in the second trimester of fetal life, especially for 
the megakaryocyte-erythroid lineage, while BM is most likely to predominantly support B 
lymphopoiesis and myelopoiesis in fetal life. 
 
 
 
Table 5.4  Myeloid progenitors in normal fetal BM compared with adult BM  
 
 
 
 
 
 
 Normal fetal BM (n=3) 
% CD34+ cells (mean + SEM)
Adult BM (n=2) 
% CD34+ cells (mean) 
MEP  
CD34+CD38+ CD45RA-CD123-) 
3.75 ± 1% 
(4.4% of CD34+CD38+ cells) 
9.4% 
(11.4% of CD34+CD38+ cells)
CMP 
 (CD34+CD38+ CD45RA-CD123lo) 
2.29 ± 0.75 % 
(2.8% of CD34+CD38+ cells) 
18.4% 
(21.6% of CD34+CD38+ cells)
GMP  
(CD34+CD38+CD45RA+CD123lo) 
8.2 ± 0.21% 
(9.8% of CD34+CD38+ cells) 
12.2% 
(14.3% of CD34+CD38+ cells)
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a) Fetal BM 
                     
 
b) Adult BM 
                                  
 
Figure 5.16 Representative FACS plots of myeloid progenitors in (a) normal fetal BM 
and (b) adult BM  
Normal fetal BM and adult BM CD34+ cells were analysed by flow cytometry, gated on 
CD34+CD38+ cells and the CMP, MEP and GMP sub-populations identified as described 
above. Data shown are representative of 3 fetal BM and 2 adult BM samples. 
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5.6.1.2 Myeloid colony read out in clonogenic assays of normal fetal BM myeloid 
progenitors  
 
To confirm the myeloid potential of the immunophenotypically-defined CMP, MEP and GMP 
in normal human fetal BM, clonogenic assays were performed on the only available second 
trimester sample. The myeloid progenitor populations were isolated by flow sorting and 
plated at 100 cells/well of a 24-well plate in methyl cellulose with SCF, Flt3, IL3, IL6, IL11, 
GM-CSF, TPO and EPO as described in section 2.4. CD19+/ CD2+ cells were gated out 
during the sort. The clonogenicity of normal fetal BM CMP, MEP and GMP was 32%, 40% 
and 6% respectively (Figure 5.17). The MEP subpopulation gave rise to predominantly 
erythroid colonies; GMP to CFU-GM/G/M only and CMP to erythroid, and G/M colonies. 
Interestingly there were no megakaryocytic/ megakaryocyte-erythroid colonies generated 
from fetal BM CMP or MEP unlike the corresponding FL populations. The clonogenicity of 
normal fetal BM CMP and MEP appears to be slightly higher than that seen in normal FL and 
cord blood, however it is difficult to comment with data from just one fetal BM sample. 
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Figure 5.17 Myeloid colony readout of sorted normal fetal BM myeloid progenitors.  
Clonogenic readout on day 14 of normal fetal BM (n=1) CMP (CD34+38+45RA-123+), MEP 
(CD34+38+45RA-123-) and GMP (CD34+38+45RA+123lo), after 100 cells from each 
population were cultured for 14 days in methyl cellulose with IL3, IL6, IL11, SCF, FLT3, 
GM-CSF, TPO and EPO.  
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5.6.2 The myeloid progenitor compartment in DS fetal BM 
5.6.2.1 Immunophenotypic analysis of myeloid progenitors in DS fetal BM 
The CD34+CD38+ compartment of second trimester DS  fetal BM was analysed by flow 
cytometry to determine the relative proportions of CMP, MEP and GMP (defined as in 5.4 
above).  
Compared to normal second trimester fetal BM, there was a.7-fold increase in the proportion 
of MEP within the CD34+CD38+ compartment, while there was a 4-fold increase in CMP 
and 1.5-fold increase in GMP (Table 5.5; Figures 5.18 and 5.19). 
 
 
Table 5.5 Immunophenotypic analysis of the myeloid progenitor compartment in DS 
fetal BM 
CD34+ cells were isolated from DS second trimester fetal BM (n=4) using immunomagnetic 
beads and analysed by flow cytometry. Data are expressed as the mean+SEM. Normal fetal 
BM data are derived from Table 5.4.  
 DS fetal BM (n=4) 
% CD34+ cells  
Normal fetal BM (n=3) 
% CD34+ cells  
p value 
MEP  
CD34+CD38+ CD45RA-CD123-) 
25.4 ± 5.2% 
(34.2% of CD34+CD38+) 
3.75 ± 1% 
(4.4% of CD34+CD38+) 
0.09 
0.09 
CMP 
 (CD34+CD38+ CD45RA-CD123lo) 
9.7 ± 2.5 % 
(12.9% of CD34+CD38+) 
2.29 ± 0.75 % 
(2.8% of CD34+CD38+) 
0.09 
0.09 
GMP  
(CD34+CD38+CD45RA+CD123lo) 
12.4 ± 2.1% 
(16.9% of CD34+CD38+) 
8.2 ± 0.21% 
(9.8% of CD34+CD38+) 
0.410 
0.09 
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Figure 5.18 Frequency of myeloid progenitors in normal fetal BM and DS fetal BM 
CD34+ cells were isolated by immunomagnetic selection and the frequency of CMP 
(CD34+38+45RA-123+), MEP (CD34+38+45RA-123-) and GMP (CD34+38+45RA+123lo) 
in normal (n=3) and DS fetal BM (n=4) was determined by flow flow cytometry. Data are 
expressed as mean ± SEM.  
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Figure 5.19  Representative FACS plots of myeloid progenitors in DS fetal BM. DS fetal BM CD34+
cells were analysed by flow cytometry, gated on CD34+CD38+ cells and the CMP, MEP and GMP 
populations identified as described above. Data shown are representative of 4 DS fetal BM samples. 
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5.6.2.2 Myeloid colony read out in clonogenic assays of DS fetal BM myeloid progenitors   
To confirm the myeloid potential of the immunophenotypically-defined CMP, MEP and GMP 
in DS fetal BM, these populations were isolated from 2 second trimester DS fetal BM samples 
by flow sorting and cultured as described in section 2.4. CD19+/ CD2+ cells were gated out 
during the sort. Although DS fetal BM CMP, MEP and GMP appeared to have slightly lower 
clonogenicity compared to normal fetal BM GMP, the myeloid colony readout was different 
from normal fetal BM in that more megakaryocyte/megakaryocyte-erythroid colonies were 
generated from DS fetal BM CMP and MEP. (Figure 5.20). This suggests that DS fetal BM 
myeloid progenitors are more megakaryocyte-erythroid primed than normal fetal BM at the 
expense of myeloid and lymphoid differentiation. This could be due to differential gene 
expression/ regulation of lineage specific genes; however I was unable to investigate this 
further because of very limited availability of samples. 
a) DS fetal BM                                                                b) Normal fetal BM 
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Figure 5.20 Myeloid colony readout of sorted myeloid progenitors from DS fetal BM 
compared to normal fetal BM  
Day 14 clonogenic readout of normal and DS fetal BM CMP (CD34+38+45RA-123+), MEP 
(CD34+38+45RA-123-) and GMP (CD34+38+45RA+123lo) (n=2) compared to normal fetal 
BM (n=1) after 100 cells from each population were cultured for 14 days in methyl cellulose 
with IL3, IL6, IL11, SCF, FLT3, GM-CSF, TPO and EPO.  
 .  
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5.7 Identification and characterisation of myeloid progenitors in normal and DS cord 
blood (CB) 
 
5.7.1 Immunophenotypic analysis of myeloid progenitors in normal CB 
CMP, MEP and GMP in CB were analysed by flow cytometry as described for FL and fetal 
BM. Representative plots are shown in Figure 5.21). Although not lineage depleted, CMP, 
MEP and GMP were consistently CD2- and CD19- indicating no or minimal contamination 
with B/ T progenitors. 
 
 
                                       
         
                                                
 
 
Figure 5.21 Representative FACS plots of myeloid progenitors in normal cord blood: CB 
CD34+ cells were analysed by flow cytometry, gated on CD34+CD38+ cells and CMP 
(CD34+38+45RA-123+), MEP (CD34+38+45RA-123-) and GMP (CD34+38+45RA+123lo) 
identified as described above. Data are representative of 10 normal CB samples.  
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5.7.2 Clonogenicity and myeloid colony read out of myeloid progenitors in normal CB 
 
To determine clonogenicity and confirm the lineage specification of the 
immunophenotypically identified progenitors in CB, I plated flow-sorted CMP, MEP and 
GMP) from normal CB in methylcellulose as described in section 2.4.  MEP subpopulation 
gave rise to almost entirely erythroid and megakaryocytic colonies; GMP to CFU-GM/G/M 
with a very occasional erythroid blast colony and CMP to erythroid, megakaryocytic and G/M 
colonies (Figure 5.22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.22 Clonogenicity of flow sorted term cord blood myeloid progenitors 
Normal CB CD34+ cells (n=4) were flow sorted on the basis of the immunophenotype: CMP- 
CD34+CD38+CD45RA-CD123lo, MEP- CD34+CD3+CD45RA-CD123-; and GMP- 
CD34+CD38+CD45RA+CD123lo and cultured in methylcellulose with SCF, Flt3, IL3, IL6, 
IL11, GM-CSF, TPO and EPO. Colonies were counted on day 14. Data are expressed as mean 
± SEM 
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5.7.3 Immunophenotypic analysis of myeloid progenitors in DS CB 
 
The CD34+CD38+ compartment of DS cord blood was analysed by flow cytometry to 
determine the relative proportions of CMP, MEP and GMP (defined as in 5.4 above).  
 
Compared to normal term cord blood, there was no difference in the proportion of MEP, CMP 
or GMP within the CD34+CD38+ compartment (Table 5.6; Figures 5.23 and 5.24). 
 
 
Table 5.6 Immunophenotypic analysis of the myeloid progenitor compartment in DS CB 
CD34+ cells were isolated from normal (n =10) and DS second trimester CB (n=3) using 
immunomagnetic beads and analysed by flow cytometry. Data are expressed as the 
mean+SEM. There is no significant difference in the frequency of MEP, CMP and GMP in 
DS CB compared to normal CB. 
 
 
 DS cord blood (n=3) 
% CD34+ cells  
Normal cord blood (n=10)
% CD34+ cells  
p value
MEP  
CD34+CD38+ CD45RA-CD123-) 
22.5 ± 3.4% 
(30.9% of CD34+CD38+) 
23.5 ± 3.1% 
(28.4% of CD34+CD38+) 
 
p=0.78
CMP 
 (CD34+CD38+ CD45RA-CD123lo) 
20.5 ± 6.3 % 
(28.3% of CD34+CD38+) 
15.2 ± 0.5 % 
(18.5% of CD34+CD38+) 
 
p=0.7 
GMP  
(CD34+CD38+CD45RA+CD123lo) 
10.4 ± 1.7% 
(14.6% of CD34+CD38+) 
21.9 ± 2.0% 
(26.5% of CD34+CD38+) 
 
p= 0.1 
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Figure 5.23 Frequency of myeloid progenitors in normal fetal BM and DS fetal BM 
Proportion of MEP, CMP and GMP in the normal cord blood and DS cord blood 
CD34+CD38+ compartment by flow cytometry. Data are expressed as mean ± SEM. 
 
                             
               
       
 
Figure 5.24 Representative FACS plots of myeloid progenitors in DS CB Data shown are 
representative of 3 DS CB samples. 
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5.7.4 Clonogenicity and myeloid colony read out of myeloid progenitors in DS CB 
 
To confirm the myeloid potential of the immunophenotypically-defined CMP, MEP and GMP 
in DS CB, these populations were isolated from 3 second trimester DS CB samples by flow 
sorting and cultured as described in section 2.4. CD19+/ CD2+ cells were gated out during the 
sort. DS CB CMP and MEP appeared to have higher clonogenicity compared to normal CB 
myeloid progenitors although this just failed to reach statistical significance (p=0.09; Figure 
5.25) probably because of the small number of DS CB samples available for analysis.  The 
myeloid colony readout was different from normal CB in that many more 
megakaryocyte/megakaryocyte-erythroid colonies were generated from DS CB CMP and 
MEP. (Figure 5.25). In addition to typical MkE colonies, there were large sheet like clusters 
of megakaryocytic colonies (Figure 5.26). Cytospin of these cells showed megakaryoblasts 
(Figure 5.26). This suggests that DS CB myeloid progenitors are more megakaryocyte-
erythroid primed than normal CB and indeed appear to be very similar to DS FL myeloid 
progenitors in their properties. However I was unable to investigate this further because of 
very limited availability of samples. 
a) Normal cord blood         b) DS cord blood  
 
 
 
 
 
 
 
 
 
 
Figure 5.25 Myeloid colony readout of sorted myeloid progenitors from DS CB 
compared to normal CB Day 14 clonogenic readout of normal and DS CB CMP 
(CD34+38+45RA-123+), MEP (CD34+38+45RA-123-) and GMP (CD34+38+45RA+123lo) 
(n=3) compared to normal  CB (n=4) after 100 cells from each population were cultured for 
14 days in methyl cellulose with IL3, IL6, IL11, SCF, FLT3, GM-CSF, TPO and EPO. There 
was a trend towards higher clonogenicity of DS CB CMP and MEP compared to normal CB 
CMP and MEP (p=0.09 for both). 
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a) Megakaryocyte colony                b) Cytospin of colony 
                   
 x 4    x  10 
Figure 5.26 Megakaryocyte colonies grown in myeloid methylcellulose culture from DS 
CB CMP and MEP 
a) Appearance of megakaryocytic colony under the inverted microscope and b) cytospin of 
cells plucked from the same colony showing a megakaryoblast. 
 
 
5.8 Summary and discussion 
 
5.8.1  Myelopoiesis in normal second trimester human fetal liver 
Traditionally myelopoiesis has been described to follow defined pathways with a common 
myeloid progenitor (CMP) giving rise to megakaryocyte erythroid progenitors (MEP) and 
granulocyte macrophage progenitors (GMP). Fetal myeloid progenitors have been described 
in murine fetal liver and bone marrow (Akashi et al., 2000; Traver et al., 2001) and have also 
been characterised in human adult BM and cord blood (Manz et al., 2002) but there are no 
published detailed studies in human FL.  
 
Using the immunophenotypic criteria described by Manz et al, I have confirmed the presence 
of myeloid progenitors in normal second trimester FL where they formed a significant 
proportion (52%) of the CD34 compartment. Normal FL CMP, MEP and GMP gave the 
expected colony readout in myeloid semi solid cultures with CMP giving a multilineage 
readout (CFU-G/M/GM; erythroid and megakaryocyte colonies); MEP giving rise to BFU-E 
and CFU-Mk/MkE only; and GMP giving rise to CFU-G/M/GM only. Although it was not 
possible to confirm that MEP and GMP are the direct progeny of CMP, the clonogenic data 
certainly suggests progressive lineage restriction from CMP to MEP and GMP.  FL MEP and 
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CMP also gave rise to type I and II erythroid blast colonies as seen in the FL HSC/MPP 
compartment. 
  
Real time qPCR data also support the hypothesis that CMP are a developmentally more 
immature population than MEP and GMP, with higher expression of immature stem cell/ 
MPP-associated genes while also expressing erythroid, myeloid and megakaryocyte specific 
genes at levels lower than those found in MEP and GMP. MEP demonstrated a clear up 
regulation of erythroid and megakaryocyte specific genes when compared to CMP, while 
GMP demonstrated an up regulation of myeloid specific genes. This confirms that MEP and 
GMP are progenitors that are undergoing lineage restriction to megakaryocyte-erythroid and 
myeloid lineage respectively and suggests that MEP and GMP both arise from CMP, although 
this does not exclude an additional route of GMP development directly from LMPP. Taken 
together my data also confirm that CMP are myeloid primed /committed progenitors and my 
data show, from both their gene expression and clonogenicity, that they are likely to be 
derived from MPP, their more immature counterpart in the CD34+CD38lo/- compartment  
 
 
The CD34+CD38+CD45RA+CD123+ (GMP) compartment in normal FL also contained B 
and T lymphoid potential as well as GM potential. There are two possible interpretations of 
this observation. It may represent a mixed progenitor population of GMP, B progenitors and T 
progenitors, or alternatively it might represent a mixture of the human equivalent of 
progenitors with combined granulocyte/macrophage and B cell (MB) and those with 
combined granulocyte/ macrophage and T cell potential (MT) reported in mouse FL (Buza-
Vidas et al., 2007; Katsura, 2002; Kawamoto et al., 2000; Kawamoto et al., 1998; Lu et al., 
2002; Luc et al., 2007). I found some evidence in favour of there being a mixture of T 
progenitors, B progenitors and GMP in the CD34+CD38+CD45RA+ compartment when I 
looked more closely at my flow cytometric data and found that I could identify T progenitors 
with no clonogenic myeloid activity in the CD34+CD38+CD45RA+CD123hi population 
(Figure 5.27) and B progenitors with no clonogenic myeloid activity in the 
CD34+CD38+CD45RA+CD123- population (Figure 5.27). However, flow sorted 'true' GMP 
(CD34+CD38+CD45RA+CD123loCD2-CD19-) were used in the qRT-PCR studies and still 
contained B and T lineage priming supporting the presence of human FL MB and MT 
progenitors. The only way this could be confirmed is by single cell flow sorting and assay. 
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Figure 5.27 Representative FACS plots of CD34+CD38+CD45RA+ progenitors in 
normal FL: Normal FL CD34+ cells were analysed by flow cytometry, gated on 
CD34+CD38+ cells and the CD45RA+ sub-populations were further characterised by 
immunophenotyping as described above. Data shown here are representative of 11 normal 
fetal liver samples. 
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5.8.2  Myelopoiesis in DS second trimester fetal liver 
 
My data confirmed and extended the previous work in our lab which identified for the first 
time that FL myeloid progenitors were abnormal in DS FL and that the abnormalities were 
present prior to acquisition of GATA1 mutations (Tunstall-Pedoe et al., 2008). The main new 
findings were that I was able to demonstrate that the increase in MEP was even greater than 
had previously been suspected and that the clonogenicity of MEP and CMP, but not GMP, 
was increased. Indeed, the clonogenicity of GMP was actually reduced in DS FL. This effect 
had been masked in the original study since clonogenicity was studied in whole CD34+ cells 
(which included HSC, MPP and LMPP as well as myeloid progenitors) rather than in purified 
GMP. This suggests that there is likely to be a hitherto unexpected defect in GMP or CMP to 
GMP maturation in DS FL which may contribute to the abnormalities in neutrophils reported 
in TMD and neonates with DS (Henry et al., 2007; Norton, 2010). 
 
Gene expression data from purified CMP, MEP and GMP provided some clues to the 
mechanism of the marked changes in the composition and function of the myeloid progenitor 
compartment in DS FL. Most of the gene expression differences were seen in the CMP 
population which is not surprising given that the data in normal FL suggest that MEP arise 
from CMP.  In comparison with normal FL, trisomic CMP appeared to be 
erythroid/megakaryocyte primed, expressing higher levels of the majority of genes important 
for erythroid/megakaryocyte specification, proliferation and for erythroid maturation: GATA1, 
GATA2, FOG1, EPOR, GYPA and ERAF.   
 
In DS FL MEP the erythroid signature was downregulated compared to the levels of 
expression in CMP and compared to normal FL MEP. Presumably this largely reflects 
increased megakaryocyte differentiation bias in these cells, as shown in the clonogenic assays.  
Unfortunately too few megakaryocyte-specific genes were included in my panel to confirm 
this, although interestingly of the 6 genes overexpressed in DS FL MEP compared to normal 
FL MEP, Mef2c and RUNX1 would both be predicted to increase megakaryocyte 
proliferation and differentiation (Gekas et al., 2009; Huang et al., 2009a).  
 
There were no consistent increases in the level of expression of any of the Hsa21 genes in DS 
FL committed myeloid progenitors and more samples need to be tested to determine this. 
However, it seems likely that there are multiple changes in gene expression which operate 
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from the HSC level onwards, ie the erythroid/megakaryocyte bias arises upstream of the 
committed progenitors and that significant intrinsic abnormalities of CMP and MEP in DS FL 
(and possibly GMP), as well as those at the HSC level, are likely to exacerbate the abnormal 
haematopoiesis seen in DS.   
 
 
5.8.3   Myelopoiesis in normal and DS second trimester fetal BM 
 
Although very few samples were available for detailed studies, I was able to investigate some 
novel aspects of haematopoiesis in normal second trimester fetal bone marrow. Relative to 
FL, there were relatively few myeloid progenitors (~14% of CD34+ cells) compared to 
normal FL (52% of CD34+ cells) and there was a bias towards GMP with a relative reduction 
in CMP and MEP consistent with previous reports, using immunohistochemistry and very 
limited flow cytometry, suggesting that fetal BM is predominantly a site of granulopoiesis and 
lymphopoiesis. Similarly, a higher proportion of the clonogenic cells in normal fetal BM were 
CFU-G/GM/M compared to normal FL. Since fetal BM myeloid progenitors are believed to 
derive from HSC which originated in FL, this suggests that the microenvironment plays a role 
in determining the lineage pathways taken by HSC as they mature.  
 
Previous work in the lab suggested that there were normal numbers of each type of myeloid 
progenitor in DS fetal BM and that the marked expansion of MEP seen in DS FL was not 
evident in DS fetal BM (Tunstall-Pedoe et al.). However, my data, using purified CD34+ cells 
from DS fetal BM, revealed a relative increase in the myeloid progenitors in DS fetal BM, 
where they formed almost 50% of the CD34+ cells compared to ~14% of normal fetal BM 
CD34+ cells). Furthermore, the proportion of MEP was 7-fold higher in DS fetal BM 
compared to normal fetal BM. Indeed the myeloid progenitor profile in DS fetal BM 
resembled that seen in normal FL (Figure 5.28). This suggests maintenance of a ‘FL’ 
megakaryocyte-erythroid phenotype despite the absence of the FL microenvironment, 
presumably because of failure to downregulate megakaryocyte-erythroid genes in DS fetal 
BM and/or an inability to normally upregulate lymphoid genes. Further experiments both on 
BM/FL stromal cells and purified progenitors would be required to investigate the role of the 
FL versus fetal BM microenvironment on gene expression in normal and DS fetal BM 
progenitors and understand how this might increase susceptibility to leukaemia in DS. 
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Figure 5.28 Comparison of the myeloid and lymphoid progenitor profile in normal and 
DS FL and fetal BM  
 
5.8.4 Conclusion 
 
In conclusion, I have confirmed the presence of all 3 types of myeloid progenitors in normal 
human FL and fetal BM and, in FL, demonstrated their hierarchical relationship as reflected 
by their transcription factor gene expression signatures.  In addition, my data strongly suggest 
the presence of progenitors with dual GM and lymphoid lineage in normal FL as previously 
reported for murine fetal liver.  Taken together with the data in chapter 3, my data also show 
very similar gene expression and clonogenic readout in the MPP and CMP populations of 
normal FL supporting a hierarchical relationship with CMP immediately downstream of MPP 
and similarly a similar hierarchical relationship between LMPP and GMP. Finally, I found 
that haematopoiesis is strongly biased towards the lymphoid lineage in normal fetal BM 
compared to FL which suggests an important role for the microenvironment in determining 
lineage fate. In DS, I have shown that the MEP compartment is expanded both in FL and fetal 
BM and that both FL and fetal BM myeloid progenitors had markedly increased 
megakaryocyte-erythroid potential compared to their normal counter parts. Myelopoiesis, 
(especially megakaryo-erythropoiesis) continues to be the predominant haematopoietic 
pathway instead of lymphopoiesis in DS fetal BM, unlike normal fetal BM. This suggests that 
the continued megakaryocyte-erythroid priming, although partially dependant on the FL 
microenvironment; is inherent to T21 and could be due to differential gene expression/ 
regulation as an effect of the extra copy of chromosome 21. 
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CHAPTER 6 
 
DISCUSSION
 238
6.1 Background 
 
Children with DS have a marked increase in their risk of developing acute leukaemia, either 
AMKL or ALL. For AMKL, it is clear that the leukaemia has a fetal origin and that T21 itself 
is involved in leukaemia initiation through changes in the growth and differentiation of FL 
myeloid progenitors (Malinge et al., 2009) and recent evidence suggests that DS-ALL is also 
likely to have its origin in fetal or early post-natal life (Hertzberg et al., 2010). My project 
aims to identify and characterise abnormalities in haematopoiesis in human fetal DS in order 
to understand how T21 leads to the increase in leukaemia susceptibility in DS.  
 
My work has focused on investigating three major hypotheses: 
 
1. That the expansion of the MEP and CMP populations in DS FL originates from 
perturbation of the HSC/ MPP/ LMPP compartment. 
 
2. That T21 also causes abnormal lymphoid progenitor commitment and/or development 
either via effects on committed lymphoid progenitors or secondary to abnormalities in the 
HSC/ MPP/ LMPP compartment. 
 
3. That the effects of T21 on haematopoiesis are not limited to FL HSC/progenitors, but also 
affect the growth and development of fetal BM and cord blood HSC and progenitors.  
 
In this chapter, I will first summarise my findings before discussing their significance and 
limitations, their impact on our understanding of the pathological processes underlying DS-
associated leukaemias and leukaemia in general, and the opportunities for future work in the 
field. 
 
At the outset, I would like to mention that a major limitation of my study was the small 
sample numbers available (n=20 for normal fetal tisssues and n=9 for DS fetal tissues) for 
analysis. As my work involved isolating CD34 cells (0.5-5% of total cells) from fetal tissues 
and then analysing sub-populations within this fraction; it meant that I had to work with very 
small numbers of cells. The fact that certain sub-populations were over or under represented 
in the CD34 fraction of DS fetal tissues meant that the yield was different for the same sub-
population in normal FL or fetal BM when compared to DS FL or fetal BM. As such it was 
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not always possible to perform multiple experiments (clonogenic assays, lymphoid stromal 
cell cultures, RT-PCR, qRT-PCR) on all the sub-populations from all of the samples. This 
resulted in low ‘n’ numbers for some experiments; thereby causing much of the data to be 
underpowered; or failing to achieve statistical significance. However, despite the low sample 
numbers, the consistency of the results in the DS samples compared to their normal controls, 
suggests that the data obtained from my study indicate that the experimental approach used is 
powerful enough to address my hypotheses.  
 
6.2 Defining normal FL haematopoiesis 
 
Prior to my work, there were few data available about normal human fetal haematopoiesis. 
Although much work has been done in defining murine fetal haematopoiesis, there were many 
gaps in knowledge in understanding how haematopoiesis progresses in human FL and fetal 
BM. Therefore, before I investigated abnormalities in DS fetal haematopoiesis; I had to define 
normal human fetal haematopoiesis. While our lab has previously investigated the myeloid 
progenitor compartment in normal FL, my work has, to my knowledge, for the first time 
thrown light on the HSC and lymphoid compartment in normal FL and BM; thereby providing 
the first comprehensive definition of normal human fetal haematopoiesis in the second 
trimester. 
 
6.2.1 Normal FL HSC, MPP and LMPP 
 
My results show that immunophenotypically defined (Majeti et al., 2007) HSC and MPP with 
multilineage (myeloid, erythroid, megakaryocytic and B/ T/ NK lymphoid) potential exist in 
normal FL. This was done using multiparameter flow cytometry, FACS sorting and in vitro 
assays that included semisolid myeloid colony assays and lymphoid culture assays on stromal 
cells. In addition, gene expression profiling by qRT-PCR confirmed multilineage priming in 
these populations, with the data suggesting that MPP are more mature than HSC in the FL 
haematopoietic hierarchy, showing relatively lower expression of stem cell genes and 
upregulation of megakaryocyte-erythroid and lymphoid specific genes in MPP compared to 
the HSC. 
 
While a small number of FL transplants indicate that FL contains cells with long-lived 
reconstitution potential consistent with the presence of HSC in FL (Touraine et al., 1987), my 
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work is the first to specifically quantitate and characterise these cells. Formal proof of self 
renewal of the HSC/ MPP I have identified would require transplantation studies in a 
xenograft model. These experiments are currently being performed as part of another project 
by a post-doc in the lab. Both HSC and MPP in normal FL were markedly skewed towards the 
erythroid/megakaryocyte lineage compared to previous reports of adult BM HSC/MPP and 
cord blood HSC/MPP (Majeti et al., 2007). This may reflect the high demand for increasing 
red cell and platelet production during this period of very rapid fetal growth at the expense of 
granulocyte/monocyte and lymphocyte production which is likely to be less of a priority in the 
protected in utero environment. 
. 
I was also able to identify LMPP in normal FL using modified immunophenotypic criteria 
previously described for cord blood (Majeti et al., 2007). As reported for murine data 
(Adolfsson et al., 2005; Lai and Kondo, 2006; Luc et al., 2007; Mansson et al., 2007; Yoshida 
et al., 2006), and more recently in abstract form, in human adult BM (Goardon, 2010), normal 
FL LMPP had no megakaryocyte-erythroid potential in vitro, but retained limited myeloid 
potential (mainly CFU-M) and produced B, NK and T cells very efficiently in stromal co-
culture systems, confirming that they are lymphoid primed. The in vitro data were supported 
by qRT-PCR results which showed that stem cell genes were further downregulated, 
megakaryocyte-erythroid genes were silenced and lymphoid-specific genes were upregulated 
in LMPP. 
 
 
6.2.2 Normal FL and fetal BM lymphoid compartment 
 
Lymphopoiesis, especially B lymphopoiesis, in human fetuses is poorly understood when 
compared to fetal and adult mice and adult human BM.  Although B progenitors have been 
reported in human fetal BM, prior to my project, the extent to which the full profile of normal 
B lymphopoiesis occurred in human FL was unknown.  It was also not clear whether B 
progenitors were actually generated within the FL or had merely circulated there from other 
sites such as the AGM, BM or spleen. 
 
My studies have shown for the first time that, using the immunophenotypic criteria used to 
define early and committed B progenitors in CB and adult BM (Davi et al., 1997; Hao et al., 
2001; Hoebeke et al., 2007; Reynaud et al., 2003; Ryan et al., 1997), all of the previously 
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described B progenitors can also be identified in normal second trimester FL and that they are 
present in proportions consistent with a hierarchy of progenitor differentiation from CLP to 
ELP to CBP. Furthermore, the identity of the early and committed B progenitor populations 
was confirmed by their patterns of in vitro differentiation and gene expression. Together these 
data strongly suggest that B lymphopoiesis is likely to be actively occurring in normal FL 
rather than the progenitors 'passing through' in the circulation.   
 
 
Failure to identify a true CLP in human FL 
 
Adopting the immunophenotypic criteria used to define CLP in human CB and in mouse fetal 
BM (Serwold et al., 2009), I failed to identify a true 'common lymphoid' progenitor without 
myeloid potential in human FL. The in vitro read out and gene expression pattern of 'CLP' 
was, in fact, so close to that of the LMPP population, that it seems likely that the 
immunophenotypic CLP definition which I used (CD34+CD38lo/-CD45RA+CD7+) simply 
identified a non-distinct subset of LMPP which could not be separated from it.  This may also 
partly be due to the increased expression CD7 in all FL sub populations when compared to 
CB and ABM, making it a fairly non specific marker to identify very small sub-populations. I 
also found that immunophenotypically-defined ELP, which had T/B/NK potential, retained a 
small amount of myeloid clonogenic activity and expressed very low levels of some myeloid 
lineage genes, compared to LMPP. This suggests that although they are downstream of 
CLP/LMPP, ELP also are not uniquely committed to lymphoid differentiation (see Figure 
6.1). 
 
It remains possible that the CBP1 population contains true CLP, as reported in human adult 
and fetal BM studies which suggested that CLP were CD34+lin-CD38+CD10+  (Galy et al., 
1995). However, my in vitro assays and gene expression studies suggest that CBP1 is a mixed 
population of several lineages, including myeloid and possibly erythroid, and flow cytometry 
plots also indicate that this very small population is rather diffuse and poorly defined.  
Progenitors with various potentials, including M/E/T/B, M/E, M/T/B, M/T, and M/B, (M: 
myeloid; E: erythroid; T: T cell; B: B cell) have been described in mouse FL (Katsura, 2002; 
Kawamoto et al., 2000; Kawamoto et al., 1998; Lu et al., 2002) and my results are more in 
keeping with this finding. 
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A unique fetal B progenitor differentiation scheme is evident in fetal liver and bone marrow 
 
The most notable feature of normal FL and fetal BM B lymphopoiesis was the predominance 
of CBP3, B progenitors which co-expressed CD34 and CD19 but did not express CD10 
(CD34+10-19+). This population has not been previously described in human adult BM, 
where B progenitors have been shown to mature from CD34+10+19+ (Pro B2 cells i.e. CBP2) 
to CD34-CD10+CD19+ (Pre B cells) rather than to CBP3 as they lose their CD34 expression 
before losing their CD10 expression.  By contrast, my studies show that normal FL CBP3, 
acquire CD10 during their maturation in vitro while still expressing CD34 strongly suggesting 
that in FL CBP2 arise from CBP3. This hypothesis is also supported by the qRT-PCR data 
which show higher expression of B cell specific genes, such as PAX5 and CD19, which would 
be expected to increase during maturation, in CBP2 compared to CBP3. CBP3 do not 
therefore fit in to the classically described adult B progenitor differentiation scheme and 
instead fit most closely with the CD34+CD10-CD19+ pre/pro-B cell progenitors very recently 
described by Sanz et al (Sanz et al., 2010) in CB.    
 
The proportion of CBP3 was particularly high in fetal BM (>50% of total CD34 cells) 
suggesting that this pathway of B lymphopoiesis is especially active in second trimester fetal 
BM. This strongly suggests that the alternative pathway for B lymphoid development 
whereby CD34+ B progenitors (ELP) first acquire CD19 (CD34+CD19+CD10-; CBP3; 
pre/pro-B) and then acquire CD10 (i.e. CD34+CD19+CD10+; CBP2; Pro-B2) is specific to 
fetal life. Since CBP3 may give rise to, or arise from the previously reported 'leukaemia-
associated immunophenotype' (LAIP; CD34+CD38lo/-CD19+) (Hong et al., 2008), it is 
possible that this population in fetal BM provides the preleukaemic substrate for childhood 
common ALL unrelated to DS. This may be of particular relevance in understanding the 
origins of childhood ALL, especially infant ALL. 
 
 
 
6.2.3 Normal FL and fetal BM myeloid compartment 
 
Traditionally myelopoiesis has been described to follow defined pathways with a common 
myeloid progenitor (CMP) giving rise to megakaryocyte erythroid progenitors (MEP) and 
granulocyte macrophage progenitors (GMP). Fetal myeloid progenitors have been described 
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in murine FL and BM (Akashi et al., 2000; Traver et al., 2001) and have also been 
characterised in human adult BM and cord blood (Manz et al., 2002) but the only studies in 
human FL are those from our lab (Tunstall-Pedoe et al., 2008) and Mitch Weiss' lab (Chou et 
al., 2008) which focused on DS FL and described normal FL only by very limited 
immunophenotypic parameters. However, using a combined approach of immunophenotyping 
and clonogenic assays and gene expression studies on sorted CMP, MEP and GMP from the 
same samples I used to study the HSC/MPP and LMPP populations, I have characterised the 
pattern of haematopoietic progenitor development in normal human FL for the first time.  
 
These data strongly suggest that both MEP and GMP are the direct progeny of CMP; that 
CMP are immediately downstream of MPP, with which they share a very similar gene 
expression pattern; and that GMP are immediately downstream of LMPP. Gene expression 
and culture studies showed that the GMP compartment in normal FL also contained B and T 
lymphoid potential consistent with the presence of granulocyte/macrophage and B cell (MB) 
progenitors and those with combined granulocyte/ macrophage and T cell potential (MT) 
progenitors, as reported in mouse FL (Buza-Vidas et al., 2007; Katsura, 2002; Kawamoto et 
al., 2000; Kawamoto et al., 1998; Lu et al., 2002; Luc et al., 2007). Taken together my results 
suggest a schematic representation of normal human fetal haematopoiesis in the second 
trimester (Figure 6.1) which is distinct from those previously described in murine FL (see 
Figures 1.5 and 1.6). Gene expression and culture of single progenitor cells would be required 
to confirm this. 
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Figure 6.1 Normal human fetal haematopoiesis   
Key: HSC, haematopoietic stem cell; MPP, multipotent progenitor; LMPP, lymphoid 
primed multipotent progenitor; CMP, common myeloid progenitor; MEP, megakaryocyte 
erythroid progenitor; GMP, granulocyte macrophage progenitor; ELP, early lymphoid 
progenitor; ETP, early T progenitor; CBP. Committed B progenitor; G/T, granulocyte and T 
progenitor; M/B, granulocyte and B progenitor. Immunophenotypic definitions used to 
define the sub populations (in black font) and their in vitro output (in red font) are denoted in 
brackets.   
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6.3 Abnormalities in DS FL haematopoiesis 
 
Prior to my work, there were no published data describing the HSC or lymphoid progenitor 
compartment in DS. Although much work has been done with mouse models of DS, there is 
paucity of information about human DS fetal tissues. Our lab (Tunstall-Pedoe et al., 2008) and 
(Chou et al., 2008) described abnormalities in the myeloid progenitor compartment in DS FL, 
but my data provide the first comprehensive review of human DS fetal haematopoiesis 
especially in the FL. 
 
6.3.1 Abnormalities in DS FL HSC and myeloid progenitor compartments 
 
Using a number of approaches, my data have confirmed that there are several important 
differences in the size, composition and function of the HSC compartment in DS FL. First, I 
found that the HSC compartment was around 3-fold larger in DS FL compared to normal FL; 
there was a commensurate reduction in MPP in DS FL suggesting that there may also be a 
block to normal HSC differentiation in DS FL. In addition, I found a large, 'aberrant' CD7+ 
population of HSC and progenitors in DS FL. Thirdly, DS FL HSC, MPP and LMPP were all 
much more clonogenic than their counterparts in normal FL HSC and MPP with a marked 
megakaryocyte-erythroid bias. Finally, I also found that, unlike the corresponding normal FL 
populations, DS FL HSC/MPP and LMPP did not generate B cells in MS5 co-culture 
suggesting specifically impaired B-lymphoid differentiation and proliferation since T cell 
differentiation, though not optimal when compared to normal FL, was less affected.  
 
Taken together my data indicate that T21 perturbs the proliferation and differentiation of 
HSC/ MPP/ LMPP and causes a pronounced megakaryocyte-erythroid differentiation bias 
which may partially, or completely, block normal B lymphoid differentiation. This is 
accompanied by, and almost certainly underlies, functional and gene expression abnormalities 
in the downstream CMP, MEP and GMP, extending and supporting previous data from our 
lab (Tunstall-Pedoe et al., 2008). The abnormal, expanded HSC compartment in DS FL may 
in fact represent the pre-leukaemic stem cells in DS-AMKL and provide the substrate on 
which GATA1 mutations occur. Gene expression data provide a number of clues to the 
molecular basis for the haematological abnormalities in DS FL HSC but also raise questions 
about how these changes in gene expression relate to the extra copy of Hsa21.  
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There appears to be an increase in expression of GATA1 in DS FL HSC and CMP and of 
GATA2 in CMP; together with a possible increase in RUNX1 in DS FL HSC; and the 
reduction in B lymphoid and myeloid priming in DS FL HSC. The increase in GATA1/2 may  
explain the increase in megakaryocyte-erythroid clonogenicity of DS FL HSC/CMP (Huang 
et al., 2009b; Iwasaki et al., 2003) and suggests that acquisition of GATA1 mutations in these 
cells (rather than only in the committed progenitor cells, as postulated in earlier work 
(Tunstall-Pedoe et al., 2008) would contribute a second 'transformation' step to HSC that are 
already proliferating more rapidly. In addition, at least two conserved microRNAs, miR-144 
and miR-451, are known to be direct targets of GATA1 and, interestingly, zebrafish embryos 
depleted of miR-451 using antisense morpholinos have impaired erythroid development  
suggesting that increased expression of GATA1 might perturb megakaryocyte-erythroid 
differentiation in very complex ways (Dore et al., 2008).  
 
Of the genes on Hsa21, none of the 6 genes tested (DSCR1, DNMT3L, DYRK1A, ERG, 
GABPA, RUNX1) appeared to be clearly increased in DS FL HSC or myeloid progenitors, 
although RUNX1 appeared to be slightly increased in DS FL HSC and this would be 
important to determine by studying more samples. Increased expression of RUNX1 might add 
to the megakaryocyte-erythroid bias since RUNX is essential for normal megakaryocyte 
differentiation (Huang et al., 2009a) and there is evidence that RUNX1 cooperates with 
GATA1 during megakaryocyte differentiation (Elagib et al., 2003) and may also provide an 
additional proliferative advantage to these cells since mutations in RUNX1 are well recognised 
in AML, including those with T21 (Christiansen et al., 2004; Harada et al., 2004; Nakao et al., 
2004; Osato et al., 1999; Owen et al., 2008; Preudhomme et al., 2000). The main difficulty in 
understanding the role of RUNX1, is that, expression of RUNX1 appears to be decreased in 
DS-AMKL (Bourquin et al., 2006). However, mutations of RUNX1 in non-DS AML appear to 
be leukaemogenic mainly as a result of reduced, rather than increased, levels of expression of 
RUNX1 (Nakao et al., 2004; Preudhomme et al., 2000) and therefore whether and how 
increased expression of RUNX1 in DS FL HSC contributes to leukaemogenesis remains to be 
investigated. 
 
The mechanism(s) behind the reduction in expression of B lymphoid genes (IKAROS, IL7RA, 
E2A, EBF and PAX5) and the impaired granulocyte differentiation suggested by the lower 
levels of CEBPα expression in DS FL HSC and LMPP was not clear from my work. Since 
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levels of expression of all these genes is reduced, rather than increased, and if all of these 
changes are, as seems likely, closely linked, it is tempting to speculate that increased 
expression of one or more of the miRs encoded on Hsa21 might be responsible.  A 
preliminary search of the miR databases (Chaudhuri and Chatterjee, 2007) indicates that none 
of these genes is known to be targeted by one of the 5 miRs on Hsa21.  However, the putative 
role of miRs is further discussed in 6.4. 
 
Another finding of possible importance is the apparently reduced expression of IGF1R and 
IGF2R in DS FL HSC, MPP and LMPP (Appendix 3; Figures B8 and B9) since the IGF 
signalling pathway has recently been implicated in the pathogenesis of TMD and AMKL in 
DS. (Klusmann et al., 2010a). MEF2C and SHIP1 expression also appears to be lower in DS 
FL HSC, MPP and LMPP (Appendix 3; Figures C10 and C11), as does the expression of 
NOTCH1, DLL1 and HES (Appendix 3; Figure D). This may be important in understanding 
the lymphoid differentiation defect seen in DS FL HSC and LMPP since all of these genes 
have been shown to play a role in normal B cell development. (Gekas et al., 2009; Northrup 
and Allman, 2008). The significance of these data needs to be confirmed by anaysing more 
samples. 
 
Another important finding from my studies, although relying on a relatively small number of 
samples, is the first evidence that perturbation of the haematopoiesis in DS is not confined to 
FL cells. I consistently found (in every sample tested) both a megakaryocyte-erythroid bias in 
clonogenic assays of fetal BM and CB HSC and also increased clonogenicity. This strongly 
supports the cell-intrinsic nature of the haematopoietic abnormalities in DS and indicates that 
they persist beyond the second trimester and at least until birth. This has several implications. 
First, it adds further weight to the contention that T21, and not just the FL microenvironment, 
drives the haematopoietic abnormalities. Second, it suggests that T21 HSC may be abnormal 
during adult, as well as fetal, life since BM is the site of life-long haematopoiesis and 
abnormalities were still detectable at birth. Although DS-AMKL is almost confined to the first 
5 years of life (Hasle et al., 2008), adults with DS appear to have an increased risk of 
developing myelodysplasia and/or bone marrow failure in later life as well as having a high 
frequency of abnormal B cell function (McLean et al., 2009).   
 
It is also possible that the abnormalities in DS CB reflect the predominance of HSC of FL 
origin, rather than BM origin, in CB; however, this is unclear since there is no published work 
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which has identified the source of the HSC circulating in CB.  Finally, although both fetal BM 
and CB HSC were abnormal in DS, the abnormalities were less than in FL; in particular flow 
cytometry showed normal numbers of MEP in DS CB despite their abnormal function. This 
observation suggests that the DS FL microenvironment does contribute an additional 
proliferative advantage to T21 HSC. Recent work from Klusmann et al (Klusmann et al., 
2010a) in DS-AMKL and TAM suggests that this might involve abnormal insulin growth 
factor (IGF) signaling. 
 
 
6.3.2 Abnormalities in DS fetal lymphoid compartment 
 
As children with DS have a higher incidence of B ALL than children without DS (Hasle et al., 
2000), I hypothesised that T21 would perturb B lymphopoiesis in fetal life. Using both 
multiparameter flow cytometry and progenitor cultures I have shown that B progenitor 
development is severely impaired in vivo and in vitro, strongly suggesting an intrinsic defect 
in B cell development in DS FL.  A profound block in fetal B progenitor differentiation was 
also evident in fetal BM, particularly at the late CBP stage. Genes important for early 
lymphoid development (IKAROS, IL7RA and E2A) and later B progenitor development (EBF 
and PAX5) (Northrup and Allman, 2008) were all expressed at lower levels in DS FL B 
lymphoid progenitors when compared to normal FL suggesting a failure to upregulate the B 
lymphoid programme in DS FL progenitors. Furthermore, studies in the DS FL 
HSC/MPP/LMPP compartment suggested that the failure of lymphoid priming began at the 
HSC level.  Thus, my data suggest that the impairment in fetal B cell development in DS is, at 
least in part, an intrinsic defect due to abnormalities in gene expression; whether there is also 
a failure of the DS microenvironment to provide the signals necessary to drive the marked 
amplification in B progenitor numbers as seen in normal fetal BM, remains to be established 
since this was not studied in my project.  
 
Interestingly, two of the genes I tested from Hsa21 may be upregulated in DS FL B lymphoid 
progenitors- GABPA was slightly increased in all committed B progenitors, while DYRK1A 
was marginally increased in CBP2. DYRK1A (and DSCR1 which is also on Hsa21) are crucial 
components of the NFAT signaling pathway (Arron et al., 2006; Gwack et al., 2006) and 
known to be important for normal B and T lymphoid progenitor development (Gallo et al., 
2008; Winslow et al., 2006; Wu et al., 2007a; Wu et al., 2007b). GABPA has also been shown 
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to be necessary for normal B cell development (Xue et al., 2007), although its role, and that of 
DYRK1A, in fetal B progenitor development and ALL is unknown. 
 
6.4 The role of T21 in abnormal DS fetal haematopoiesis and DS-associated 
leukaemias 
 
Although my studies have identified a number of candidate genes on Hsa21 which might 
contribute to the perturbation of fetal haematopoiesis in DS (RUNX1, GABPA and DYRK1A), 
it seems likely that additional genetic changes are also involved since T21 may impact on 
biology in multiple complex ways (Roper and Reeves, 2006). These effects may be mediated 
directly, via the effects of changes in expression of genes on Hsa21, including miRs, as 
discussed below. Alternatively, the effects may be exerted indirectly via disomic genes 
perhaps interacting with Hsa21 genes on the same cellular pathways or via miRs. 
Nevertheless, despite the potential complexity of downstream consequences, the primary 
genetic lesion is altered DNA dosage of all or part of Hsa21. Although genotype-phenotype 
studies in DS children with partial T21 have progressively refined the DSCR to a 4.3-5.4 Mb 
region of 21q22. (Delabar et al., 1993; Ronan et al., 2007), it is not yet clear if there is a 
DSCR associated with leukaemia susceptibility, although one recent paper localises the 
critical chromosomal region of Hsa21 involved in DS-AMKL and TMD to an 8.3Mb segment 
(Korbel et al., 2009). The putative roles of candidate genes in the DSCR likely to be relevant 
to haematopoiesis is currently under active investigation using iPS (induced pluripotent stem 
cells) derived from fibroblasts of patients with DS (Park et al., 2008).  
 
Finally, several studies have now found evidence of changes in expression of miRs in patients 
with DS (Kuhn et al., 2008) that may influence haematopoiesis. There are 5 miRs, single-
stranded non-coding RNA molecules of 19-24 nucleotides which control gene expression at a 
post-transcriptional level by translational repression or mRNA cleavage (Kuhn et al., 2008; 
Kuhn et al., 2010), in the DSCR: miR-99a, let-7c, miR-125b2, miR-155, and miR-802 
(Antonarakis et al., 2004). They are over-expressed by ~1.5-2-fold in fetal brain and heart 
from individuals with DS (Kuhn et al., 2008; Kuhn et al., 2010). miR-155 controls several 
aspects of normal and malignant haematopoeisis. Mir-155 knock out mice have normal B 
progenitors but defective germinal cell development, lower memory and plasma cells and 
production of IgG1 antibodies (Thai et al., 2007; Turner and Vigorito, 2008; Vigorito et al., 
2007). Transgenic mice in which miR-155 transcription is driven by a B cell specific 
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promoter display pro- to pre-B cell block and eventually B lymphoblastic lymphoma 
(Costinean et al., 2006) while over-expression of miR-155 in HSC by retroviral transduction 
leads to a myeloproliferative disorder (O'Connell et al., 2008). In both cases, abnormal 
haematopoiesis has been linked to the ability of miR-155 to target SHIP1 while SHIP-/- mice 
also have reduced BCP and myeloproliferation (Maeda et al., 2009; Nakamura et al., 2004; 
O'Connell et al., 2009).  
 
Interestingly, the miR-812b2 cluster and miR-155 were the focus of a recent study in T21-
related B-ALL (DS-ALL and non-DS T21) in the context of hyperdiploidy or 
intrachromosomal amplification of an Hsa21 area around Runx1; (Gefen et al., 2010). 
Expression of miR-125b cluster was found to be lower in T21 as compared to blasts from the 
common TEL-AML1 B-ALL while levels of miR-155 were similar in both T21 and non-T21 
ALL. However, levels of these miRs were not compared to normal and DS non-leukaemic B 
progenitors and therefore the question whether DSCR miRs are overexpressed in DS and non-
DS-related T21 is still to be addressed. A recent study had also found that miRNA-125b2 is 
indeed higher in TMD and DS AMKL blasts compared to normal megakaryocytes (Klusmann 
et al., 2010b).  
 
 
6.5 Future work 
 
Abnormalities detected in DS fetal haematopoiesis in this study, provide insight into the role 
of T21 in abnormal haematopoiesis in general, as well as, potentially, into its role in the 
development of childhood leukaemias. The results of these studies also characterise normal 
FL and BM haematopoiesis, identifying a fetal pathway of B progenitor development and 
thereby posing exciting new questions about how this may explain the fetal origins of many 
childhood leukaemias.  
 
The abnormalities in the DS fetal HSC compartment suggest that DS ALL, as well as DS 
AMKL, is likely to arise in utero. The abnormalities of the HSC compartment and indeed all 
other progenitor populations (especially lymphoid) need to be confirmed by in vivo 
experiments to show their engraftment potential in xenograft models which was out with the 
scope of my PhD and is already underway in the lab as part of another project. The 
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foreseeable challenge in this methodology is the small number of rare cells that are available 
to work with.  
My work has only touched on the role of the microenvironment in perturbing DS fetal 
haematopoiesis, by showing the differences between the effects of T21 on FL, fetal BM and 
CB haematopoiesis. Further experiments both on BM/FL stromal cells and purified 
progenitors would be required to investigate the role of the FL versus fetal BM 
microenvironment on gene expression in normal and DS fetal progenitors and understand how 
this might increase susceptibility to leukaemia in DS. The in vitro culture assays and qRT-
PCR performed with sorted FL sub-populations shed light on lineage priming and lineage 
potential of specific immunophenotypically defined populations. However the question 
remains whether these populations represent homogenous populations or a mixture of 
progenitors. Several of these conclusions would need to be tested in a much larger number of 
samples, with very rigorous cell sorting and then confirmed at the single cell level. 
 
Key to understanding the role of T21 in fetal haematopoiesis and leukaemogenesis in 
particular, would be the identification of specific Hsa21 genes that regulate haematopoiesis. 
The role of selected genes (DSCR1 and DYRK1a) in lymphopoiesis in DS children is being 
investigated in the lab by gene expression studies, gain-and-loss of function studies and in 
vivo xenograft models. Finally, the role of epigenetic changes, including miRs, in mediating 
the effects of T21 on haematopoiesis is only just beginning to be investigated. 
 
 
6.6 Conclusion 
 
These studies have characterised normal human fetal haematopoiesis for the first time and 
show that HSC, MPP and LMPP populations with full lymphoid differentiation are present in 
FL indicating that FL, and not just BM, is an active site of lymphopoiesis during fetal life 
which has implications for the origin of infant ALL.  I have also demonstrated that T21 
perturbs haematopoiesis at the HSC level, leading both to myeloid progenitor expansion and a 
block to B-cell differentiation. These findings increase our understanding of the role of T21 in 
initiating and maintaining leukaemia-initiating cells and suggest a tractable model for 
investigating the effects of aneuploidy on cell growth and differentiation. However further 
work is required to determine the exact mechanism of the genetic or epigenetic changes in 
fetal haematopoiesis brought about by an extra copy of chromosome 21. 
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APPENDIX 1 
 
Fluorochrome conjugated antibodies used for flow cytometry: 
 
All antibodies were from BD (Beckton-Dickinson, Oxford, UK) unless otherwise stated.  
 
Surface 
marker 
Fluorochrome 
 PerCP APC PE FITC PE-Cy7 PE-Cy5 Alexaflour 
700 
Pacific 
Blue 
CD34 • • •  •    
CD38 • •      • 
CD45RA  •  •     
CD45RO   • •     
hCD45       • 
eBioscience 
 
CD7  •  
(Caltag) 
• •   •  
CD2    •  •   
CD3  •  •  •   
CD4   •      
CD8 •        
CD127   •      
CD10    •     
CD19  •  •     
CD123   • •     
CD33   •      
CD14   • •     
CD11b   •      
CD61 •   •     
CD135   •      
GlyA   •      
CD90      • • • 
Lineage 
cocktail* 
   •     
 
Caltag (Caltag Medsystems, Buckingham,UK) 
 
* (cocktail of: CD3, CD14, CD16, CD19, CD20, and CD56)  
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APPENDIX 2  cDNA SPECIFIC PRIMERS FOR RT-PCR 
 
 
GENE PRIMERS 
pTCRα F:TCC AGC CCT ACC CAC AGG TG 
 R: TAG AAG CCT CTC CTG ACA GAT GCA 
PAX5 F:CCA GTC CCA GCT TCC AGT CAC AG 
 R: GG AGA CTC CTG AAT A CC TTC GTC TC 
 F2: CCAGTCACAGCATAGTGTCC  
 R2: TAC CTT CGT CTC TCT TGC GC 
GATA1 F: ACA GGA GCA GCC GAA GGA CC 
 R: GAG GAG AAG GAC ACC ACC CC   
 F2: GCTGGTGGCTTTATGGTGGTGG 
 R2: CTG GAG GCC ATG CTC TGT GC  
PU.1 F: G GAA GGG TTT CCC CTC GTC 
 R: G GTC GCT ATG GCT CTC CCC    
CEBPα F:  ACA TCA GCG CCT ACA TCG ACC CG 
 R: TGC TTG GCT TCA TCC TCC TCG C 
 F2: GCCGCCTTCAACGACGAGTT  
 R2: TCC TGC TTG ATC ACC AGC GGC 
IL-7Rα F: CA GGG GAG ATG GAT CCT ATC 
 R: CC ATA CGA TAG GCT TAA TCC 
 F2: GTGCCTGAATTTCAGGAAACTACAAG  
 R2: CTGGATAAATTCACATGCGTCCAT 
CD45 F: GCT GAC TTC CAG ATA TGA CC 
 R: TTC AGA GGC ATT AAG GTA GGC 
GATA2 F: TTC ACC CCT AAG CAG CGC AG 
 R: AG GTG CCA TGT GTC CAG CC 
EBF1 F: GTCTCCGAGGCATCACAAGCC               
 R: GGC CAT GGT GGG GCT GGA TGG C    
 F2: GCCACCAATCAGGGTTTCACCC 
 R2: GGATGGCACTATGGCATAGG 
E2A F: TACGACGGGGGTCTCCACGG 
 R: CGTCCTCGGGGTGGCTGCC 
 F2: GGCCTGCAGAGTAAGATAGAAGACC 
 R2: TGG CTG CCT CCA ACC AGG C 
 
 
 
SPECIFIC PRIMERS FOR PCR 
 
 
GENE PRIMERS 
GATA1 exon 2 F: AAAGGAGGGAAGAGGAGCAG 
 R: AAGCTTCCAGCCATTTCTGA 
GATA1 exon 3 F: GGAACTTGGCCACCATGTTGG 
 R: AGCCGCTCTGTCTTCAAAGTCTC 
JAK2  F: CCA GAA ACA CAA ACC ATG TCA GCC 
 R: CAT GCC CTT TAC ACC ACT GC 
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APPENDIX 3  GENE EXPRESSION IN NORMAL AND DS FL  
Genes studied by qRT-PCR using the nanofluidic BioMark 48.48 Dynamic Array and 
TaqMan Expression Assays  
Transcription factors Figure     A1 
A2 
A3 
A4 
A5 
A6 
A7 
A8 
GATA1 
GATA2 
GATA3 
FOG1 
RUNX1 
PU.1 
CEBPα 
ERG 
Growth factor receptors Figure     B1 
B2 
B3 
B4 
B5 
B6 
B7 
B8 
B9 
B10 
B11 
B12 
c-MPL 
GM-CSFR 
G-CSFR 
CSF1R 
EpoR 
c-kit 
IL3Rα 
IGF1R 
IGF2R 
CRLF2 
Flt3 
IL7R 
Lymphoid genes Figure     C1 
C2 
C3 
C4 
C5 
C6 
C7 
C8 
C9 
C10 
C11 
Ikaros 
IL7R 
PTCRA 
RAG1 
EBF1 
E2A 
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Figure A    Relative expression of transcription factors in DS and normal FL  
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Figure A  Relative expression of transcription factors in DS and normal FL  
Gene expression levels are shown relative to GAPDH and are the mean ± SEM of 3 normal 
FL and 3 DS FL samples from which 50 cells of each CD34+ sub population were sorted in 
triplicate for analysis by qRT-PCR. 
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B Relative expression of growth factor receptors in DS and normal FL 
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Figure B  Relative expression of growth factor receptors in DS and normal FL Gene expression 
levels are shown relative to GAPDH and are the mean ± SEM of 3 normal FL and 3 DS FL samples 
from which 50 cells of each CD34+ sub population were sorted in triplicate for analysis by qRT-PCR 
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C Relative expression of lymphoid genes in DS and normal FL 
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Figure C  Relative expression of lymphoid genes in DS and normal FL  
Gene expression levels are shown relative to GAPDH and are the mean ± SEM of 3 normal 
FL and 3 DS FL samples from which 50 cells of each CD34+ sub population were sorted in 
triplicate for analysis by qRT-PCR. 
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D Relative expression of Notch receptors and signaling genes in DS and normal FL 
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Figure D  Relative expression of NOTCH receptors & signaling genes in DS and normal FL 
Gene expression levels are shown relative to GAPDH and are the mean ± SEM of 3 normal FL and 3 
DS FL samples from which 50 cells of each CD34+ sub population were sorted in triplicate for 
analysis by qRT-PCR 
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E Relative expression of selected chromosome 21 genes in DS and normal FL 
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Figure E  Relative expression of selected Chr 21 genes in DS and normal FL Gene expression 
levels are shown relative to GAPDH and are the mean ± SEM of 3 normal FL and 3 DS FL samples 
from which 50 cells of each CD34+ sub population were sorted in triplicate for analysis by qRT-PCR 
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F Relative expression of selected other genes in DS and normal FL 
0
0.001
0.002
0.003
0.004
0.005
0.006
CD34 HSC MPP LMPP ELP CBP1 CBP2 CBP3 CMP MEP GMP
G
YP
A
 e
xp
re
ss
io
n 
le
ve
l r
el
at
iv
e 
to
 G
A
PD
H T21 FL
NORMAL FL
 
0
0.0001
0.0002
0.0003
0.0004
0.0005
0.0006
0.0007
CD34 HSC MPP LMPP ELP CBP1 CBP2 CBP3 CMP MEP GMP
C
D
7 
ex
pr
es
si
on
 le
ve
l r
el
at
iv
e 
to
 G
A
PD
H
T21 FL
NORMAL FL
 
0
0.001
0.002
0.003
0.004
0.005
0.006
0.007
0.008
CD34 HSC MPP LMPP ELP CBP1 CBP2 CBP3 CMP MEP GMP
C
XA
D
R
 e
xp
re
ss
io
n 
le
ve
l r
el
at
iv
e 
to
 G
A
PD
H
T21 FL
NORMAL FL
 
F1 
F2 
F3 
 291
0
0.0005
0.001
0.0015
0.002
0.0025
CD34 HSC MPP LMPP ELP CBP1 CBP2 CBP3 CMP MEP GMP
ER
A
F 
ex
pr
es
si
on
 le
ve
l r
el
at
iv
e 
to
 G
A
PD
H T21 FL
NORMAL FL
 
0
0.00005
0.0001
0.00015
0.0002
0.00025
0.0003
0.00035
0.0004
CD34 HSC MPP LMPP ELP CBP1 CBP2 CBP3 CMP MEP GMP
W
EE
2 
ex
pr
es
si
on
 le
ve
l r
el
at
iv
e 
to
 G
A
PD
H
T21 FL
NORMAL FL
 
0
0.0002
0.0004
0.0006
0.0008
0.001
0.0012
0.0014
0.0016
0.0018
CD34 HSC MPP LMPP ELP CBP1 CBP2 CBP3 CMP MEP GMP
C
D
K
N
1C
 e
xp
re
ss
io
n 
le
ve
l r
el
at
iv
e 
to
 G
A
PD
H
T21 FL
NORMAL FL
 
 
F4 
F5 
F6 
 292
0
0.005
0.01
0.015
0.02
0.025
0.03
0.035
0.04
0.045
CD34 HSC MPP LMPP ELP CBP1 CBP2 CBP3 CMP MEP GMP
TG
FB
1 
ex
pr
es
si
on
 le
ve
l r
el
at
iv
e 
to
 G
A
PD
H T21 FL
NORMLA FL
 
Figure F  Relative expression of selected other genes in DS and normal FL Gene 
expression levels are shown relative to GAPDH and are the mean ± SEM of 3 normal FL and 
3 DS FL samples from which 50 cells of each CD34+ sub population were sorted in triplicate 
for analysis by qRT-PCR. 
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APPENDIX 4  GENERATION OF T AND B CELLS FROM NORMAL FL GMP
  
 
 
a) 
       
  
 
 
 
      
 
 
b) 
 
     
 
 
 
 (CD7+CD2+CD4+/CD8+) T cells (red arrows) and  (CD34-CD19+) B cells (blue arrow) 
were detected after 14 days of co culture of normal FL GMP 
(CD34+CD38+CD45RA+CD123+) on a) OP9-DL1 and b) MS5 stromal cells. 
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